triptolide profile

Triptolide is a diterpenoid triepoxide isolated from the Chinese medicinal herb *Tripterygium wilfordii*. It has a complex structure with multiple chiral centers and a unique epoxy group. It exhibits a wide range of biological activities, including anti-inflammatory, immunosuppressive, and anticancer effects. Triptolide is being studied for its potential therapeutic uses in various diseases, including rheumatoid arthritis, systemic lupus erythematosus, and certain types of cancer. However, its clinical development has been hampered by its toxicity, and further research is needed to optimize its therapeutic index. The synthesis of triptolide is challenging due to its complex structure and the presence of multiple reactive functional groups. Several synthetic strategies have been developed, but a practical and scalable synthesis remains a challenge.'

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Tripterygium	genus	A plant genus of the family CELASTRACEAE that is a source of triterpenoids and diterpene epoxides such as triptolide.[MeSH]	Celastraceae	A plant family of the order Celastrales, subclass Rosidae, class Magnoliopsida.[MeSH]

ID Source	ID
PubMed CID	107985
CHEMBL ID	463763
CHEBI ID	9747
SCHEMBL ID	413634
MeSH ID	M0042303

Synonym
HY-32735
BRD-K39484304-001-02-5
pg-490
BIO2_000315
BIO2_000795
BSPBIO_001595
MLS001424107
triptolide ,
C09204
38748-32-2
trisoxireno[4b,7:8a,9]phenanthro[1,2-c]furan-1(3h)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, [3br-(3b.alpha.,4a.alpha.,5as,6.beta.,6a.beta.,7a.beta.,7b.alpha.,8as,8b.beta.)]-
trisoxireno[4b,7:8a,9]phenanthro[1,2-c]furan-(3h)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, [3br-(3b.alpha.,4a.alpha.,5as,6.beta.,6a.beta.,7a.beta.,7b.alpha.,8as,8b.beta.)]-
triptolid
nsc163062
nsc-163062
smr000466307
MLS000759410
cpd000466307
IDI1_034065
NCGC00163411-02
NCGC00163411-01
pg490
trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3h)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bs,4as,5as,6r,6ar,7as,7bs,8as,8bs)-
nsc 163062
KBIOGR_000315
KBIO2_002883
KBIO2_005451
KBIO3_000630
NCI60_001223
KBIO3_000629
KBIO2_000315
KBIOSS_000315
NCGC00163411-03
(3bs,4as,5as,6r,6ar,7as,7bs,8as,8bs)-6-hydroxy-8b-methyl-6a-(propan-2-yl)-3b,4,4a,6,6a,7a,7b,8b,9,10-decahydrotrisoxireno[6,7:8a,9:4b,5]phenanthro[1,2-c]furan-1(3h)-one
HMS2051N13
HMS1989P17
triptolide, 1
bdbm50241049
HMS1791P17
HMS1361P17
CHEMBL463763 ,
chebi:9747 ,
BRD-K39484304-001-06-6
S3604
CCG-100957
unii-19ald1s53j
19ald1s53j ,
pg 490
AM84923
CS-0286
(3bs,4as,5as,6r,6ar,7as,7bs,8as,8bs)-3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-6a-isopropyl-8b-methyltrisoxireno(6,7:8a,9:4b,5)phenanthro(1,2-c)furan-1(3h)-one
triptolide [mi]
(3bs,4as,5as,6r,6ar,7as,7bs,8as,8bs)-3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3h)-one
triptolide [who-dd]
AB00639938-08
SCHEMBL413634
AB00639938-06
AKOS022168197
MLS006010844
NC00207
T2899
DFBIRQPKNDILPW-CIVMWXNOSA-N
(3bs,4as,5as,6r,6ar,7as,7bs,8as,8bs)-3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3h)-one
Q-100450
HMS3402P17
DTXSID5041144
mfcd00210565
(5bs,6as,7as,8r,8ar,9as,9bs,10as,10bs)-8-hydroxy-8a-isopropyl-10b-methyl-2,5,5b,6,6a,8,8a,9a,9b,10b-decahydrotris(oxireno)[2',3':4b,5;2'',3'':6,7;2''',3''':8a,9]phenanthro[1,2-c]furan-3(1h)-one
NCGC00163411-07
(5bs,6as,7as,8r,8ar,9as,9bs,10as,10bs)-8-hydroxy-8a-isopropyl-10b-methyl-1,5,5b,6,6a,8,8a,9a,9b,10b-decahydrotris(oxireno)[2',3':4b,5;2'',3'':6,7;2''',3''':8a,9]phenanthro[1,2-c]furan-3(2h)-one
DB12025
triptolide, tripterygium wilfordii - cas 38748-32-2
(6as,7as,8r,8ar,9as,9bs,10as,10bs)-8-hydroxy-8a-isopropyl-10b-methyl-1,5,5b,6,6a,8,8a,9a,9b,10b-decahydrotris(oxireno)[2',3':4b,5;2'',3'':6,7;2''',3''':8a,9]phenanthro[1,2-c]furan-3(2h)-one.
BS-16697
144539-79-7
Q906351
BRD-K39484304-001-16-5
BP-25386
(1s,2s,4s,5s,7r,8r,9s,11s)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one
(1s,2s,4s,5s,7r,8r,9s,11s,13s)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one
nsc839303
nsc-839303
trisoxireno[6,7:8a,9:4b,5]phenanthro[1,2-c]furan-1(3h)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bs,4as,5as,6r,6ar,7as,7bs,8as,8bs)-
EX-A7744A

Excerpt	Reference	Relevance
"Triptolide is a potent natural product, with documented antiproliferative, immunosuppressive, anti-inflammatory, antifertility, and antipolycystic kidney disease effects. "	( Triptolide directly inhibits dCTP pyrophosphatase. Aberle, N; Cavga, H; Corson, TW; Crews, CM, 2011)	3.25
"Triptolide (TP) is a diterpene epoxide component extracted from Tripterygium wilfordii and has been shown to possess an impressive anticancer effect. "	( ATB Bao, S; Chen, R; Kou, L; Lin, G; Lin, Y; Lou, D; Lou, Z; Luo, Q; Shangguan, H; Zhang, H, 2021)	2.06
"Triptolide is a diterpenoid epoxide extracted from"	( Triptolide is a Promising Therapeutic Approach in Treating Thyroid Cancer Based on in silico and in vitro Experiment. An, SJ; Lan, J; Li, CQ; Li, JJ; Sun, CH; Wang, F; Yin, Y; Zhao, WJ, 2021)	2.79
"Triptolide is a key effective component from Tripterygium wilfordii."	( The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking. Li, Y; Wang, Y; Zhao, J; Zhu, W, 2022)	1.78
"Triptolide (TPL) is an active component derived from Tripterygium wilfordii Hook F (TwHF) with therapeutic potential for rheumatoid arthritis (RA). "	( Triptolide inhibits cell growth and inflammatory response of fibroblast-like synoviocytes by modulating hsa-circ-0003353/microRNA-31-5p/CDK1 axis in rheumatoid arthritis. Guo, JC; Liu, J; Sun, YQ; Wan, L; Wang, J; Wang, X; Wen, JT; Xin, L, 2022)	3.61
"Triptolide (TP) is a major active component of colquhounia root tablet, which has been long been used in China to treat diabetic nephropathy (DN) due to its marked anti‑inflammatory, antiproteinuric, and podocyte‑protective effects."	( Prediction of the Potential Mechanism of Triptolide in Improving Diabetic Nephropathy by Utilizing A Network Pharmacology and Molecular Docking Approach. An, X; Fan, D; Tian, R; Yan, M; Yin, Z; Zhang, J; Zhou, Y, 2022)	2.43
"Triptolide is a potent anti-inflammatory agent that also possesses anticancer activity, including against colorectal cancer (CRC), one of the most frequent cancers around the world. "	( Mechanisms of action of triptolide against colorectal cancer: insights from proteomic and phosphoproteomic analyses. Fan, J; He, H; Song, X; Wang, L; Zhang, Y, 2022)	2.47
"Triptolide (TP) is a major active ingredient and toxic component of Tripterygium wilfordii Hook F (TWHF), which exhibits multiple activities and remarkable hepatotoxicity, the latter of which limits its clinical application due to the risk of liver injury. "	( Th17/Treg imbalance mediates hepatic intolerance to exogenous lipopolysaccharide and exacerbates liver injury in triptolide induced excessive immune response. Jiang, Z; Nong, C; Tang, Q; Wang, J; Yu, Q; Yuan, Z; Zhang, H; Zhang, L; Zhou, S; Zhu, Y, 2022)	2.37
"Triptolide (TPL) is an active component of Tripterygium wilfordii and was recently discovered to suppress the growth of some cancers, including ALL, but the underlying mechanism has yet to be elucidated."	( Triptolide inhibits T-cell acute lymphoblastic leukaemia by affecting aberrant epigenetic events in the Wnt signalling pathway. Huang, M; Li, Y; Ma, Y; Meng, Y, 2023)	3.07
"Triptolide (TPL) is a bioactive component extracted from the traditional Chinese herb Tripterygium wilfordii Hook F., and has multiple pharmacological activities, such as anti-tumor activity. "	( New mechanism of nephrotoxicity of triptolide: Oxidative stress promotes cGAS-STING signaling pathway. Dong, H; Lin, R; Liu, P; Lu, J; Sun, J; Wen, F; Zhang, Y; Zhu, L, 2022)	2.44
"Triptolide is a natural active compound that has significant neuroprotective properties and shows promising effects in the treatment of Alzheimer's disease (AD). "	( Neuroprotection of Triptolide against Amyloid-Beta1-42-induced toxicity via the Akt/mTOR/p70S6K-mediated Autophagy Pathway. Gao, J; Peng, Y; Tan, J; Wang, T; Wu, Z; Xu, J; Xu, P; Zheng, F, 2022)	2.49
"Triptolide (TP) is a major active compound derived from the traditional Chinese medicine Tripterygium wilfordii. "	( Exploring the anti-influenza virus activity of novel triptolide derivatives targeting nucleoproteins. Chen, X; Cheng, Y; Jiang, N; Li, H; Li, R; Liu, D; Quan, L; Zhou, Y, 2022)	2.41
"Triptolide is a major active ingredient isolated from the traditional Chinese medicine Tripterygium wilfordii, which has anti-inflammatory, anti-cancer, and immunomodulatory effects. "	( Triptolide exposure induces oxidative stress and decreases oocyte quality in mouse. Hao, QQ; Liu, Y; Liu, YC; Nie, H; Qi, ZQ; Qiao, FX; Sun, MX; Wang, HL; Xu, CL; Xu, ZR, 2023)	3.8
"Triptolide (TP) is a kind of epoxy diterpene lactone extracted from the roots, flowers, leaves, or grains of the Celastraceae plant, Tripterygium wilfordii."	( Triptolide inhibits intrahepatic cholangiocarcinoma growth by suppressing glycolysis via the AKT/mTOR pathway. Chen, X; Deng, D; Hu, J; Li, L; Meng, Y; Qiu, Z; Wang, C; Wang, Q; Zhang, B; Zheng, G, 2023)	3.07
"Triptolide is an epoxidized diterpene lactone isolated from Tripterygium wilfordii. "	( Triptolide injection reduces Alzheimer's disease-like pathology in mice. Mao, R; Sun, G; Wang, Y; Xu, S; Yang, K; Yang, W; Yu, Y; Zhang, Z; Zuo, Z, 2023)	3.8
"Triptolide is a valuable multipotent antitumor diterpenoid in Tripterygium wilfordii, and its C-14 hydroxyl group is often selected for modification to enhance both the bioavailability and antitumor efficacy. "	( Tandemly duplicated CYP82Ds catalyze 14-hydroxylation in triptolide biosynthesis and precursor production in Saccharomyces cerevisiae. Gao, J; Gao, W; Hu, T; Huang, L; Li, D; Liu, Y; Lu, Y; Ma, L; Su, P; Tong, Y; Tu, L; Wang, J; Wu, X; Yin, Y; Zhang, Y; Zhao, H; Zhao, Y; Zhou, J, 2023)	2.6
"Triptolide (TRI) is an active diterpenoid lactone compound isolated from Tripterygium wilfordii,We focused on investigating the effect and mechanism of Triptolide (TRI) on liver injury."	( Toxicological mechanism of triptolide-induced liver injury: Caspase3-GSDME-mediated pyroptosis of Kupffer cell. Guo, L; Han, C; Kong, Y; Li, W; Pei, H; Sheng, Y; Wang, J; Yang, Y; Zhou, X, 2023)	2.65
"Triptolide is a latency-promoting agent (LPA) that inhibits HIV-1 transcription and replication; wogonin had a stronger ability to inhibit HIV-1 latent reactivation than triptolide."	( Wogonin inhibits latent HIV-1 reactivation by downregulating histone crotonylation. Cai, J; Deng, K; Deng, L; Hong, Z; Huang, T; Li, C; Xia, J; Zhang, H; Zhao, J; Zhou, J; Zhu, H, 2023)	1.63
"Triptolide (TP) is a highly active natural medicinal ingredient with significant potential in anticancer. "	( HnRNP A2/B1 as a potential anti-tumor target for triptolide based on a simplified thermal proteome profiling method using XGBoost. Chen, P; Hu, M; Lei, T; Li, L; Liu, B; Lu, C; Shi, J; Wang, L; Zhao, P, 2023)	2.61
"Triptolide (TPL) is a diterpenoid isolated from the traditional Chinese medicine Tripterygium wilfordii. "	( The roles of TPL in hematological malignancies. Ge, S; Liu, SB; Xu, T; Zhu, Y, 2023)	2.35
"Triptolide is a diterpene triepoxide extracted from Chinese medicine Tripterygium wilfordii Hook F, with potent immunosuppressive and anti-inflammatory properties."	( Triptolide regulates the balance of Tfr/Tfh in lupus mice. Guo, F; Ji, W; Liu, W; Lu, Y; Zhao, X, 2023)	3.07
"Triptolide (TP) is an important active compound from Tripterygium wilfordii Hook F (TwHF), however, it is greatly limited in clinical practice due to its severe toxicity, especially testicular injury. "	( Mitigation of triptolide-induced testicular Sertoli cell damage by melatonin via regulating the crosstalk between SIRT1 and NRF2. Huang, J; Huang, M; Huang, Z; Jiang, S; Jin, J; Qin, Z; Song, J; Zhang, G, 2023)	2.71
"Triptolide is a predominant active component of Triptergium wilfordii Hook. "	( Recent advances in the pharmacological applications and liver toxicity of triptolide. Cui, D; Fu, R; Liu, W; Ma, W; Tang, Y; Xu, D; Yan, C; Yue, S, 2023)	2.58
"Triptolide is a natural immunosuppressive agent with demonstrated effectiveness in ameliorating liver fibrosis, but whether it exerts anti-liver fibrotic effects via immunoregulation remains obscure."	( Triptolide attenuates CCL Feng, J; Jiang, S; Jiang, Y; Kong, J; Li, J; Li, X; Li, Y; Lian, H; Lu, Z; Zhang, F, 2023)	3.07
"Triptolide,which is a natural diterpenoid active ingredient derived from of Tripterygium wilfordii,as one of the highly active components,has anti-inflammatory,immunosuppressive,anti-tumor and other multiple effects."	( [Research progress on anti-tumor effects and mechanisms of triptolide and its combined application]. Chen, L; Fu, CM; Li, J; Li, JX; Luo, RF; Luo, YY; Shi, JF; Zhang, JM, 2019)	1.48
"Triptolide is an active ingredient isolated from an ancient Chinese herb (Tripterygium wilfordii Hook. "	( Triptolide induces atrophy of myotubes by triggering IRS-1 degradation and activating the FoxO3 pathway. Bao, Z; Gao, X; Huan, C; Lu, S; Ren, D; Wang, J; Yao, Y; Zhang, M; Zhang, P; Zheng, L; Zhou, J, 2020)	3.44
"Triptolide is a trace natural product of Tripterygium wilfordii. "	( Genome of Tripterygium wilfordii and identification of cytochrome P450 involved in triptolide biosynthesis. Gao, L; Gao, W; Hu, T; Huang, L; Jia, M; Liu, Y; Lu, Y; Peters, RJ; Song, Y; Su, P; Tong, Y; Tu, L; Wang, J; Xu, C; Yang, J; Zhang, Y; Zhang, Z; Zhao, Y; Zhou, J, 2020)	2.23
"Triptolide (TP) is a promising tumor suppressor extracted from the Chinese herb Tripterygium wilfordii."	( Triptolide interrupts rRNA synthesis and induces the RPL23‑MDM2‑p53 pathway to repress lung cancer cells. Cao, BB; Chen, JN; Gong, X; Li, FQ; Wang, J; Wang, W; Zhang, ZQ, 2020)	2.72
"Triptolide is a multi-functional natural small molecular compound extracted from a traditional Chinese medicinal herb. "	( Triptolide impairs genome integrity by directly blocking the enzymatic activity of DNA-PKcs in human cells. Cai, B; Hu, Z; Jiang, Y; Liu, B; Mao, Z; Tang, H; Wan, X; Xu, X, 2020)	3.44
"Triptolide (TPL) is a natural compound and active component of Tripterygium wilfordii Hook F., an Asian native woody vine widely used for over 200 years in Chinese medicine. "	( Therapeutic applications and delivery systems for triptolide. Bentley, MVLB; Kravicz, M; Praça, FG; Viegas, JSR, 2020)	2.25
"Triptolide (TP) is an anti-inflammatory molecule but its use to treat RA is limited due to poor solubility and extremely high toxicity."	( Construction of a pH-responsive, ultralow-dose triptolide nanomedicine for safe rheumatoid arthritis therapy. Han, H; Hou, T; Jin, J; Liang, Q; Liu, Y; Wang, C; Wang, Y; Xu, H; Yang, G; Yang, Y; Zhang, L; Zhang, W; Zhao, Y, 2021)	1.6
"Triptolide is a therapy derived from the thunder god vine that has shown potent anti-proliferative and immunosuppressive properties but exhibits significant adverse systemic effects."	( Systemic dendrimer delivery of triptolide to tumor-associated macrophages improves anti-tumor efficacy and reduces systemic toxicity in glioblastoma. Appiani La Rosa, S; Kannan, RM; Liaw, K; Salazar, S; Sharma, A; Sharma, R, 2021)	1.63
"The Triptolide (TP) is a natural anti-tumor drug with a world patent, but its target and mechanism are yet unknown."	( The Anti-Tumor Mechanism and Target of Triptolide Based on Network Pharmacology and Molecular Docking. Du, F; Hu, Y; Huang, Y; Ji, H; Kaboli, PJ; Li, M; Wang, S; Wu, M; Wu, X; Wu, Z; Xiao, Z; Zhao, Y; Zou, T, 2021)	1.37
"Triptolide (TPL) is a natural product isolated from the traditional Chinese herb which possesses potent anti-tumor activity in human cancers."	( Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ. Cai, J; Li, G; Li, X; Tan, Y; Xiang, B; Xiong, W; Yi, M; Zeng, Z, 2021)	1.69
"Triptolide is a major active compound found in Tripterygium wilfordii., also known as Thunder God Vine. "	( Supplementation with Triptolide Increases Resistance to Environmental Stressors and Lifespan in C. elegans. Beak, SM; Kim, SJ; Park, SK, 2017)	2.22
"Triptolide is a major active constituent isolated from Tripterygiumwilfordii Hook F, a Chinese herbal medicine. "	( STUDIES ON THE INTERACTION BETWEEN TRIPTOLIDE AND BOVINE SERUM ALBUMIN (BSA) BY SPECTROSCOPIC AND MOLECULAR MODELING METHODS. Pang, J; Shi, H; Song, X; Sun, Z; Wang, H; Xu, C, 2016)	2.15
"Triptolide (TP) is an active ingredient isolated from Tripterygium wilfordii Hook. "	( Glycyrrhetinic Acid Accelerates the Clearance of Triptolide through P-gp In Vitro. Cao, L; Fang, P; Guo, Z; Hou, Z; Li, Z; Yan, M; Zhang, B, 2017)	2.15
"Triptolide is a monomeric compound isolated from a traditional Chinese herb, which exerts protective roles in many kinds of glomerular diseases."	( Triptolide prevents extracellular matrix accumulation in experimental diabetic kidney disease by targeting microRNA-137/Notch1 pathway. Chang, B; Chang, Y; Chen, L; Han, F; Han, Z; Li, C; Sun, B; Wang, S; Yang, J, 2018)	2.64
"Triptolide is a principal diterpene triepoxide from the Chinese medical plant Tripterygium wilfordii Hook. "	( Triptolide suppresses growth and hormone secretion in murine pituitary corticotroph tumor cells via NF-kappaB signaling pathway. Hu, F; Huang, Y; Lei, T; Li, R; Sun, W; Wang, J; Xie, R; Zhang, Z, 2017)	3.34
"Triptolide is a vine extract used in traditional Chinese medicines and associated with hepatotoxicity. "	( Characterization of Triptolide-Induced Hepatotoxicity by Imaging and Transcriptomics in a Novel Zebrafish Model. Berends, C; Buckley, C; de Potter, CMJ; Dear, JW; Del Pozo, J; Mullins, JJ; Schneemann, S; Tucker, C; Vliegenthart, ADB; Webb, DJ; Wei, C, 2017)	2.22
"Triptolide (TP) is a diterpene triepoxide with various biological activities, but its clinical applications have been limited by potential hepatotoxicity, which can be attributed to T helper 17 (Th17)/T regulatory (Treg) cell imbalance. "	( Quercetin protects mouse liver against triptolide-induced hepatic injury by restoring Th17/Treg balance through Tim-3 and TLR4-MyD88-NF-κB pathway. Jiang, R; Tao, K; Wei, CB; Yuan, CS; Zhang, QH; Zhou, LD, 2017)	2.17
"Triptolide is an active component in traditional Chinese medicine Tripterygium wilfordii. "	( [Advanced progress of main pharmacology activities of triptolide]. Chen, X; Cui, J; Su, JC, 2017)	2.15
"Triptolide is a unique diterpene triepoxide that possesses potent antitumor activities.However, the effects and mechanism of triptolide on OS cells remain unknown."	( Triptolide induces mitochondrial apoptosis through modulating dual specificity phosphatase 1/mitogen-activated protein kinases cascade in osteosarcoma cells. Chen, Z; Li, J; Li, S; Ling, C; Miao, Y; Qin, W; Shi, Q; Wang, J; Wang, Y, )	2.3
"Triptolide (TP) is a diterpenoid triepoxide extracted from the traditional Chinese medical herb Tripterygium wilfordii that exerts prominent broad-spectrum anticancer activity to repress proliferation and induce cancer cell apoptosis through various molecular pathways. "	( ITRAQ-Based Proteomics Analysis of Triptolide On Human A549 Lung Adenocarcinoma Cells. Jin, X; Li, F; Liu, Q; Wang, J; Wang, W; Yang, S; Zhao, D, 2018)	2.2
"Triptolide is an active component from a Chinese herb, Tripterygium wilfordii which has been applied for treating immune-related diseases over centuries. "	( Triptolide sensitizes breast cancer cells to Doxorubicin through the DNA damage response inhibition. Deng, Y; He, P; Li, F; Li, Q; Liu, J; Mei, X; Shu, Z; Tong, Y; Yang, J; Yang, Y; Zhang, Y; Zhao, Q, 2018)	3.37
"Triptolide is a structurally unique diterpene triepoxide with potent antitumor activity. "	( C-Myc-dependent repression of two oncogenic miRNA clusters contributes to triptolide-induced cell death in hepatocellular carcinoma cells. Chen, Z; Li, SG; Ling, CQ; Miao, YQ; Qin, LP; Qin, WX; Shi, QW; Wang, Y; Yuan, LY, 2018)	2.15
"Triptolide is a major active ingredient of tripterygium glycosides, used for the therapy of immune and inflammatory diseases. "	( Triptolide-induced mitochondrial damage dysregulates fatty acid metabolism in mouse sertoli cells. Chen, G; Cheng, Y; Huang, Z; Kong, J; Pan, J; Shen, F; Wang, L; Xi, Y, 2018)	3.37
"Triptolide (TP) is a bioactive compound derived from Tripterygium wilfordii Hook F, which has been used in folk medicine as a treatment for a variety of inflammatory disorders, including RA, for many centuries."	( Triptolide inhibits the inflammatory activities of neutrophils to ameliorate chronic arthritis. Huang, G; Lu, Q; Luo, G; Sheng, H; Xu, A; Yu, R; Yuan, K; Zhang, S; Zhu, M; Zhu, Q, 2018)	2.64
"Triptolide is a major active component of Tripterygium wilfordii Hook F that exhibits potent antiproteinuric effects."	( Triptolide attenuates proteinuria and podocyte apoptosis via inhibition of NF-κB/GADD45B. Chen, Z; Hou, Q; Liu, Z; Wang, L; Zhang, L; Zhu, X, 2018)	2.64
"Triptolide is a natural product extracted from Tripterygium and shows anti-cancer activities."	( Triptolide inhibits Epstein-Barr nuclear antigen 1 expression by increasing sensitivity of mitochondria apoptosis of nasopharyngeal carcinoma cells. Liu, L; Liu, Y; Long, C; Sun, X; Wang, C; Wang, H; Zhang, Y; Zhou, H, 2018)	2.64
"Triptolide is a natural compound isolated from the Tripterygium wilfordii, which possesses anti-inflammatory and anti-tumor activities. "	( Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin. Cao, X; Chi, X; Gao, X; Ji, J; Liu, L; Mao, W; Sun, C; Wang, Y; Yang, Y; Zhang, L; Zhang, Z; Zhao, Z, 2019)	3.4
"Triptolide is a biologically active component of the Chinese antirheumatic herbal remedy Tripterygium wilfordii Hook F, which has been shown to be effective in treating murine lupus. "	( Triptolide ameliorates lupus via the induction of miR-125a-5p mediating Treg upregulation. Chen, H; Li, Z; Song, H; Sun, L; Tang, X; Wang, D; Yan, Q; Zhao, X, 2019)	3.4
"Triptolide (TPL) is an epoxy diterpenoid lactone compound extracted from Tripterygium wilfordii HOOK."	( Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway. Guo, L; Jiang, P; Li, Y; Tong, X; Yan, M; Zhang, BK; Zhang, HM, 2019)	1.54
"Triptolide is a major active ingredient isolated from the traditional Chinese herb "	( Autophagy in Triptolide-Mediated Cytotoxicity in Hepatic Cells. Chang, YX; Liu, BW; Luan, ZH; Ren, JH; Wang, YH; Wei, YM; Xue, HQ, )	1.94
"Triptolide(T9) is a predominant bioactive component extracted from Chinese herb Tripterygium wilfordii Hook F. "	( Triptriolide antagonizes triptolide-induced nephrocyte apoptosis via inhibiting oxidative stress in vitro and in vivo. Han, XD; Liu, B; Liu, XS; Lu, ZY; Mao, W; Tian, RM; Wang, XW; Xu, HT; Xu, P; Yang, YQ, 2019)	2.26
"Triptolide is an immunosuppressive fraction purified from a Chinese medicinal plant. "	( Immunosuppression with a combination of triptolide and cyclosporin A in rat vascularized groin flap allotransplantation. Lan, S; Levin, LS; Liu, F; Luo, X; Wang, S; Yang, J; Zhang, X, 2013)	2.1
"Triptolide (TPL) is a purified diterpenoid isolated from the Chinese herb Tripterygium wilfordii Hook F that has shown antitumor activities in various cancer cell types."	( Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase. Hua, ZC; Li, J; Lin, Y; Peng, N; Zhuang, H, 2013)	1.46
"Triptolide (TPL) is a diterpenoid triepoxide derived from the Chinese herb Tripterygium wilfordii and possesses anti-tumor activity against a range of cancer cells. "	( Triptolide inhibits the multidrug resistance in prostate cancer cells via the downregulation of MDR1 expression. Guo, Q; Hu, SB; Liang, BL; Luo, Y; Nan, XX; Wei, YB; Xu, YF; Yang, JR; Yi, L; Zhang, H; Zhu, N, 2013)	3.28
"Triptolide (TPL) is an active component extracted from the traditional Chinese herbal medicine Tripterygium wilfordii Hook F that has shown antitumor activities in various cancer cell types."	( Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180. Hua, ZC; Lin, Y; Lu, M; Yang, X; Zhang, J; Zheng, W; Zhuang, H, 2013)	1.46
"Triptolide (TP) is a major active component in Tripterygium root, but its therapeutic window was very narrow due to its severe multi-organ toxicity. "	( In vivo effect of triptolide combined with glycyrrhetinic acid on rat cytochrome P450 enzymes. Chen, Y; Han, FM; Peng, ZH; Wang, JJ, 2013)	2.17
"Triptolide is a diterpene triepoxide natural product isolated from Tripterygium wilfordii Hook F, a traditional Chinese medicinal herb. "	( Design, synthesis and structure-activity relationships studies on the D ring of the natural product triptolide. Feng, H; Li, Y; Tang, H; Xu, H, 2014)	2.06
"Triptolide is a diterpenoid epoxide isolated from the herb Tripterygium wilfordii, which has long been used as a natural medicine in China for many diseases including cancer. "	( Triptolide sensitizes liver cancer cell lines to chemotherapy in vitro and in vivo. Hu, S; Li, Y, 2014)	3.29
"Triptolide (TP) is a biologically active diterpene triepoxide from the Chinese herb Tripterygium wilfordii Hook f. "	( TAB1: a target of triptolide in macrophages. Ding, S; Feng, X; Li, J; Li, L; Lu, Y; Shen, P; Zhang, Y; Zheng, W, 2014)	2.18
"Triptolide (TPL) is a major active component isolated from the natural herb Tripteryglum wilfordii Hook. "	( Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo. Li, G; Liu, Y; Xiao, E; Yuan, L, 2014)	3.29
"Triptolide is a traditional Chinese medicinal herb-derived antineoplastic agent. "	( Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas. Ding, H; Fu, T; Gong, X; Li, JM; Li, QQ; Lu, Y; Ma, Y; Wang, L; Weintraub, M; Wu, J; Wu, S; Zhou, H, 2014)	2.13
"Triptolide (TP) is an active component of Tripterygium wilfordii Hook. "	( Role of CYP3A in regulating hepatic clearance and hepatotoxicity of triptolide in rat liver microsomes and sandwich-cultured hepatocytes. Kong, L; Li, H; Shen, G; Tan, Y; Xiao, W; Zhuang, X, 2014)	2.08
"Triptolide is a diterpenoid epoxide isolated from Tripterygium wilfordii Hook F that possesses a broad range of bioactivities, including anti-inflammatory, immunosuppressive and anti-tumor properties."	( Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein. Chen, X; Wan, Z, 2014)	2.57
"Triptolide is a diterpene triepoxide, extracted from the Chinese herb Tripterygium wilfordii Hook F, which has been shown to have antitumor activity in a number of cancers. "	( Triptolide inhibits cell proliferation and tumorigenicity of human neuroblastoma cells. Cui, H; Hu, R; Huang, M; Ke, XX; Yan, X; Zhao, H, 2015)	3.3
"Triptolide (PG490) is an active compound of the medicinal herb Tripterygium wilfordii Hook F (TWHF) or Lei Gong Teng with known anti-inflammatory properties."	( Triptolide inhibits osteoclast formation, bone resorption, RANKL-mediated NF-қB activation and titanium particle-induced osteolysis in a mouse model. Ang, ES; Chim, SM; Ding, Y; Feng, H; Huang, J; Liu, Q; Pavlos, N; Tan, RX; Tickner, J; Wu, H; Xu, J; Xue, W; Ye, J; Zhao, J; Zhou, L, 2015)	2.58
"Triptolide is a compound of Tripterygium extracts, showing anti-inflammatory, immunosuppressive, and anti-cancer activities."	( Triptolide inhibits proliferation of Epstein-Barr virus-positive B lymphocytes by down-regulating expression of a viral protein LMP1. Guo, W; Long, C; Sun, X; Wang, H; Wang, J; Zhou, H, 2015)	2.58
"Triptolide is a natural compound extracted from the traditional Chinese medicine Tripterygium wilfordii Hook F with distinguishing pharmacological activities and evident toxicities. "	( Gender Differences in the Toxicokinetics of Triptolide after Single- and Multiple-dose Administration in Rats. Jiang, Z; Ju, W; Liu, L; Wang, T; Wang, Z; Xu, D; Zhang, J; Zhang, L, 2015)	2.12
"Triptolide (TPL) is a diterpene triepoxide with potent immunosuppressive and anti-inflammatory properties. "	( Triptolide alleviates isoprenaline-induced cardiac remodeling in rats via TGF-β1/Smad3 and p38 MAPK signaling pathway. Chen, J; Huang, D; Huang, Y; Ke, J; Li, L; Liu, M; Wu, W, 2015)	3.3
"Triptolide is a therapeutic diterpenoid derived from the Chinese herb Tripterygium wilfordii Hook f. "	( Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity. Bhise, N; Chauhan, L; Feldberg, T; Fridley, BL; Jenkins, GD; Lamba, JK; Mitra-Ghosh, T, 2015)	2.07
"Triptolide (TP) is a diterpene triepoxide with variety biological activities, such as anti-inflammatory, anti-cancerogenic, immunomodulatory and pro-apoptotic activities. "	( Protection of Quercetin against Triptolide-induced apoptosis by suppressing oxidative stress in rat Leydig cells. Chen, X; Gao, P; Hu, J; Ji, J; Jiang, Z; Ren, Y; Shao, S; Yan, M; Yu, Q; Zhang, L; Zhao, F, 2015)	2.14
"Triptolide is an extract from Tripterygium wilfordii used in traditional Chinese medicine to treat autoimmune disorders. "	( Triptolide Inhibits Lung Cancer Cell Migration, Invasion, and Metastasis. Kim, JY; Raz, DJ; Reno, TA, 2015)	3.3
"Triptolide is a bioactive component of Chinese herbal plant Tripterygium wilfordii Hook F that has recently been noted to attenuate hepatic and cerebral ischemia/reperfusion (I/R) injuries in rodents. "	( Triptolide Attenuates Myocardial Ischemia/Reperfusion Injuries in Rats by Inducing the Activation of Nrf2/HO-1 Defense Pathway. Gao, Y; Qi, G; Shi, L; Sun, Y; Yu, H; Zhao, S, 2016)	3.32
"Triptolide is an active component derived from Tripterygium wilfordii and it possesses numerous pharmacological activities. "	( Inhibitory Effects of Triptolide on Human Liver Cytochrome P450 Enzymes and P-Glycoprotein. Rui, H; Ya, G; Zhang, H, 2017)	2.21
"Triptolide (T10) is a monomeric compound isolated from a traditional Chinese herb."	( Triptolide Promotes the Clearance of α-Synuclein by Enhancing Autophagy in Neuronal Cells. Fu, X; Gong, X; Hu, G; Liu, M; Liu, Y; Wang, L; Wang, W; Wang, X; Zhang, T, 2017)	2.62
"Triptolide is a most important active ingredient extracted from traditional Chinese medicine Tripterygium, which has been widely used to treat glomerulonephritis as well as immune-mediated disorders, likely for its immunosuppressive, anti-proliferative and anti-inflammatory effects."	( Protective effects of triptolide on TLR4 mediated autoimmune and inflammatory response induced myocardial fibrosis in diabetic cardiomyopathy. Chang, BC; Chen, LM; Guo, X; Li, CJ; Ma, ZJ; Wang, SS; Wang, XY; Xue, M; Yang, W; Zhang, XN; Zhao, R, 2016)	2.19
"Triptolide, is a main and effective component of Tripterygium wilfordii Hook F, which exerts an broad-spectrum anti-malignant tumor function."	( Triptolide inhibits the migration and invasion of human prostate cancer cells via Caveolin-1/CD147/MMPs pathway. Chen, X; Fan, B; Wang, L; Wang, S; Yang, D; Yuan, Q; Yuan, S; Zhang, H, 2016)	2.6
"Triptolide (TPL) is an active compound extracted from a Chinese herbal medicine tripterygium wilfordii Hook. "	( Triptolide Suppresses Alkali Burn-Induced Corneal Angiogenesis Along with a Downregulation of VEGFA and VEGFC Expression. Ahmed, N; Li, N; Li, X; Liu, H; Lv, X; Ma, J; Wang, G; Zhang, Y, 2017)	3.34
"Triptolide (TPL) is a purified diterpenod isolated from the Chinese herb, Tripterygium wilfordii Hook."	( Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells. Huang, J; Jin, J; Pan, HZ; Yang, M, 2008)	2.51
"Triptolide (TP) is a major active component of Tripterygium wilfordii Hook F (TWHF), which is used to treat rheumatoid arthritis (RA). "	( In vivo evaluation of the safety of triptolide-loaded hydrogel-thickened microemulsion. Chen, H; Chen, Q; Pan, J; Qiu, Y; Xu, H; Xu, L; Yang, X; Yu, Q, 2008)	2.06
"Triptolide is a key anti-inflammatory compound of the Chinese herbal medicine Tripterygium wilfordii Hook. "	( Triptolide functions as a potent angiogenesis inhibitor. But, PP; Ge, W; He, MF; Huang, YH; Shaw, PC; Wu, LW, 2010)	3.25
"Triptolide is a purified component from a traditional Chinese herb Tripterygium wilfordii Hook F. "	( The effect of triptolide on CD4+ and CD8+ cells in the Peyer's patch of DA rats with collagen induced arthritis. Chan, A; Chen, S; Liu, Z; Lu, AP; Lu, C; Tang, JC; Xiao, C; Yang, D; Zhao, L; Zhao, N, 2009)	2.16
"Triptolide is a potent inhibitor of colon cancer proliferation and migration in vitro. "	( Triptolide inhibits proliferation and migration of colon cancer cells by inhibition of cell cycle regulators and cytokine receptors. Evers, BM; Johnson, SM; Wang, X, 2011)	3.25
"Triptolide is a biologically active component purified from Chinese herbal plant Tripterygium wilfordii Hook F. "	( Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer-binding protein alpha. Ma, X; Zhang, Y, 2010)	3.25
"Triptolide T10 is a monomeric compound isolated from tripterygium wilfordii Hook.f."	( Triptolide T10 enhances AAV-mediated gene transfer in mice striatum. Ding, W; Hu, J; Ren, X; Wang, X; Zhang, T, 2010)	2.52
"Triptolide (TPT) is a diterpenoid triepoxide extracted from the Chinese herb Tripterygium wilfordii Hook. "	( Triptolide prolonged allogeneic islet graft survival in chemically induced and spontaneously diabetic mice without impairment of islet function. Cui, SH; Li, F; Liu, S; Luo, B; Sun, HC; Sun, JB; Xin, MJ, 2010)	3.25
"Triptolide is an active component of extracts derived from the medicinal vine Tripterygium Wilfordii Hook. "	( Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and down-regulation of IL-17. Li, JS; Li, N; Li, Y; Qi, X; Xie, Y; Yu, C; Zhu, WM, 2010)	3.25
"Triptolide is a compound isolated from the traditional Chinese medicinal herb Tripterygium wilfordii that shows potent anti-tumor activities, but its effects on acute myeloid leukemia with t(8;21) remain unclear. "	( Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells. Chen, XQ; Fang, HT; Hu, AM; Hu, Z; Pan, XF; Xu, L; Zhang, FX; Zhou, GB; Zhou, GS, 2011)	2.13
"Triptolide (1) is a structurally unique diterpene triepoxide isolated from a traditional Chinese medicinal plant with anti-inflammatory, immunosuppressive, contraceptive and antitumor activities. "	( XPB, a subunit of TFIIH, is a target of the natural product triptolide. Bhat, S; Dang, Y; Demain, AL; Gilman, B; Goodrich, JA; He, QL; Kugel, JF; Liu, JO; Low, WK; Miller, PS; Smeaton, M; Titov, DV, 2011)	2.05
"Triptolide is a major component of the herb Tripterygium wilfordii Hook f, extracts of which are used in traditional Chinese medicine, and it has been found to possess immunosuppressive and anti-inflammatory properties. "	( Inhibition of poly(I:C)-induced matrix metalloproteinase expression in human corneal fibroblasts by triptolide. Kimura, K; Nishida, T; Nomi, N; Orita, T; Yan, ZH, 2011)	2.03
"Triptolide is an extract from the herb Tripterygium wilfordii Hook F, and has been used in Chinese medicine for over two centuries and is now used to treat certain autoimmune diseases, such as rheumatoid arthritis."	( Does triptolide induce lysosomal-mediated apoptosis in human breast cancer cells? Halaby, R; Messina, ME, 2011)	1.6
"Triptolide is a potent immunosuppressive drug capable of inhibiting T cell activation and proliferation. "	( Intrathecal administration of triptolide, a T lymphocyte inhibitor, attenuates chronic constriction injury-induced neuropathic pain in rats. Hu, JY; Li, CL; Wang, YW, 2012)	2.11
"Triptolide is a diterpenoid triepoxide derived from the traditional Chinese medical herb Tripterygium wilfordii. "	( Triptolide inhibits colon cancer cell proliferation and induces cleavage and translocation of 14-3-3 epsilon. He, M; Jiang, Y; Li, H; Liu, Y; Peng, K; Song, F; Sun, X; Wu, WK; Yang, Y; Zhao, L, 2012)	3.26
"Triptolide (TPL) is a diterpenoid triepoxide that effectively induces apoptosis in a wide variety of cancer cells. "	( Triptolide triggers the apoptosis of pancreatic cancer cells via the downregulation of Decoy receptor 3 expression. Hong, B; Li, X; Lv, G; Sun, W; Wang, W; Zhang, L; Zhang, M, 2012)	3.26
"Triptolide is a major active ingredient of the Chinese herb Tripterygium wilfordii Hook f. "	( Role of Nrf2 in protection against triptolide-induced toxicity in rat kidney cells. Guan, C; Huang, M; Huang, Z; Jin, J; Li, J; Li, M; Qiu, Y; Wang, W; Zhu, S, 2012)	2.1
"Triptolide is a bioactive ingredient in traditional Chinese medicine that exhibits diverse biologic properties, including anticancer properties. "	( Natural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase II. Capranico, G; Ding, J; He, JX; Li, YC; Manzo, SG; Marinello, J; Miao, ZH; Wang, YQ; Zhou, ZL, 2012)	2.17
"Triptolide is a potent immunosuppressive compound isolated from an anti-inflammatory Chinese herbal medicine."	( Triptolide attenuates idiopathic pneumonia syndrome in a mouse bone marrow transplantation model by down-regulation of IL-17. Su, Y; Xiong, M; Xu, X; Xu, Y; Zhou, H; Zou, P, 2012)	2.54
"Triptolide (PG490) is a natural, biologically active compound extracted from the Chinese herb Tripterygium wilfordii. "	( Triptolide inhibits murine-inducible nitric oxide synthase expression by down-regulating lipopolysaccharide-induced activity of nuclear factor-kappa B and c-Jun NH2-terminal kinase. Choi, SW; Kim, YH; Kwon, TK; Lee, JY; Lee, SH; Park, JW, 2004)	3.21
"Triptolide is a purified component from a traditional Chinese herb Tripterygium wilfordii Hook F. "	( Triptolide affects the differentiation, maturation and function of human dendritic cells. Cheng, H; Hao, GL; Lao, LM; Mao, XH; Shen, QY; Zhu, KJ, 2005)	3.21
"Triptolide (TPT) is a chemically defined, potent immunosuppressive compound isolated from an anti-inflammatory Chinese herbal medicine. "	( Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. Chen, X; Howard, OM; Murakami, T; Oppenheim, JJ, 2005)	3.21
"Triptolide is a natural, biologically active compound extracted from the Chinese herb Tripterygium Wilfordii hook, that possesses potent immunosuppressive properties. "	( Triptolide attenuates oxidative stress, NF-kappaB activation and multiple cytokine gene expression in murine peritoneal macrophage. Bao, X; Chan, S; Cui, J; Liu, D; Shen, P; Wu, Y; Young, DO, 2006)	3.22
"Triptolide is a compound extracted from the Chinese herb Tripterygium wilfordii Hook. "	( Mechanism of triptolide-induced apoptosis: Effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide. Liu, Y; Matta, R; Nelin, LD; Pei, D; Shen, G; Wang, X, 2006)	2.15
"Triptolide is a purified component from a traditional Chinese herb Tripterygium wilfordii Hook F. "	( The effect of triptolide on CD4+ and CD8+ cells in Peyer's patch of SD rats with collagen induced arthritis. Chan, AS; Jia, H; Lu, AP; Lu, C; Tang, JC; Xiao, C; Yang, D; Zhao, L; Zhao, N; Zhou, J, 2006)	2.14
"Triptolide is a potent immunosuppressant."	( [Progress in research on mechanisms of anti-rheumatoid arthritis of triptolide]. Lin, N; Liu, CF, 2006)	1.29
"Triptolide is a potential anti-immune agent, and has shown multi-organic toxicity, however its toxic mechanism remained undiscovered. "	( Pharmacokinetic study of triptolide, a constituent of immunosuppressive chinese herb medicine, in rats. A, J; Shao, F; Sun, J; Wang, G; Xie, H; Zhu, X, 2007)	2.09
"Triptolide is a naturally occurring diterpene triepoxide whose anti-inflammatory effects correlate with transcriptional inhibition of various cytokines. "	( Triptolide binds covalently to a 90 kDa nuclear protein. Role of epoxides in binding and activity. Gurnett, A; Kwon, S; Leavitt, P; Liu, W; McCallum, C; Shen, DM, 2007)	3.23
"Triptolide is a potential therapeutic agent that can be used to prevent the progression and metastases of pancreatic cancer."	( Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Borja-Cacho, D; Dawra, RK; Dudeja, V; Grizzle, WE; McCarroll, JA; Phillips, PA; Saluja, AK; Vickers, SM, 2007)	2.5
"Triptolide (TPT) is a component of the Chinese herb Triptergium wilfordii and has potent immunosuppressive and anti-inflammatory effects. "	( Triptolide, a component of Chinese herbal medicine, modulates the functional phenotype of dendritic cells. Chen, Y; Lamb, JR; Liu, Y; Tam, PK, 2007)	3.23
"Triptolide appeared to be a potent immunomodulatory inhibitor of CIA in rats and this may account for the previously observed anti-rheumatic properties of crude extracts of TWHf, although more extensive studies will be needed to confirm these effects."	( Inhibition of type II collagen-induced arthritis in rats by triptolide. Brandwein, SR; Gu, WZ, 1998)	1.26
"Triptolide is an oxygenated diterpene that is derived from a traditional Chinese herb that has potent immunosuppressive and antitumor activity."	( PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis. Gao, M; Krishna, G; Liu, K; Raffin, TA; Rosen, GD; Shigemitsu, H, 2001)	1.33
"Triptolide is a potent inhibitor of NF-kappa B activation in T lymphocyte and this effect is partly due to the upregulation of I kappa B alpha mRNA expression."	( Triptolide: a potent inhibitor of NF-kappa B in T-lymphocytes. Chen, ZH; Li, LS; Liu, H; Liu, ZH; Yang, JW, 2000)	3.19
"Triptolide is a diterpenoid triepoxide purified from a Chinese herb Tripterygium Wilfordii Hook F (TWHF). "	( Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Chen, BJ, 2001)	3.2
"Triptolide is a potent inhibitor of VEGF expression and production in endothelial cells. "	( Triptolide inhibits vascular endothelial growth factor expression and production in endothelial cells. Guo, XH; Hu, KB; Li, LS; Liu, D; Liu, ZH, 2001)	3.2
"Triptolide is a potent inhibitor of VEGF expression and production, suggesting that the inhibitory influence of triptolide on VEGF expression and production may be one of the mechanisms underlying its anti-proteinuric effect on glomerular nephritis. "	( [Triptolide inhibits vascular endothelial growth factor expression and production by endothelial cells]. Hu, K; Liu, D; Liu, Z, 2001)	2.66
"Triptolide (Tri) is a diterpenoid triepoxide isolated from Tripterygium wilfordii Hook F. "	( Inhibitory effect of triptolide on colony formation of breast and stomach cancer cell lines. Adachi, I; Wei, YS, 1991)	2.04
"Triptolide (Tri) is an active principle of Tripterygium hypoglaucum Hutch, which has been used to treat cancers and autoimmune diseases in folk medicine. "	( [Effects of triptolide on T lymphocyte functions in mice]. Pu, LX; Zhang, TM, 1990)	2.1

Excerpt	Reference	Relevance
"Triptolide has a protective effect on cardiovascular damage in a dose-dependent manner in endotoxemia rats,probably through TLR4/NF-κB p65 signaling pathway to improve endothelial function."	( [TLR4/NF-kappaB p65 signaling pathway mediates protective effect of triptolide on endothelium in rats with endotoxemia]. Diao, GH; Guo, MD; Su, P; Sun, BB; Wang, HH; Wang, J; Wang, SY; Zong, JQ, 2019)	1.47
"Triptolide (TP) has an anti-proteinuric effect and is used for the treatment of podocytopathies. "	( Differential toxicities of triptolide to immortalized podocytes and the podocytes in vivo. Liu, Z; Shi, S; Song, H; Sun, M; Wang, J; Xu, X; Yang, Q; Ye, Y; Zhang, J; Zhu, X, 2019)	2.25
"Triptolide has an notable inhibiting effect on proliferation of RA-HFLS and the molecule mechanism is due in part to the direct suppression of abnormal activation of Ras-MAPKs pathway."	( [Effects of triptolide on cell proliferation and regulation of Ras-MAPKs pathway in synoviocytes induced by tumor necrosis factor]. Kong, X; Lian, J; Lin, N; Wang, J, 2010)	2.18
"Triptolide has a long history in traditional Chinese medicine for treating inflammatory diseases and has been proven to inhibit cytokines released from glial cells."	( Triptolide prevents and attenuates neuropathic pain via inhibiting central immune response. Chen, L; Li, JL; Li, YQ; Mei, XP; Tang, J; Wang, W; Wu, SX; Xu, LX, )	2.3
"Triptolide has attracted attention to be used in ADC development."	( Site-specific construction of triptolide-based antibody-drug conjugates. Chen, H; Chen, J; Jiang, B; Li, J; Mao, Y; Wei, D; Xu, Z, 2021)	1.63
"Triptolide (TP) has anti-inflammatory properties, and it can protect the cartilage matrix, but its clinical application has been limited due to poor solubility, low bioavailability and systemic toxicity."	( Folate-modified triptolide liposomes target activated macrophages for safe rheumatoid arthritis therapy. Geng, HX; Guo, RB; Kong, L; Li, XT; Liu, Y; Wang, YJ; Wu, YN; Yan, DK; Yu, YJ; Zhang, XY, 2022)	1.79
"Triptolide (TP) has limited usage in clinical practice due to its side effects and toxicity, especially liver injury. "	( Triptolide Induces Liver Injury by Regulating Macrophage Recruitment and Polarization via the Nrf2 Signaling Pathway. Huang, X; Jiang, ZZ; Liu, L; Mohammed, I; Sun, LX; Wang, T; Wang, XZ; Xing, X; Xu, XT; Zhang, LY; Zhang, X, 2022)	3.61
"Triptolide (TP) has its unique curative effect in the treatment of rheumatoid arthritis (RA), but its application is limited by the poor water solubility and multi-organ toxicity. "	( Triptolide and l-ascorbate palmitate co-loaded micelles for combination therapy of rheumatoid arthritis and side effect attenuation. Jiang, M; Li, M; Wang, G; Wang, Z; Wu, X; Yan, Y; Zeng, H; Zhang, Z, 2022)	3.61
"Triptolide (TP) has demonstrated innumerous biological effects and pharmacological potential against different cancer types. "	( Triptolide Inhibits the Biological Processes of HUVECs and HepG2 Cells via the Serine Palmitoyltransferase Long Chain Base Subunit 2/Sphingosine-1-Phosphate Signaling Pathway. Huang, L; Huang, S; Jia, L; Luo, Y; Su, H; Tan, Q; Xiao, J; Xu, S; Zhu, M; Zhu, S, 2022)	3.61
"Triptolide might also has effect on immune response through inhibiting proliferating GC B cells."	( Triptolide regulates the balance of Tfr/Tfh in lupus mice. Guo, F; Ji, W; Liu, W; Lu, Y; Zhao, X, 2023)	3.07
"Triptolide has a protective effect on cardiovascular damage in a dose-dependent manner in endotoxemia rats,probably through TLR4/NF-κB p65 signaling pathway to improve endothelial function."	( [TLR4/NF-kappaB p65 signaling pathway mediates protective effect of triptolide on endothelium in rats with endotoxemia]. Diao, GH; Guo, MD; Su, P; Sun, BB; Wang, HH; Wang, J; Wang, SY; Zong, JQ, 2019)	1.47
"Triptolide (TP) has broad anti-inflammatory and anti-tumor activities, but its clinical application is limited due to hepatotoxicity."	( Metabolic profiling of 19 amino acids in triptolide-induced liver injured rats by gas chromatography-triple quadrupole mass spectrometry. Hu, C; Ke, J; Li, H; Tang, X; Wu, L; Xiong, Y; Yu, X, 2021)	1.61
"Triptolide (TPL) has been employed to treat hepatocellular carcinoma (HCC). "	( γ-Cyclodextrin metal-organic framework as a carrier to deliver triptolide for the treatment of hepatocellular carcinoma. Gong, C; Li, Z; Wang, J; Wang, R; Wang, Y; Yang, G; Yang, M; Yuan, Y, 2022)	2.4
"Triptolide has wide clinical applications due to its anti-inflammatory, anti-tumor and immunosuppressive activities. "	( [Effect of isopentenyl pyrophosphate translocation on the biosynthesis of triptolide]. Gao, H; Gao, W; Liu, Y; Wu, X; Xia, M; Zhang, Y, 2021)	2.29
"Triptolide has been shown to have anti-inflammatory and anticancer activities."	( Supplementation with Triptolide Increases Resistance to Environmental Stressors and Lifespan in C. elegans. Beak, SM; Kim, SJ; Park, SK, 2017)	1.5
"Triptolide (TP) has been used as one of the most common systemic treatments for various diseases since the 1960s. "	( Synthesis, Characterization, and Evaluation of Triptolide Cell-Penetrating Peptide Derivative for Transdermal Delivery of Triptolide. Li, K; Song, Y; Sun, Y; Tian, T; Wang, Q, 2018)	2.18
"Triptolide has been widely reported to exhibit potential therapeutic value in multiple inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis. "	( Triptolide prevents osteoarthritis via inhibiting hsa-miR-20b. Qian, K; Shi, K; Zhang, L, 2019)	3.4
"Triptolide has proven to possess anticancer potential and been widely used for anti-cancer research. "	( Co-Delivery of Triptolide and Curcumin for Ovarian Cancer Targeting Therapy via mPEG-DPPE/CaP Nanoparticle. Duan, Y; Gao, P; Huang, C; Li, H; Liu, L; Ru, D; Shen, M; Sun, Y; Xiong, X; Zhang, X, 2018)	2.28
"Triptolide (TPL) has been reported to be a potential anticancer agent."	( Triptolide inhibits benign prostatic epithelium viability and migration and induces apoptosis via upregulation of microRNA-218. Li, H; Yao, C; Zhang, W, )	2.3
"Triptolide (TP) has an anti-proteinuric effect and is used for the treatment of podocytopathies. "	( Differential toxicities of triptolide to immortalized podocytes and the podocytes in vivo. Liu, Z; Shi, S; Song, H; Sun, M; Wang, J; Xu, X; Yang, Q; Ye, Y; Zhang, J; Zhu, X, 2019)	2.25
"Triptolide has been indicated potent anti-cancer effect involving multiple molecular targets and signaling pathways. "	( Triptolide Suppresses Growth of Breast Cancer by Targeting HMGB1 in Vitro and in Vivo. Chen, M; Jiang, W; Liang, Z; Liao, X; Mao, A; Qin, Q; Tan, Q; Wei, C; Xiao, C; Yang, W, 2019)	3.4
"Triptolide (TP) has outstanding biological activities, but it induces toxicities, particular hepatotoxicity, severely limiting its clinical application. "	( In vivo protective effects of chlorogenic acid against triptolide-induced hepatotoxicity and its mechanism. Chen, RX; Cheng, YX; Cui, Y; Ding, NN; Liu, C; Wang, JM; Zhang, LL, 2018)	2.17
"Triptolide has been proven to possess anticancer efficacy; however, its application in the clinical practice was limited by poor water solubility, hepatotoxicity, and nephrotoxicity. "	( The Effect of Triptolide-Loaded Exosomes on the Proliferation and Apoptosis of Human Ovarian Cancer SKOV3 Cells. Ding, C; Duan, Y; Li, H; Liu, H; Ru, D; Shen, M, 2019)	2.32
"Triptolide has been shown to exert various pharmacological effects on systemic autoimmune diseases and cancers. "	( Dysregulation of lncRNA and circRNA Expression in Mouse Testes after Exposure to Triptolide. Cai, Y; Li, Y; Peng, N; Shen, C; Song, D; Wang, X; Xiang, Y; Xiong, S; Zeng, X; Zhang, P; Zhang, X, 2019)	2.18
"Triptolide has potent anti-inflammatory and anti-proliferative properties, and extensively used in the treatment of chronic inflammatory disorders."	( Triptolide protects rat heart against pressure overload-induced cardiac fibrosis. Ding, Y; Dong, Z; Gong, K; Ni, Y; Qin, J; Qu, X; Sun, H; Yan, X; Zhang, K; Zhang, Z; Zhao, P, 2013)	2.55
"Triptolide has previously been shown to possess antitumor, anti-inflammatory, immunosuppressive, and antifertility activities."	( Design, synthesis and structure-activity relationships studies on the D ring of the natural product triptolide. Feng, H; Li, Y; Tang, H; Xu, H, 2014)	1.34
"Triptolide has been reported to cause antifertility in male rats and mice. "	( Effect of triptolide on reproduction of female lesser bandicoot rat, Bandicota bengalensis. Dhar, P; Singla, N, 2014)	2.25
"Triptolide has profound antitumor effect on CCA, probably by inducing apoptosis through inhibition of Mcl-1. "	( Triptolide induces apoptotic cell death of human cholangiocarcinoma cells through inhibition of myeloid cell leukemia-1. Ding, X; Huang, S; Lv, Y; Pan, J; Pei, Q; Yang, Y; Zhang, B; Zhu, Z; Zou, X, 2014)	3.29
"Triptolide has been reported to exhibit antitumor effects in several cancers. "	( Triptolide induces apoptosis of gastric cancer cells via inhibiting the overexpression of MDM2. Cao, J; Chen, JW; Liu, QY; Wang, BY, 2014)	3.29
"Triptolide has been shown to induce apoptosis by activation of pro-apoptotic proteins, inhibiting NFkB and c-KIT pathways, suppressing the Jak2 transcription, activating MAPK8/JNK signaling and modulating the heat shock responses."	( Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity. Bhise, N; Chauhan, L; Feldberg, T; Fridley, BL; Jenkins, GD; Lamba, JK; Mitra-Ghosh, T, 2015)	1.35
"Triptolide has anticancer effects in vitro and is reported to impair cancer cell migration."	( Triptolide Inhibits Lung Cancer Cell Migration, Invasion, and Metastasis. Kim, JY; Raz, DJ; Reno, TA, 2015)	2.58
"Triptolide/Minnelide has been shown to be effective against pancreatic cancer in preclinical trials."	( Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer. Arora, N; Banerjee, S; Dudeja, V; Giri, B; Kir, D; Majumder, K; Modi, S; Saluja, AK, 2016)	1.16
"Triptolide has been shown to exhibit anticancer activity. "	( Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer. Li, J; Qu, Z; Su, T; Wang, Y; Xiong, J; Yang, Q; Zhou, S, 2016)	3.32
"Triptolide has shown antitumor activity in a broad range of solid tumors and on leukemic cells in vitro."	( Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells. Belloc, F; Jeanneteau, M; Lacombe, F; Mahon, FX; Milpied, N; Pigneux, A; Reiffers, J; Uhalde, M, 2008)	3.23
"Triptolide has severe toxicities on digestive, urogenital and blood circulatory system."	( Effect of poly(D, L-lactic acid) nanoparticles as triptolide carrier on abating rats renal toxicity by NMR-based metabolic analysis. Dong, J; Liu, M; Xu, H; Yang, X; Yang, Y, 2008)	1.32
"Triptolide, which has been used to treat inflammatory diseases, has also been reported to inhibit proliferation of cancer cells. "	( Heat shock protein 72 protects kidney proximal tubule cells from injury induced by triptolide by means of activation of the MEK/ERK pathway. Fan, D; Hou, Y; Jin, H; Li, C; Mei, Q; Wang, Z, )	1.8
"Triptolide has shown potent activity in not only anti-inflammation and immune modulation, but also antiproliferative and proapoptotic activity in many different types of cancer cells."	( RNA polymerase - an important molecular target of triptolide in cancer cells. Pan, J, 2010)	1.34
"Triptolide has been used for treating various autoimmune diseases. "	( Triptolide inhibits extracellular matrix protein synthesis by suppressing the Smad2 but not the MAPK pathway in TGF-beta1-stimulated NRK-49F cells. Cheng, XX; Lin, Y; Lu, Y; Wang, YJ; Wei, S; Zhu, B; Zhu, CF; Zhu, XL, 2010)	3.25
"Triptolide has an notable inhibiting effect on proliferation of RA-HFLS and the molecule mechanism is due in part to the direct suppression of abnormal activation of Ras-MAPKs pathway."	( [Effects of triptolide on cell proliferation and regulation of Ras-MAPKs pathway in synoviocytes induced by tumor necrosis factor]. Kong, X; Lian, J; Lin, N; Wang, J, 2010)	2.18
"Triptolide therapy has been associated with reduced expression of Hsp-70, suggesting a mechanism of cell killing involving Hsp-70 inhibition."	( Role of Hsp-70 in triptolide-mediated cell death of neuroblastoma. Antonoff, MB; Borja-Cacho, D; Chugh, R; Clawson, KA; Dudeja, V; Saluja, AK; Skube, SJ; Vickers, SM, 2010)	1.42
"Triptolide has multiple pharmacological activities including anti-inflammatory, immune modulation, antiproliferative and proapoptotic activity."	( Triptolide and its expanding multiple pharmacological functions. Liu, Q, 2011)	2.53
"Triptolide has been shown to reduce interleukin (IL)-17 expression in inflammatory bowel disease and arthritis."	( Triptolide protects mice from ischemia/reperfusion injury by inhibition of IL-17 production. Lu, L; Wang, P; Wu, C; Xia, Y; Zhang, F, 2011)	2.53
"Triptolide has turned out to be the active substance of TwHF extracts and has been shown to exert potent anti-inflammatory and immunosuppressive effects in vitro and in vivo."	( Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Gerdes, S; Han, R; Mrowietz, U; Rostami-Yazdi, M, 2012)	2.54
"Triptolide (TP) has been used in the treatment of rheumatoid arthritis (RA), but its mechanism of action is not understood. "	( Effect of triptolide on T-cell receptor beta variable gene mRNA expression in rats with collagen-induced arthritis. Jiang, W; Liu, L; Wang, A; Wang, J; Xu, Y; Zeng, H; Zhu, Y, 2012)	2.22
"Triptolide has a long history in traditional Chinese medicine for treating inflammatory diseases and has been proven to inhibit cytokines released from glial cells."	( Triptolide prevents and attenuates neuropathic pain via inhibiting central immune response. Chen, L; Li, JL; Li, YQ; Mei, XP; Tang, J; Wang, W; Wu, SX; Xu, LX, )	2.3
"Triptolide (TP) has been shown to have anti-inflammatory, immunosuppressive, anti-fertility and anti-neoplastic activities. "	( Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Chen, H; Mei, Z; Weng, T; Yang, X; Yang, Y, 2003)	2
"Triptolide has been reported to be effective in the treatment of auto-immune diseases. "	( Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Jie, J; Yinjun, L; Yungui, W, 2005)	3.21
"Triptolide (TP) has been shown to have anti-inflammatory, immunosuppressive, anti-fertility and anti-neoplastic activity. "	( The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle. Hu, S; Li, X; Mei, Z; Wu, Q; Yang, X, 2005)	2.01
"Triptolide (TP), which has potent immunosuppressive effects, anti-inflammatory and severe toxicity on digestive, urogenital, blood circulatory system, was used as a model drug in this study. "	( Anti-inflammatory effects of triptolide loaded poly(D,L-lactic acid) nanoparticles on adjuvant-induced arthritis in rats. Dong, J; Liu, M; Xu, H; Yang, X; Yang, Y, 2005)	2.06
"Triptolide (TP) has been shown to have anti-inflammatory, antifertility, antineoplastic, and immunosuppressive activity. "	( Triptolide loaded solid lipid nanoparticle hydrogel for topical application. Hu, S; Li, X; Mei, Z; Wu, Q; Yang, X, 2005)	3.21
"Triptolide has been used extensively in China for the treatment of autoimmune diseases and tumor for many centuries. "	( Triptolide inhibits B7-H1 expression on proinflammatory factor activated renal tubular epithelial cells by decreasing NF-kappaB transcription. Chen, Y; Li, J; Tang, Y; Wu, Y; Zhang, J; Zhang, X; Zhao, T; Zou, L, 2006)	3.22
"f. Triptolide has potent anticancer activity."	( Mechanism of triptolide-induced apoptosis: Effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide. Liu, Y; Matta, R; Nelin, LD; Pei, D; Shen, G; Wang, X, 2006)	1.22
"Triptolide (TPL) has been identified as the active component of the Tripterygium wilfordii hook F plant and demonstrated to possess antitumor properties and induce apoptosis in a variety of tumor cell lines. "	( Role of triptolide as an adjunct chemotherapy for ovarian cancer. Nilsson, EE; Skinner, MK; Westfall, SD, 2008)	2.22
"Triptolide has been clinically used to treat patients with rheumatoid arthritis, in which chemokine receptors play an important role in immune and inflammatory responses. "	( Triptolide inhibits CCR5 expressed in synovial tissue of rat adjuvant-induced arthritis. Dengming, W; Junkan, S; Yanping, L; Yifan, W; Zheng, L, )	3.02
"Triptolide has been identified as the major component responsible for the immunosuppressive and anti-inflammatory effects of TWHF."	( Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Chen, BJ, 2001)	2.47

Excerpt	Reference	Relevance
"Triptolide was found to suppress the inducible and constitutive activation of signal transducer and activator of transcription 3 (STAT3), which is closely associated with inflammation and tumorigenesis."	( Triptolide blocks the STAT3 signaling pathway through induction of protein tyrosine phosphatase SHP-1 in multiple myeloma cells. Kim, JH; Park, B, 2017)	2.62
"Triptolide caused an increase in ROS production, a decrease in mitochondrial depolarization, a diminution of ATP generation, a decline in mitochondrial DNA copy number, mitochondrial fragmentation, and disturbance in mitochondrial dynamics in a concentration-dependent manner in L02 cells."	( Drp1-associated mitochondrial dysfunction and mitochondrial autophagy: a novel mechanism in triptolide-induced hepatotoxicity. Hasnat, M; Jiang, Z; Khan, A; Naveed, M; Raza, F; Sun, L; Ullah, A; Xu, D; Yuan, Z; Zhang, L, 2019)	1.46
"Triptolide (TPL) can enhance the sensitivity of pancreatic cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), but available research is limited to whether TPL can affect the relevant downstream signaling pathways of TRAIL. "	( Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1. Bie, P; Chen, Z; Dai, H; Jiang, Y; Luo, Y, 2019)	3.4
"Triptolide may inhibit airway goblet cell hyperplasia and Muc5ac expression in asthmatic mice via NF-κB. "	( Triptolide suppresses airway goblet cell hyperplasia and Muc5ac expression via NF-κB in a murine model of asthma. Chen, M; Huang, L; Jiang, S; Liang, R; Lin, X; Lv, Z; Shi, J; Zhang, W, 2015)	3.3
"Triptolide could also suppress the level of autophagy."	( Triptolide Inhibited Cytotoxicity of Differentiated PC12 Cells Induced by Amyloid-Beta₂₅₋₃₅ via the Autophagy Pathway. Li, Z; Wang, H; Xu, P; Yang, Z; Zhang, X, 2015)	2.58
"Triptolide did not inhibit P-glycoprotein (P-gp) drug efflux and reduced P-gp and MDR1 mRNA resulting from transcription inhibition."	( Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44. Huan, XJ; Miao, ZH; Song, SS; Wang, YQ; Yi, JM; Zhou, H, 2016)	2.6
"Triptolide (TP) displays a strong immunosuppression function in immune-mediated diseases, especially in the treatment of rheumatoid arthritis. "	( Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo. Huang, J; Li, J; Li, Q; Liang, Q; Wang, T; Wang, Y; Xu, H; Zhang, L, 2016)	2.16
"Glutriptolide did not inhibit XPB activity in vitro but demonstrated significantly higher cytotoxicity against tumor cells over normal cells with greater water solubility than triptolide."	( Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation. Datan, E; He, QL; Head, SA; Liu, JO; Minn, I; Pomper, MG; Wang, Q; Xu, P; Yu, B, 2016)	1.2
"Triptolide (TPL) plays an important role in immunosuppressive, anti-fertility, anti-cystogenesis and anticancer activities."	( Triptolide inhibits tumor growth by induction of cellular senescence. Li, R; Shen, C; Tao, Y; Tian, X; Wang, F; Wang, Z; Zhang, Q; Zhang, X; Zhang, Y, 2017)	2.62
"Triptolide could also cause cell morphological changes (the number of floating cells and nuclear pyknosis increase), induce cell apoptosis, and change the distribution of cell cycle phase in A431 cells."	( [Effect of triptolide on the proliferation and apoptosis of human epidermal squamous cell carcinoma cell line A431 in vitro]. Chen, M; Chen, X; Jian, D; Tan, S; Xie, H; Yi, M; Zhang, G, 2009)	1.46
"Triptolide can activate the transcription of C/EBPalpha, and phosphorylation of Ser21 and Thr222/226 critical for C/EBPalpha inhibition of p40."	( Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer-binding protein alpha. Ma, X; Zhang, Y, 2010)	2.52
"Triptolide did not inhibit the chymotrypsin-like activity of purified 20S proteasome. "	( Inhibition of tumor cellular proteasome activity by triptolide extracted from the Chinese medicinal plant 'thunder god vine'. Cui, QC; Dou, QP; Kanwar, J; Lu, L; Schmitt, S; Zhang, C; Zhao, C, 2011)	2.06
"Triptolide treatment can suppress Akt/Hdm2 signaling pathway, and lead to p53 accumulation, thereby up-regulating DR5 expression."	( Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation. Xiaowen, H; Yi, S, 2012)	2.54
"Triptolide can suppress immunological rejection reaction. "	( [Effect of triptolide on allogenic tendon transplantation in repairing tendon defect in chicken]. Bai, J; Dou, B; Feng, J; Ni, H; Tian, D; Wang, J; Zhang, Y, 2012)	2.21
"Triptolide can suppress immunological rejection reaction, strengthen tendon healing strength, and reduce tendon adhesion in allogenic tendon transplantation."	( [Effect of triptolide on allogenic tendon transplantation in repairing tendon defect in chicken]. Bai, J; Dou, B; Feng, J; Ni, H; Tian, D; Wang, J; Zhang, Y, 2012)	2.21
"Triptolide could inhibit pDCs from differentiation into mDCs, the latter displayed more immature morphology than untreated-pDCs."	( [Regulations of function and maturation of plasmacytoid dendritic cells from primary immune thrombocytopenia patients by triptolide]. Han, XH; He, GS; Lin, GQ; Liu, LM; Si, YJ; Sun, YM; Wu, DP; Zhang, XX; Zhang, YM; Zhao, GS, 2012)	1.31
"Triptolide and celastrol inhibit the proliferation of glioma cells in vitro, which was associated with promoting the expression of Bax and inhibiting the expression of Bcl-2 and accelerating cell apotosis."	( [Several monomes from Tripterygium wilfordii inhibit proliferation of glioma cells in vitro]. Huang, YL; Sun, CF; Xu, QN; Ye, M; Zhou, D; Zhou, YX, 2002)	1.76
"Triptolide could inhibit PBMC to secrete IL-2, IL-4 and IL-5 in vitro (P < 0.01), but IFN-gamma was also under the detection sensitivity."	( [Effect of Tripterygium wilfordii on Th1, Th2 cytokines production in asthma patients]. Lin, KX; Qian, GS; Wang, CZ, 2001)	1.03
"Triptolide could inhibit the migration of ECs by reducing the gene and protein expression of u-PA. "	( [Effects of triptolide on migration of vascular endothelial cells]. Ding, Y; Li, YG; Wang, QL; Wang, SR; Zhang, J; Zhao, QL, 2005)	2.15
"Triptolide could inhibit IFN-gamma-induced activation of RFs derived from patients with Graves' ophthalmopathy."	( Inhibitory effects of Triptolide on interferon-gamma-induced human leucocyte antigen-DR, intercellular adhesion molecule-1, CD40 expression on retro-ocular fibroblasts derived from patients with Graves' ophthalmopathy. Wang, Y; Yan, SX, 2006)	2.09
"Triptolide could lower the production of TNF-alpha from G/ G genotype PBMC, but had no effect on the level of TNF-alpha from non-G/G genotype PBMC."	( Relationship between single nucleotide polymorphism in TNF-alpha gene promoter region and inhibitory effects of triptolide on TNF-alpha production in peripheral blood mononuclear cells of healthy humans. Chen, H; Hu, Y; Liu, P; Sheng, D; Tu, S, 2006)	1.27
"Triptolide can inhibit the proliferation of B-NHL cell line Raji cells. "	( Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro. Chen, Y; Cui, GH; Liu, F; Wu, QL; Zhang, C, 2006)	2.1
"Triptolide can inhibit the production of IFN-gamma in human PBMC and downregulate IL-8 level in HaCaT keratinocytes induced by rhIFN-gamma. "	( [Effects of triptolide on the production of interferon-gamma in human peripheral blood mononuclear cell and phosphorylation of signal transducer and activator of transcription-1 and production of interleukin-8]. Gao, JW; Li, XY; Qian, ZY; Zheng, JR, 2007)	2.16
"Triptolide might inhibit VEGF expression and production by interfering with transcription factor AP-1 formation."	( [Triptolide inhibits vascular endothelial growth factor expression and production by endothelial cells]. Hu, K; Liu, D; Liu, Z, 2001)	1.94
"Triptolide was found to inhibit skin allograft rejection in a dose-dependent manner."	( Immunosuppression of triptolide and its effect on skin allograft survival. Gao, HL; Long, ZZ; Xie, SS; Yang, SX; Zhang, WR, 1992)	1.32

Excerpt	Reference	Relevance
"Triptolide treatment also markedly increased bone volume of tibia, but suppressed epiphyseal plate thickness of both femur and tibia."	( The antioxidant effect of triptolide contributes to the therapy in a collagen-induced arthritis rat model. Huang, JJ; She, XJ; Yu, GM; Zeng, BX; Zhou, LF, 2021)	1.64
"Triptolide treatment protected against Aβ1-42-induced cytotoxicity by decreasing autophagosome accumulation, and inducing autophagic degradation in PC12 cells."	( Neuroprotection of Triptolide against Amyloid-Beta1-42-induced toxicity via the Akt/mTOR/p70S6K-mediated Autophagy Pathway. Gao, J; Peng, Y; Tan, J; Wang, T; Wu, Z; Xu, J; Xu, P; Zheng, F, 2022)	1.77
"Triptolide, a prominent treatment for RA, has satisfactory anti-inflammatory effects."	( Triptolide improves chondrocyte proliferation and secretion via down-regulation of miR-221 in synovial cell exosomes. Chen, J; Chen, Z; Chu, C; Feng, W; Gong, Z; Li, N; Lin, C; Xu, Q, 2022)	2.89
"The triptolide-treated group exhibited meiotic failure of oocytes due to impaired spindle assembly, chromosome alignment, and tubulin stability."	( Triptolide exposure induces oxidative stress and decreases oocyte quality in mouse. Hao, QQ; Liu, Y; Liu, YC; Nie, H; Qi, ZQ; Qiao, FX; Sun, MX; Wang, HL; Xu, CL; Xu, ZR, 2023)	2.83
"Triptolide treatment drastically altered the expression of autophagic and apoptotic proteins."	( Triptolide Induces Apoptosis and Autophagy in Cutaneous Squamous Cell Carcinoma Wang, X; Wu, Y; Xi, N; Xu, X; Yan, G; Zeng, Q; Zhang, G; Zheng, Y; Zheng, Z, 2023)	3.07
"Triptolide treatment led to the translocation of Drp1 from the cytosol into outer mitochondrial membrane where it started mitochondrial fission."	( Mitochondria-dependent apoptosis in triptolide-induced hepatotoxicity is associated with the Drp1 activation. Baig, MMFA; Hasnat, M; Jiang, Z; Khan, A; Naveed, M; Raza, F; Su, Y; Sun, L; Ullah, A; Xu, D; Yuan, Z; Zhang, L, 2020)	1.55
"Triptolide treatment induced apoptosis in both SKOV3 and SKOV3/DDP cells."	( Antitumor activity of triptolide in SKOV3 cells and SKOV3/DDP in vivo and in vitro. Hu, H; Huang, G; Tan, B; Tong, Y; Yang, L; Zhu, S, 2020)	1.59
"Triptolide treatment distinctly inhibited the proliferation of colon cancer cells and induced apoptosis in vitro."	( Triptolide decreases tumor-associated macrophages infiltration and M2 polarization to remodel colon cancer immune microenvironment via inhibiting tumor-derived CXCL12. Cao, G; Gao, C; Gao, G; Jiang, X; Wang, W; Zhao, J, 2021)	2.79
"Triptolide (TP) pretreatment has neuroprotective effects through its anti-inflammatory and antiapoptotic features in ischemic stroke mice."	( Combinational Pretreatment of Colony-Stimulating Factor 1 Receptor Inhibitor and Triptolide Upregulates BDNF-Akt and Autophagic Pathways to Improve Cerebral Ischemia. Amin, N; Botchway, BOA; Chen, S; Du, X; Fang, M; Gao, F; Hu, Z, 2020)	1.51
"Triptolide treatment concentration-dependently suppressed EMT in NCI-H1299 cells, evidenced by significantly elevated E-cadherin expression and reduced expression of ZEB1, vimentin, and slug."	( Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial-mesenchymal transition. Chen, J; Chen, MS; Deng, QD; Huang, LJ; Ke, YY; Lei, XP; Li, SP; Li, Z; Liang, L; Lin, ZX; Liu, Q; Yu, XY; Zhang, Y; Zhong, YH, 2021)	2.79
"Triptolide treatment tended to promote retinal ganglion cell survival rather than optic nerve regeneration as well as inhibit the expression of tumor necrosis factor-α and activation of nuclear factor-kappa B."	( Effect of Triptolide on retinal ganglion cell survival in an optic nerve crush model. Chen, XF; Li, YF; Zhang, W; Zou, YF, 2017)	1.58
"Triptolide pretreatment significantly inhibited tumor necrosis factor-α-induced expression of the interleukin (IL)-1β, IL-6, and IL-8 genes in MH7A cells."	( Atomic Force Microscopy Study of the Anti-inflammatory Effects of Triptolide on Rheumatoid Arthritis Fibroblast-like Synoviocytes. Ao, M; Su, Z; Sun, H; Zhao, C, 2017)	1.41
"Triptolide treatment sensitized the effect of cisplatin in A2780/CP70, as evidenced by decreased survival fraction of A2780/CP70 cells."	( Triptolide antagonized the cisplatin resistance in human ovarian cancer cell line A2780/CP70 via hsa-mir-6751. Liu, Y; Ma, X; Su, S; Wang, R, 2018)	2.64
"Triptolide treatment resulted in death in both cell lines within 72 hours, with sustained increases in intracellular calcium. "	( Triptolide-mediated cell death in neuroblastoma occurs by both apoptosis and autophagy pathways and results in inhibition of nuclear factor-kappa B activity. Banerjee, S; Dudeja, V; Krosch, TC; Mujumdar, N; Saluja, AK; Sangwan, V; Vickers, SM, 2013)	3.28
"Triptolide treatment induces cell death in neuroblastoma by different mechanisms with multiple pathways targeted. "	( Triptolide-mediated cell death in neuroblastoma occurs by both apoptosis and autophagy pathways and results in inhibition of nuclear factor-kappa B activity. Banerjee, S; Dudeja, V; Krosch, TC; Mujumdar, N; Saluja, AK; Sangwan, V; Vickers, SM, 2013)	3.28
"Triptolide treatment markedly inhibited AC-induced increases in myocardial collagen volume fraction, collagen type I/III deposition, left ventricular end-diastolic pressure, expressions of pro-fibrogenic factors (transforming growth factor-β and angiotensin II) and pro-inflammatory cytokines (IL-1β and IL-6), NF-κB activation and inflammatory cell infiltration in left ventricles compared with vehicle, without affecting cardiac hypertrophy."	( Triptolide protects rat heart against pressure overload-induced cardiac fibrosis. Ding, Y; Dong, Z; Gong, K; Ni, Y; Qin, J; Qu, X; Sun, H; Yan, X; Zhang, K; Zhang, Z; Zhao, P, 2013)	2.55
"The triptolide-treated group rats were administered triptolide intraperitoneally for 30 days after microinjection of aggregated Aβ1-40 into hippocampus."	( Effects of triptolide on degeneration of dendritic spines induced by Aβ1-40 injection in rat hippocampus. Hu, X; Li, Y; Lü, C; Nie, J; Wan, B; Wen, W; Yang, B; Zhou, M, 2014)	1.27
"Triptolide treatment resulted in a significant decrease in mRNA expression levels in genes encoding Bcl-2, cyclin D1, p27 and survivin and an increase in those encoding Bax and p21 in THP-1 cells."	( Triptolide induces apoptosis of PMA-treated THP-1 cells through activation of caspases, inhibition of NF-κB and activation of MAPKs. Kim, YI; Park, SW, 2013)	2.55
"Triptolide treatment increased VSV replication in the human prostate cancer cell line PC3 and in other VSV-resistant cells in a dose- and time-dependent manner in vitro and in vivo."	( Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis. Ben Yebdri, F; Goulet, ML; Hiscott, J; Lin, R; Stojdl, DF; Tang, VA; Van Grevenynghe, J; Wu, JH, 2013)	2.55
"Triptolide treatment affected the histomorphology of uterus by causing a decrease in lumen and columnar cell height and number of uterine glands and ovary by increasing the number of atretic follicles and decreasing the number of developing follicles."	( Effect of triptolide on reproduction of female lesser bandicoot rat, Bandicota bengalensis. Dhar, P; Singla, N, 2014)	1.53
"Triptolide treatment in vivo significantly inhibited tumor growth compared with mock treatment."	( Triptolide-induced in vitro and in vivo cytotoxicity in human breast cancer stem cells and primary breast cancer cells. Huang, Y; Li, J; Li, X; Liu, R; Shen, X; Yang, Y, 2014)	2.57
"Triptolide-treated mice exhibited significantly reduced leukocyte, myeloperoxidase (MPO) activity, edema of the lung, as well as TNF-α, IL-1β, and IL-6 production in the bronchoalveolar lavage fluid compared with LPS-treated mice."	( Anti-inflammatory effects of triptolide in LPS-induced acute lung injury in mice. Huang, Z; Wei, D, 2014)	1.41
"Triptolide‑treated mice exhibited significantly reduced levels of leukocytes, myeloperoxidase activity and edema of the lung, as well as tumour necrosis factor‑α, interleukin (IL)‑1β and IL‑6 production in the bronchoalveolar lavage fluid compared with LPS‑treated mice."	( Anti-inflammatory effects of triptolide by inhibiting the NF-κB signalling pathway in LPS-induced acute lung injury in a murine model. Ding, Y; Duan, W; Gong, P; Liu, B; Wang, X; Wu, X; Zhang, L, 2014)	1.41
"Triptolide treatment leads to an improvement in Diabetic Cardiomyopathy (DCM) in streptozotocin-induced diabetic rat model. "	( Triptolide improves systolic function and myocardial energy metabolism of diabetic cardiomyopathy in streptozotocin-induced diabetic rats. Jiang, W; Leo, S; Liang, Z; Ouyang, M; Wen, H; Yang, K, 2015)	3.3
"Triptolide treatment resulted in dose-dependent inhibition of Jurkat cells proliferation and its IC50 was 12.7 nmol/L. "	( [Triptolide induces apoptosis of human acute T lymphocytic leukemia Jurkat cells via inhibiting transcription of human endogenous retrovirus HERV-K Np9 gene]. Chen, J; Jiang, X; Lu, X; Xu, R; Zheng, W, 2015)	2.77
"Triptolide treatment reduced miR‑21 expression and enhanced phosphatase and tensin homolog (PTEN) protein expression levels in the PC‑9 cells."	( Triptolide reduces proliferation and enhances apoptosis of human non-small cell lung cancer cells through PTEN by targeting miR-21. Duan, M; Fan, W; Feng, J; Huo, R; Jia, Y; Jiao, J; Li, X; Zang, A; Zhang, J; Zhang, L; Zhu, X, 2016)	2.6
"Triptolide treatment inhibited the expression of tumor promoter Cav-1 and reduced CD147 and MMPs activities at both mRNA and protein levels."	( Triptolide inhibits the migration and invasion of human prostate cancer cells via Caveolin-1/CD147/MMPs pathway. Chen, X; Fan, B; Wang, L; Wang, S; Yang, D; Yuan, Q; Yuan, S; Zhang, H, 2016)	2.6
"Triptolide treatment of HepG2 cells caused a significant increase in the expression of p21, Bax and DR5 genes in HepG2 cells."	( Triptolide inhibits viability and induces apoptosis in liver cancer cells through activation of the tumor suppressor gene p53. Chen, XH; Ji, YC; Ma, R; Sun, YY; Wang, D; Xiao, L; Yang, YP, 2017)	2.62
"Triptolide treatment attenuated TAC-induced myocardial remodeling, improved cardiac diastolic and systolic function, inhibited the NLRP3 inflammasome and downstream inflammatory mediators (IL-1β, IL-18, MCP-1, VCAM-1), activated the profibrotic TGF-β1 pathway, and suppressed macrophage infiltration in a dose-dependent manner."	( Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression. Chen, M; Gong, K; Li, R; Lu, K; Shen, H; Wang, Y; Yao, D; Zhang, F; Zhang, Z, 2017)	2.62
"Triptolide treatment resulted in dose- and time-dependent N2a cell death and dose-dependent SKNSH killing. "	( Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo. Antonoff, MB; Borja-Cacho, D; Chugh, R; Clawson, KA; Dudeja, V; Saltzman, DA; Saluja, AK; Skube, SJ; Sorenson, BS; Vickers, SM, 2009)	3.24
"Triptolide treatment of MCF-7 breast cancer cells expressing ectopic ADAM10 or dominant negative ADAM10 (DN ADAM10) resulted in a decreased expression of ADAM10 with a concomitant increase in ADAM10 cleaved products."	( Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells. Marignani, PA; Robertson, GS; Sayat, R; Soundararajan, R, 2009)	2.52
"Triptolide treatment was also shown to decrease the ED-1 or CD11b-positive inflammatory cells at the lesion site."	( Triptolide promotes spinal cord repair by inhibiting astrogliosis and inflammation. Cao, L; Gao, L; He, C; Qiu, Y; Su, Z; Yuan, Y; Zhu, Y, 2010)	2.52
"The triptolide-treated female rats showed many abnormalities, including anorexia, diarrhea, leanness, suppression of weight gain and food intake, fatty liver, splenomegaly and atrophy of ovaries."	( Sex differences in subacute toxicity and hepatic microsomal metabolism of triptolide in rats. Chen, Y; Guo, J; Huang, X; Jiang, Z; Liu, J; Liu, L; Wang, T; Yang, L; Zhang, L; Zhang, Y; Zhou, Z, 2010)	1.07
"Triptolide treatment can suppress Akt/Hdm2 signaling pathway, and lead to p53 accumulation, thereby up-regulating DR5 expression."	( Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation. Xiaowen, H; Yi, S, 2012)	2.54
"Triptolide treatment inhibited the migration and invasion of ovarian cancer cells SKOV3 and A2780 at the concentration of 15 nM."	( Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin. Mei, Q; Wang, M; Wang, X; Wang, Y; Wang, Z; Yang, Z; Zhang, X; Zhao, H, 2012)	2.54
"Triptolide treatment increased the apoptosis of T cells in the spleen of recipients."	( Triptolide ameliorates autoimmune diabetes and prolongs islet graft survival in nonobese diabetic mice. Chen, TW; Chen, YW; Chien, MW; Chu, CC; Chu, CH; Huang, SH; Lin, GJ; Sytwu, HK; Yu, JC, 2013)	2.55
"Triptolide treatment not only reduced the diabetic incidence in NOD mice but also prolonged the survival of syngeneic or allogeneic grafts."	( Triptolide ameliorates autoimmune diabetes and prolongs islet graft survival in nonobese diabetic mice. Chen, TW; Chen, YW; Chien, MW; Chu, CC; Chu, CH; Huang, SH; Lin, GJ; Sytwu, HK; Yu, JC, 2013)	3.28
"Triptolide treatment of human tissue culture cells prevented the inducible expression of heat shock genes, shown by suppression of an HSP70 promoter-reporter construct and by suppression of endogenous HSP70 gene expression."	( Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. Kawahara, TL; Morimoto, RI; Orton, K; Westerheide, SD, 2006)	2.5
"In triptolide-treated cells, the expression of p53 increased but the transcriptional function of p53 was inhibited, and we observed a down-regulation of p21(waf1/cip1), a p53-responsive gene."	( Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. Anderson, E; Chang, WT; Gotmare, S; Kang, JJ; Lee, KY; Rosen, GD; Ross, JA; Wei, K, 2001)	2.27
"Triptolide-treated rats also had significantly less right ventricular hypertrophy (RVH) and pulmonary arterial neointimal formation."	( Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Benson, GV; Berry, GJ; Faul, JL; Kao, PN; Nishimura, T; Pearl, RG, 2000)	2.47
"Triptolide treatment decreased the activity of NF-kappa B in both PMA/PHA treated and untreated Jurkat cells."	( Triptolide: a potent inhibitor of NF-kappa B in T-lymphocytes. Chen, ZH; Li, LS; Liu, H; Liu, ZH; Yang, JW, 2000)	2.47
"Co-treatment with triptolide + celastrol (from Tripterygium wilfordii) induced intestinal bleeding in mice. "	( Celastrol as an intestinal FXR inhibitor triggers tripolide-induced intestinal bleeding: Underlying mechanism of gastrointestinal injury induced by Tripterygium wilfordii. Cheng, Y; Dai, M; Gonzalez, FJ; Huang, J; Li, F; Lin, L; Lin, Q; Liu, A; Peng, W; Rao, Q; Wu, ZE; Zhang, B; Zhang, T; Zhao, J; Zhao, Q, 2023)	1.24
"Treatment of triptolide led to activation of Akt and p70S6K, indicating that the PI3K/Akt signaling pathway may be involved in response to oxidative stress in TM4 cells."	( [Triptolide induces oxidative stress and apoptosis and activates PIK3/Akt signaling pathway in TM4 sertoli cells]. Chen, L; Wang, H; Ye, XY, 2018)	1.74
"Treatment with triptolide led to a significant decrease in the colony forming ability of AML cell lines as well as in the expression of stem cell markers."	( Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia. Banerjee, S; Dudeja, V; Giri, B; Gupta, VK; Lavania, SP; Modi, S; Roy, P; Saluja, A; Sethi, V; Vickers, SM; Watts, J; Yaffe, B, 2019)	0.85
"Pretreatment with triptolide improved graft survival both 24 (29.3 ± 0.9%) and 72 h (17.5 ± 1.2%) after transplantation of MSCs and resulted in a 2.5-fold increase in the total cell number 72 h after cell transplantation."	( Triptolide improves early survival of mesenchymal stem cells transplanted into rat myocardium. Cheng, J; Feng, Y; Nong, Y; Song, Z; Tong, S; Wei, L; Wen, L; Yao, Q; Zhang, C; Zhang, Z, 2014)	2.17
"Treatment with triptolide or HSF1 knockdown disrupts the cytosolic complex between HSF1, p97, HSP90 and the HSP90 deacetylase- Histone deacetylase 6 (HDAC6)."	( Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Dandawate, P; Ganguly, S; Home, T; Kambhampati, S; McGuirk, J; Padhye, S; Rao, R; Saluja, AK; Shi, H; Yacoub, A, 2015)	0.76
"Treatment with triptolide effectively suppressed the cell viability and induced the apoptosis of osteosarcoma MG-63 cells as detected by MTT assay and flow cytometry, respectively."	( Triptolide induces the cell apoptosis of osteosarcoma cells through the TRAIL pathway. Chen, L; Zhang, Q; Zhao, X, 2016)	2.22
"Treatment with triptolide significantly improved renal function at postnatal day 8 by inhibition of the early phases of cyst growth."	( Triptolide reduces cystogenesis in a model of ADPKD. Bencivenga, N; Crews, CM; Igarashi, P; Leuenroth, SJ; Somlo, S, 2008)	2.13
"Pretreatment with triptolide decreased the reactive oxygen species (ROS) levels, mortality rate and liver injury after LPS/D-GalN injection."	( Triptolide attenuate the oxidative stress induced by LPS/D-GalN in mice. Bao, X; Lu, Y; Shen, P; Sun, T; Xu, J; Zheng, W, 2012)	2.15
"Pretreatment with triptolide was able to dose-dependently reduce the lipopolysaccharide (LPS)-induced nitrite accumulation and tumor necrosis factor-alpha and interleukin-1beta release from LPS-activated microglia as revealed by Griess reaction and ELISA, respectively."	( Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures. He, QH; Li, FQ; Liu, XY; Niu, DB; Wang, XH; Wang, XM; Xue, B; Zhou, HF, 2003)	2.09
"Treatment with triptolide for 35 days and 105 days prevented deposition of amyloid and promoted resorption of splenic amyloid deposits."	( Experimental AA amyloidosis in mice is inhibited by treatment with triptolide, a purified traditional Chinese medicine. Cui, D; Gondo, T; Hoshii, Y; Ishihara, T; Kawano, H; Liu, Y; Sugiyama, S, 2007)	0.92
"Treatment with triptolide resulted in significant delay in time to onset of arthritis (P = 0.039), as well as significantly decreased arthritis incidence (P = 0.024), clinical arthritis severity score (P < 0.0001), histopathological arthritis severity score (P < 0.0001), and in vivo cell-mediated immunity to collagen (P = 0.0004)."	( Inhibition of type II collagen-induced arthritis in rats by triptolide. Brandwein, SR; Gu, WZ, 1998)	0.88

Excerpt	Reference	Relevance
" In the present study, we treated human normal liver L-02 cells (L-02 cells) with triptolide in vitro and investigated its toxic effects."	( Involvement of mitochondrial pathway in triptolide-induced cytotoxicity in human normal liver L-02 cells. Duan, W; He, L; Hu, L; Huang, J; Jiang, Z; Li, F; Liu, C; Shu, B; Xiao, Y; Yao, J; Zhang, L, 2008)	0.84
" A significant side-effect of triptolide is its male reproductive toxicity the mechanism of which is still unknown."	( Male reproductive toxicity and toxicokinetics of triptolide in rats. Huang, X; Jiang, Z; Liu, J; Ni, B; Tian, Y; Wang, T; Xu, F; Zhang, L; Zhang, R; Zhang, Z; Zhu, T, 2008)	0.89
"Triptolide (TP), a major active and toxic component of Tripterygium wilfordii, is reported to be converted into four mono-hydroxylated metabolites (m/z 375) by cytochrome P450 (CYP) in vitro, and CYP3A4 was the primary isoform responsible for its hydroxylation."	( Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat. Cai, R; Li, W; Mao, C; Xu, H; Yan, Y; Yang, X; Ye, X, 2010)	2.03
"The aim of this study was to investigate the adverse effects of triptolide, a diterpenoid triepoxid and a major active component isolated from Triptergium wilfordii Hook."	( Triptolide induces adverse effect on reproductive parameters of female Sprague-Dawley rats. Jiang, Z; Liu, J; Liu, L; Ma, M; Xiao, J; Zhang, L; Zhang, S; Zhang, Y, 2011)	2.05
" However, severe adverse effects, especially nephrotoxicity, limit its clinical use."	( Role of Nrf2 in protection against triptolide-induced toxicity in rat kidney cells. Guan, C; Huang, M; Huang, Z; Jin, J; Li, J; Li, M; Qiu, Y; Wang, W; Zhu, S, 2012)	0.66
" Further acute oral toxicity experiments showed that the LD50 value of this extract was 1,210 mg/kg compared to 257 mg/kg for Tripterygium glycosides."	( Biological activity and safety of Tripterygium extract prepared by sodium carbonate extraction. Fang, W; Lam, CW; Peng, F; Wan, C; Xu, H; Yang, X; Yi, T; Zhang, C, 2012)	0.38
" Artesunate, extracted from the Chinese herb Artemisia annua, has proven to be effective and safe as an anti-malarial drug that possesses anticancer potential."	( Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines. Cui, YF; Liu, Y, 2013)	0.66
" The results showed that triptolide caused oxidative stress and cell damage in HepG2 cells, and these toxic effects could be aggravated by Nrf2 knockdown or be counteracted by overexpression of Nrf2."	( Activation of Nrf2 protects against triptolide-induced hepatotoxicity. Fu, X; Guan, C; Huang, M; Huang, Z; Jin, J; Li, J; Shen, F; Sun, X; Wang, W, 2014)	0.98
"The aim of study was to investigate the toxic effect of triptolide fed in bait on reproduction of male house rat, Rattus rattus."	( Reproductive toxicity of triptolide in male house rat, Rattus rattus. Challana, S; Singla, N, 2014)	0.95
"The aim of this study is to understand the regulatory role of sphingolipid (SPL) pathways in the TP-induced toxic mechanism in the liver and kidney in delayed-type hypersensitivity (DTH) Balb\\c mouse."	( Integrated targeted sphingolipidomics and transcriptomics reveal abnormal sphingolipid metabolism as a novel mechanism of the hepatotoxicity and nephrotoxicity of triptolide. Jia, Z; Qu, F; Qu, L; Wang, C; Wu, C; Zhang, J, 2015)	0.61
" Several enzymes, including kdsr, CerS2, CerS4, CerS5 and CerS6 in the liver and Cerk in the kidney were probably responsible for the TP-induced toxic effect, identifying them as possible novel therapeutic targets."	( Integrated targeted sphingolipidomics and transcriptomics reveal abnormal sphingolipid metabolism as a novel mechanism of the hepatotoxicity and nephrotoxicity of triptolide. Jia, Z; Qu, F; Qu, L; Wang, C; Wu, C; Zhang, J, 2015)	0.61
"01) and had no side effects or toxic effects on the thymus index (P>0."	( Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo. Huang, J; Li, J; Li, Q; Liang, Q; Wang, T; Wang, Y; Xu, H; Zhang, L, 2016)	0.72
" Nrf2 knockdown revealed a more severe toxic effect of TP (P<0."	( Self-protection against triptolide-induced toxicity in human hepatic cells via Nrf2-ARE-NQO1 pathway. Feng, Z; Liang, XW; Liu, ZP; Wang, HL; Zhou, C; Zhou, LL; Zhou, XP, 2017)	0.76
" The current study aimed to explore metabolomics characteristics of the toxic reaction induced by TP and the intervention effect of licorice water extraction (LWE) against such toxicity."	( UPLC/ESI-QTOF-MS-based metabolomics survey on the toxicity of triptolide and detoxication of licorice. Duan, SM; Kong, M; Li, GF; Li, SL; Li, XY; Liu, JQ; Liu, LF; Wang, Z; Xu, JD; Zhang, GH; Zhu, H, 2017)	0.7
" Based on the traditional Chinese medicine theory, the theory of "Yi lei xiang zhi" was proposed that Chinese herbs with different efficacy can restrict each other to achieve the least adverse reactions."	( Triptolide-induced hepatotoxicity can be alleviated when combined with Panax notoginseng saponins and Catapol. Feng, Z; Liu, Z; Zhou, C; Zhou, L; Zhou, X; Zhu, H, 2018)	1.92
" However, toxicity and severe adverse effects, particularly hepatotoxicity, limit the clinical application of triptolide."	( Licorice root extract and magnesium isoglycyrrhizinate protect against triptolide-induced hepatotoxicity via up-regulation of the Nrf2 pathway. Hu, Q; Huang, SY; Jia, LL; Jin, J; Su, HZ; Tan, QY; Xiao, J; Zhang, J; Zhu, SN, 2018)	0.93
" One of its most severe adverse effects observed in the clinical use is hepatotoxicity, but the mechanism is still unknown."	( Metabolic alterations in triptolide-induced acute hepatotoxicity. Gao, X; Gonzalez, FJ; Krausz, KW; Mu, X; Patel, DP; Shi, X; Wang, Q; Xie, C; Zhao, J, 2018)	0.78
" Intraperitoneal injection of FMK or Nec-1 could counteract the toxic reactions induced by TP-LPS co-treatment."	( A new perspective of triptolide-associated hepatotoxicity: Liver hypersensitivity upon LPS stimulation. Chen, X; Ding, J; Hasnat, M; Jiang, Z; Liang, P; Sun, L; Yuan, Z; Zhang, H; Zhang, L, 2019)	0.83
" However, its main active substance, triptolide, has toxic effects on the heart, liver, and kidneys, which limit its clinical application."	( MicroRNA expression, targeting, release dynamics and early-warning biomarkers in acute cardiotoxicity induced by triptolide in rats. Chen, X; Guo, H; Ling, S; Ni, RZ; Wang, SR; Xu, JW, 2019)	1
" The nephrotoxic mechanism of Triptolide (TP), the main pharmacological and toxic component of TwHF, has not been fully revealed."	( Key role of organic cation transporter 2 for the nephrotoxicity effect of triptolide in rheumatoid arthritis. He, J; Huang, X; Jiang, Z; Shen, Q; Shu, T; Wang, J; Xu, D; Yuan, Z; Zhang, L, 2019)	1.03
" Pharmacokinetic experiments showed that oral gavage of TW at ZT2 generated higher plasma concentrations (and systemic exposure) of triptolide (a toxic constituent) compared with ZT14 dosing."	( Circadian clock regulates hepatotoxicity of Tripterygium wilfordii through modulation of metabolism. Lu, D; Tong, Y; Wu, B; Zhao, H, 2020)	0.76
" These results suggest that TP@NPs may be a safe and effective therapy for RA and other autoimmune diseases."	( Construction of a pH-responsive, ultralow-dose triptolide nanomedicine for safe rheumatoid arthritis therapy. Han, H; Hou, T; Jin, J; Liang, Q; Liu, Y; Wang, C; Wang, Y; Xu, H; Yang, G; Yang, Y; Zhang, L; Zhang, W; Zhao, Y, 2021)	0.88
" Over the past decades, considerable efforts have been dedicated to designing and developing a variety of TP delivery systems with the intention of alleviating the adverse toxicity effects and enhancing the bioavailability."	( Triptolide delivery: Nanotechnology-based carrier systems to enhance efficacy and limit toxicity. Deng, Y; Li, M; Lu, A; Lu, J; Ren, Q, 2021)	2.06
"Triptolide (TP), the main bioactive and toxic ingredient of Tripterygium wilfordii Hook F, causes severe toxicity, particularly for hepatotoxicity."	( Role of MicroRNA-155 in Triptolide-induced hepatotoxicity via the Nrf2-Dependent pathway. Gong, H; Guo, L; Hou, Z; Li, Y; Yan, M; Zhang, B, 2021)	2.37
" Therefore, we constructed folate-modified triptolide liposomes (FA-TP-Lips) to target macrophages, thereby treating RA in a safe and effective way."	( Folate-modified triptolide liposomes target activated macrophages for safe rheumatoid arthritis therapy. Geng, HX; Guo, RB; Kong, L; Li, XT; Liu, Y; Wang, YJ; Wu, YN; Yan, DK; Yu, YJ; Zhang, XY, 2022)	1.33
" However, severe adverse effects and toxicity, especially nephrotoxicity, limit its clinical application."	( New mechanism of nephrotoxicity of triptolide: Oxidative stress promotes cGAS-STING signaling pathway. Dong, H; Lin, R; Liu, P; Lu, J; Sun, J; Wen, F; Zhang, Y; Zhu, L, 2022)	1
" However, celastrol, triptolide and triptonide have certain toxic effects on the liver, kidney, cholangiocyte heart, ear and reproductive system."	( A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes. Dai, L; He, GN; Song, J, 2023)	1.5

Excerpt	Reference	Relevance
" The method was successfully applied to a pharmacokinetic study after an intragastric administration (i."	( Liquid chromatographic/mass spectrometry assay of triptolide in dog plasma and its application to pharmacokinetic study. Li, H; Liang, Y; Shao, F; Sun, J; Wang, G; Xie, H; Zhang, R; Zhu, X, 2006)	0.59
" This paper aimed at characterizing the pharmacokinetic profiles of triptolide in rats to provide the clue to approach the toxic mechanism."	( Pharmacokinetic study of triptolide, a constituent of immunosuppressive chinese herb medicine, in rats. A, J; Shao, F; Sun, J; Wang, G; Xie, H; Zhu, X, 2007)	0.88
"The aim of this paper is to develop and validate a rapid and sensitive LC-APCI/MS method for the determination of triptolide (TP) in plasma and to study the pharmacokinetic properties of TP in Beagle dogs."	( [Pharmacokinetics of triptolide in Beagle dogs]. Shao, F; Sun, JG; Wang, GJ; Xie, HT; Zhang, R; Zhu, XY, 2007)	0.87
" The simple and quantitative derivatization coupled with tandem mass spectrometric analysis yields a sensitive and robust method for the quantification of (5R)-hydroxytriptolide in Phase I pharmacokinetic studies."	( Derivatization of (5R)-hydroxytriptolide from benzylamine to enhance mass spectrometric detection: application to a Phase I pharmacokinetic study in humans. Chen, X; Li, L; Liu, J; Liu, K; Miao, H; Zhang, Y; Zhong, D, 2011)	0.85
" wilfordii tablet was regarded as the control, the plasma concentration of triptolide was determined by LC-MS/MS after different route of administration, and the pharmacokinetic parameters were calculated by DAS."	( [Pharmacokinetics of triptolide in Triptergium wilfordii microemulsion gel]. Chen, L; Guan, Y; Yan, Z; Yang, M; Zhu, W, 2011)	0.92
" And the pharmacokinetic parameters of triptolide in microemulsion gel was as follow: t(1/2) (2."	( [Pharmacokinetics of triptolide in Triptergium wilfordii microemulsion gel]. Chen, L; Guan, Y; Yan, Z; Yang, M; Zhu, W, 2011)	0.96
" Metabonomic and pharmacokinetic data revealed that rats treated with the varied diets had distinctly different metabolic patterns and showed differential C(max) values, AUC and drug metabolism after oral administration of triptolide."	( Prediction of the pharmacokinetic parameters of triptolide in rats based on endogenous molecules in pre-dose baseline serum. Aa, J; Cao, B; Gu, R; Hao, G; Li, M; Liu, L; Shi, J; Sun, R; Wang, G; Wang, X; Wu, L; Xiao, W; Yu, X; Zhao, C; Zheng, T; Zhou, J; Zhu, X, 2012)	0.82
" The pharmacokinetic study showed that the elimination of MC002 was faster than that of TP, and the concentrations and AUC0-t values of TP were higher than MC002."	( Simultaneous determination of triptolide and its prodrug MC002 in dog blood by LC-MS/MS and its application in pharmacokinetic studies. Li, CK; Li, Y; Liu, PX; Wang, J; Zhang, YJ; Zhang, ZQ; Zhou, L; Zhuang, XM, 2013)	0.68
"This validated method was successfully applied in a pharmacokinetic study of MC002 following an intravenous drip infusion in dogs."	( Simultaneous determination of triptolide and its prodrug MC002 in dog blood by LC-MS/MS and its application in pharmacokinetic studies. Li, CK; Li, Y; Liu, PX; Wang, J; Zhang, YJ; Zhang, ZQ; Zhou, L; Zhuang, XM, 2013)	0.68
" Blood samples were collected up to 4 h at predetermined time intervals, the plasma concentration of CPA was determined by high performance liquid chromatography (HPLC) and pharmacokinetic parameters were determined."	( Effects of triptolide on the pharmacokinetics of cyclophosphamide in rats: a possible role of cytochrome P3A4 inhibition. Cao, RS; He, L; Ji, SG; Li, XF; Liu, J; Wu, JC; Ye, F; Zhang, N; Zhang, XF, 2014)	0.79
" Peak plasma concentrations (Cmax) of CPA was significantly increased and plasma half-life was correspondingly extended."	( Effects of triptolide on the pharmacokinetics of cyclophosphamide in rats: a possible role of cytochrome P3A4 inhibition. Cao, RS; He, L; Ji, SG; Li, XF; Liu, J; Wu, JC; Ye, F; Zhang, N; Zhang, XF, 2014)	0.79
"5 minutes after dosing, depending on the rodent species) followed by a short elimination half-life (from about 20 minutes to less than 1 hour)."	( Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats. Lam, CW; Liu, W; Peng, F; Wan, C; Wan, J; Xu, H; Yang, X; Zhang, C, 2014)	0.64
" The pharmacokinetic study showed that blood concentrations of both TP-LE and TP reached a maximum at the end of intravenous administration (1."	( Pharmacokinetics and tissue distribution study in mice of triptolide-loaded lipid emulsion and accumulation effect on pancreas. Li, K; Li, X; Mao, Y; Shi, T; Wang, S; Yao, H; Yao, J, 2016)	0.68
" Moreover, the pharmacokinetic profiles of orally administered triptolide with and without pretreatment with verapamil were determined in rats."	( Influence of Verapamil on Pharmacokinetics of Triptolide in Rats. Lei, X; Li, J; Liu, G; Liu, M; Yang, M; Zhang, T; Zhang, Y, 2016)	0.93
" A chronic dermatitis/eczema model in mice ears and the pharmacodynamic of the TPL-nanoemulsion gels were also investigated."	( Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics. Gu, Y; Liu, J; Tang, X; Yang, D; Yang, M, 2017)	0.81
" The AUC and the Cmax are not dose proportional."	( Preclinical Pharmacokinetics of Triptolide: A Potential Antitumor Drug. Chen, Y; Liu, M; Peng, Z; Song, W; Wu, J; Zhai, H, 2019)	0.8
"The findings of this review confirm the importance of pharmacokinetic character for understanding the pharmacology and toxicology of triptolide."	( Preclinical Pharmacokinetics of Triptolide: A Potential Antitumor Drug. Chen, Y; Liu, M; Peng, Z; Song, W; Wu, J; Zhai, H, 2019)	1
" When co-administrated with single dose of DMY (100 mg/kg), the AUC, Cmax and T1/2 of TP were significantly enhanced by 98, 83 and 66%, respectively."	( Dihydromyricetin affect the pharmacokinetics of triptolide in rats. Cai, H; Chen, L; Deng, Y; Fang, P; Guo, L; He, G; Li, H; Tan, S; Xiang, D; Yan, M; Zhang, B, 2020)	0.81

Excerpt	Reference	Relevance
"To investigate the inhibitive effects of triptolide (TPL) combined with 5-fluorouracil (5-FU) on colon carcinoma HT-29 cells in vitro and in vivo and their side effects."	( Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Lin, XL; Tang, XY; Tao, WH; Wei, B; Zhu, YQ, 2007)	0.92
" TPL combined with 5-FU had synergistic effects at lower concentrations and promoted apoptosis, but did not increase the side effects of chemotherapy."	( Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Lin, XL; Tang, XY; Tao, WH; Wei, B; Zhu, YQ, 2007)	0.65
" This study also demonstrated the effectiveness of LC/HR-MS(n) in combination with multiple post-acquisition data-mining methods and the online H/D exchange technique for the rapid identification of drug metabolites."	( Metabolite identification of triptolide by data-dependent accurate mass spectrometric analysis in combination with online hydrogen/deuterium exchange and multiple data-mining techniques. Du, F; Liu, T; Wan, Y; Wang, Y; Xing, J, 2011)	0.66
"T2DM rats were induced by fed with high-sucrose-high-fat diet combined with a low dose of streptozocin."	( [Triptolide combined with irbesartan synergistically blocks podocyte injury in a type 2 diabetes rat model]. Li, YS; Liu, LQ; Ma, RX; Xu, Y; Zhang, J, 2012)	1.29
" In this work, the effect of TP combined with glycyrrhetic acid (GA) on mRNA expression and activity of four cytochrome P450 (CYP) enzymes in rat liver was studied after intragastric administration of TP (0."	( In vivo effect of triptolide combined with glycyrrhetinic acid on rat cytochrome P450 enzymes. Chen, Y; Han, FM; Peng, ZH; Wang, JJ, 2013)	0.72
"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-κB pathways."	( AMD3100 combined with triptolide inhibit proliferation, invasion and metastasis and induce apoptosis of human U2OS osteosarcoma cells. Bian, Z; Fang, X; Jiang, C; Jiang, W; Li, M; Tian, F; Wang, X; Zhang, H; Zhu, L, 2017)	1.08
"To investigate the effect and possible mechanism of low concentration of triptolide (TPL) combined with homoharringtonine (HHT) on the proliferation and apoptosis of KG-1α cells."	( [Effects of Triptolide Combined with Homoharringtonine on Proliferation and Apoptosis of KG-1α Cells]. Li, X; Lin, ZX; Liu, JY; Wu, Y; Yuan, XH, 2018)	1.09
" Westerrn blot was used to detect the expression of Akt signaling pathway related proteins before and after low dose TPL combined with HHT using."	( [Effects of Triptolide Combined with Homoharringtonine on Proliferation and Apoptosis of KG-1α Cells]. Li, X; Lin, ZX; Liu, JY; Wu, Y; Yuan, XH, 2018)	0.86
" CI values also indicated that low concentration TPL combined with HHT possessed highly synergistic effect."	( [Effects of Triptolide Combined with Homoharringtonine on Proliferation and Apoptosis of KG-1α Cells]. Li, X; Lin, ZX; Liu, JY; Wu, Y; Yuan, XH, 2018)	0.86
"Low concentration of TPL combined with HHT can synergistically inhibit KG-1α cell proliferation and induce its apoptosis through the PI3K/Akt signaling pathway and downstream protein."	( [Effects of Triptolide Combined with Homoharringtonine on Proliferation and Apoptosis of KG-1α Cells]. Li, X; Lin, ZX; Liu, JY; Wu, Y; Yuan, XH, 2018)	0.86
" This review, conducted a systematic review of TP detoxification strategies including drug combination detoxification strategies from metabolic and toxic mechanisms, as well as drug delivery detoxification strategies from the prodrug strategy and nanotechnology."	( Detoxification strategies of triptolide based on drug combinations and targeted delivery methods. Cao, Z; Li, L; Liu, B; Lu, C; Lu, P; Yan, L, 2022)	1.01
" Therefore, this study aimed to investigate whether minnelide, combined with Angptl3 knockout, could completely protect mice with AN and its mechanism."	( Minnelide combined with Angptl3 knockout completely protects mice with adriamycin nephropathy via suppression of TGF-β1-Smad2 and p53 pathways. Ji, B; Liu, J; Ma, Y; Shen, Q; Xu, H; Yin, Y; Yu, J, 2023)	0.91
" Therefore, the present study aimed to investigate whether minnelide combined with mAb could further protect mice with AN and the underlying mechanisms."	( Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis. Ji, B; Liu, J; Shen, Q; Xu, H; Yin, Y; Yu, J, 2023)	0.91
" Here, through the engineering of prodrug technology combined with the nanodrug-delivery system (NDDS) strategy, we modified the main active site of TPL C14-OH by esterification reaction to obtain a highly lipophilic prodrug, and then encapsulated the drug in a phospholipid bilayer in liposomal vehicles through the thin-film hydration method for efficient delivery."	( Synergism and attenuation of triptolide through prodrug engineering combined with liposomal scaffold strategy to enhance inhibition in pancreatic cancer. Chen, H; Chen, J; Chen, Z; Kuang, Y; Liu, M; Tai, Z; Wang, X; Wei, R; Wu, X; Yang, J; Zhu, Q, 2023)	1.2

Excerpt	Reference	Relevance
" The cumulative transdermal absorption rate in 12 h was 73."	( Triptolide loaded solid lipid nanoparticle hydrogel for topical application. Hu, S; Li, X; Mei, Z; Wu, Q; Yang, X, 2005)	1.77
" Oral absolute bioavailability was 72."	( Pharmacokinetic study of triptolide, a constituent of immunosuppressive chinese herb medicine, in rats. A, J; Shao, F; Sun, J; Wang, G; Xie, H; Zhu, X, 2007)	0.64
" Taken together, our results confirmed that inactivation of hepatic P450s abolishes the ability in metabolism of triptolide in the liver, subsequently resulting in an increase in bioavailability and toxicity of triptolide in vivo."	( Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity. Chen, M; Gong, L; Gu, J; Li, Y; Luan, Y; Qi, X; Ren, J; Wu, X; Wu, Y; Xiao, Y; Xing, G; Xue, X; Yao, J, 2011)	0.84
" The absolute oral bioavailability of triptolide is 63."	( Absorption and Metabolism Characteristics of Triptolide as Determined by a Sensitive and Reliable LC-MS/MS Method. Chen, Y; Gong, X; Wu, Y, 2015)	0.95
" Besides, the results of skin-blood synchronous microdialysis showed that the triptolide concentration in skin was higher than that in blood, and the cubic and hexagonal liquid crystals significantly increased the bioavailability of triptolide."	( Cubic and hexagonal liquid crystals as drug carriers for the transdermal delivery of triptolide. Gui, SY; Jiang, XJ; Shan, QQ; Shu, ZX; Wang, FY, 2019)	0.97
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" The present review examined the chemistry and bioavailability of celastrol and triptolide, and their molecular targets in treating RA."	( Therapeutic targets of thunder god vine (Tripterygium wilfordii hook) in rheumatoid arthritis (Review). Dai, E; Song, X; Zhang, Y, 2020)	0.79
" However, physicochemical properties such as poor solubility and bioavailability are the main concerns regarding the TPL safety and efficacy in clinical studies since trials have reported adverse side effects alongside the excellent TPL therapeutic effects."	( Therapeutic applications and delivery systems for triptolide. Bentley, MVLB; Kravicz, M; Praça, FG; Viegas, JSR, 2020)	0.81
" Therefore, we prepared TPL-loaded cyclodextrin-based metal-organic framework (TPL@CD-MOF) to improve the solubility and bioavailability of TPL, thus enhancing the anti-tumor effect on HCC."	( γ-Cyclodextrin metal-organic framework as a carrier to deliver triptolide for the treatment of hepatocellular carcinoma. Gong, C; Li, Z; Wang, J; Wang, R; Wang, Y; Yang, G; Yang, M; Yuan, Y, 2022)	0.96
" Triptolide (TP) has anti-inflammatory properties, and it can protect the cartilage matrix, but its clinical application has been limited due to poor solubility, low bioavailability and systemic toxicity."	( Folate-modified triptolide liposomes target activated macrophages for safe rheumatoid arthritis therapy. Geng, HX; Guo, RB; Kong, L; Li, XT; Liu, Y; Wang, YJ; Wu, YN; Yan, DK; Yu, YJ; Zhang, XY, 2022)	1.98
"Triptolide is a valuable multipotent antitumor diterpenoid in Tripterygium wilfordii, and its C-14 hydroxyl group is often selected for modification to enhance both the bioavailability and antitumor efficacy."	( Tandemly duplicated CYP82Ds catalyze 14-hydroxylation in triptolide biosynthesis and precursor production in Saccharomyces cerevisiae. Gao, J; Gao, W; Hu, T; Huang, L; Li, D; Liu, Y; Lu, Y; Ma, L; Su, P; Tong, Y; Tu, L; Wang, J; Wu, X; Yin, Y; Zhang, Y; Zhao, H; Zhao, Y; Zhou, J, 2023)	2.6
" The results indicate that long-term sustained release microspheres of triptolide can be considered a strategy to overcome the low bioavailability and poor patient compliance with conventional triptolide tablets."	( Development and optimization of sustained release triptolide microspheres. Deng, AP; Fu, TX; Qiu, Q; Xie, XY; Zeng, HL, 2023)	1.4

Excerpt	Relevance	Reference
" All six rats treated with a high dosage of triptolide were infertile during the second (63-70 days) mating trial."	( Triptolide: a potential male contraceptive. Baravarian, S; Chaichana, S; Leung, A; Lue, Y; Reutrakul, V; Sangsawan, R; Sinha Hikim, AP; Swerdloff, RS; Wang, C, )	1.84
" Previously, we showed that oral administration of triptolide at a dosage of 100 microg/kg per body weight for 70 days completely inhibited fertility in male rats, with little or no demonstrable detrimental effect on spermatogenesis and Leydig cell function as determined by testicular light microscopic appearance and serum and intratesticular testosterone levels."	( Posttesticular antifertility action of triptolide in the male rat: evidence for severe impairment of cauda epididymal sperm ultrastructure. Hikim, AP; Lue, YH; Reutrakul, V; Sangsuwan, R; Swerdloff, RS; Wang, C, )	0.65
" A phase I trial of PG490-88 for solid tumors began recently and safety and optimal dosing data should accrue within the next 12 months."	( PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Chung, C; Fidler, JM; Gao, M; Li, K; Rosen, GD; Ross, JA; Wei, K, 2003)	0.62
" Research and development programs are underway for a new modified release dosage form of tacrolimus (MR-4), a new analog of leflunomide (FK 778), and several novel compounds (PG 490-88, AGI 1096) in collaboration with other companies."	( New drugs to improve transplant outcomes. First, MR; Fitzsimmons, WE, 2004)	0.32
" It is very important to develop a new dosage form of high effect and low toxicity by making use of advanced technology according to its characteristics."	( [Progress in research on triptolide]. Dong, J; Liu, MX; Xu, HB; Yang, XL; Yang, YJ, 2005)	0.63
"40 microg x kg(-1) TP can significantly inhibited the CIA, and the effect equal to the dosage of 17."	( [Effect of combination glycyrrhiizin and triptolide on TNF-alpha and IL-10 in serum of collagen induced arthritis rats]. Chen, SL; Lu, AP; Lu, C; Yang, DJ; Zhang, WD; Zhao, HY, 2007)	0.61
" There were no significant differences in T(max), T1/2 alpha and T1/2 beta among the three ig dosage groups."	( [Pharmacokinetics of triptolide in Beagle dogs]. Shao, F; Sun, JG; Wang, GJ; Xie, HT; Zhang, R; Zhu, XY, 2007)	0.66
" Tri was intraperitoneally injected in the dosage of 100 microg/(kg."	( [Suppression of murine EAE by triptolide is related to downregulation of INF-gamma and upregulation of IL-10 secretion in splenic lymphocytes]. Fan, HC; Guo, MF; Ji, N; Liang, LY; Ma, CG; Ren, XR; Sun, YS; Yu, JZ, 2009)	0.64
" When dosed in vivo, triptolide potently inhibited angiogenesis at 100 nM in Matrigel plug assay."	( Triptolide functions as a potent angiogenesis inhibitor. But, PP; Ge, W; He, MF; Huang, YH; Shaw, PC; Wu, LW, 2010)	2.12
"Using in vitro and in vivo experiments, we investigated the combined effect of TPL and ATF at a low dosage on cell proliferation, cell apoptosis, cell cycle distribution, cell migration, signalling pathways, xenograft tumour growth and angiogenesis."	( Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase. Hua, ZC; Li, J; Lin, Y; Peng, N; Zhuang, H, 2013)	0.74
" Chemical acceleration of ovarian failure via oral dosing also would improve management of rat pest populations."	( Accelerated follicle depletion in vitro and in vivo in Sprague-Dawley rats using the combination of 4-vinylcyclohexene diepoxide and triptolide. Bennett, A; Dyer, CA; Fisher, T; Mayer, LP; Pyzyna, B; Raymond-Whish, S; Schmuki, S, 2013)	0.59
" They were divided into two groups: the treatment group (n = 42; Triptolide at a dosage of 1 mg/kg · d, combined with prednisone at a dosage of 2 mg/kg · d, within a course of medium-to-long-term therapy of 6 to 9 months) and the control group (n = 14; prednisone alone, with the same procedure)."	( Efficacy of triptolide for children with moderately severe Henoch-Schönlein purpura nephritis presenting with nephrotic range proteinuria: a prospective and controlled study in China. Du, L; Fu, H; Jin, X; Liu, A; Mao, J; Shen, H; Shu, Q; Wang, J; Wu, L, 2013)	1.01
" Six Gy was a moderate dosage of X-ray for CNE2, and 25 nM TPL was close to IC50 value of CNE2 and CNE2-SR."	( Triptolide inhibits cell growth and GRP78 protein expression but induces cell apoptosis in original and radioresistant NPC cells. Chen, Z; Feng, X; Lai, C; Li, C; Long, X; Lv, W; Wang, R; Zhang, B, 2016)	1.88
" Furthermore, the immune mediator TLR4, downstream activator NF-κB p65, macrophage infiltration (CD68+), pro-inflammatory cytokines (TNF-α, IL-1β), cell adhesion molecule (VCAM-1) and chemokine (MCP-1) were significantly suppressed when treated with medium and high dosage triptolide compared with the diabetic group."	( Protective effects of triptolide on TLR4 mediated autoimmune and inflammatory response induced myocardial fibrosis in diabetic cardiomyopathy. Chang, BC; Chen, LM; Guo, X; Li, CJ; Ma, ZJ; Wang, SS; Wang, XY; Xue, M; Yang, W; Zhang, XN; Zhao, R, 2016)	0.93
" Compared with low dosage TPL and HHT single-use groups, the cell proliferation and colony formation efficiency were lower, and the cell apoptosis rate was higher in the combined group."	( [Effects of Triptolide Combined with Homoharringtonine on Proliferation and Apoptosis of KG-1α Cells]. Li, X; Lin, ZX; Liu, JY; Wu, Y; Yuan, XH, 2018)	0.86
" Then the penetration rate, transdermal volume and skin reserve of three dosage forms (hydroplasy gel, ordinary gel, and cream) to investigate the transdermal properties of ferulic acid and triptolide in vitro of triptolide and ferulic acid ethosomes gel."	( [Preparation and transdermal permeation of triptolide and ferulic acid ethosomes gel Chen, LH; Guan, YM; He, LF; Jin, C; Tao, L; Wu, L; Zhu, WF, 2018)	0.93
" Significant differences in the metabolite profiles of the liver, kidney and plasma existed between the toxic and therapeutically dosed mice."	( Identification of hepatotoxic and nephrotoxic potential markers of triptolide in mice with delayed-type hypersensitivity. Li, M; Qu, L; Wang, Z; Zhang, J, 2018)	0.72
"2 mg/kg) with and without DMY in different dosage regimens, then a sensitive and reliable LC-MS/MS method was developed and applied to assess the pharmacokinetics of TP."	( Dihydromyricetin affect the pharmacokinetics of triptolide in rats. Cai, H; Chen, L; Deng, Y; Fang, P; Guo, L; He, G; Li, H; Tan, S; Xiang, D; Yan, M; Zhang, B, 2020)	0.81
"Hepatotoxicity was determined based on assessment of liver injury after dosing mice with TW at different circadian time points."	( Circadian clock regulates hepatotoxicity of Tripterygium wilfordii through modulation of metabolism. Lu, D; Tong, Y; Wu, B; Zhao, H, 2020)	0.56
"After being made into microspheres, TPL can stay in the joint tissue for a long time, further reducing the number of times joint cavity administration, and its sustained release effect was significantly improved compared with the solution dosage form."	( Pharmacokinetics, distribution and efficacy of triptolide PLGA microspheres after intra-articular injection in a rat rheumatoid arthritis model. Che, K; Liu, Y; Wang, L, 2021)	0.88
" Importantly, TPL/NPs also showed higher efficacy in shrinking tumor size and blocking lung metastasis with decreased systemic toxicity in a 4T1 breast cancer mouse model at an equivalent or lower TPL dosage compared with that of free TPL."	( Novel CD44-targeting and pH/redox-dual-stimuli-responsive core-shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis. Cao, Z; Fu, C; Gu, H; Li, J; Luo, X; Ma, J; Ren, Y; Shi, J; Wu, Y; Zhang, J, 2021)	0.84
" Suitable combination therapy, new dosage forms and new routes of administration can effectively reduce toxicity and increase the effect."	( A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes. Dai, L; He, GN; Song, J, 2023)	1.18
" However, its clinical application has been limited by the narrow therapeutic window, side effects associated with plasma drug fluctuations, low oral bioavailability, and poor patient compliance with the long and frequent dosing regimen."	( Development and optimization of sustained release triptolide microspheres. Deng, AP; Fu, TX; Qiu, Q; Xie, XY; Zeng, HL, 2023)	1.16

Role	Description
antispermatogenic agent	An agent that destroy spermatozoa in the male genitalia and block spermatogenesis.
plant metabolite	Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
organic heteroheptacyclic compound
epoxide	Any cyclic ether in which the oxygen atom forms part of a 3-membered ring.
gamma-lactam	A lactam in which the amide bond is contained within a five-membered ring, which includes the amide nitrogen and the carbonyl carbon.
diterpenoid	Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
phosphopantetheinyl transferase	Bacillus subtilis	Potency	14.1254	0.1413	37.9142	100.0000	AID1490
PPM1D protein	Homo sapiens (human)	Potency	0.0829	0.0052	9.4661	32.9993	AID1347411
TDP1 protein	Homo sapiens (human)	Potency	0.1371	0.0008	11.3822	44.6684	AID686978; AID686979
NPC intracellular cholesterol transporter 1 precursor	Homo sapiens (human)	Potency	0.0891	0.0126	2.4518	25.0177	AID485313
ras-related protein Rab-9A	Homo sapiens (human)	Potency	1.0000	0.0002	2.6215	31.4954	AID485297
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	0.3571	0.0079	8.2332	1,122.0200	AID2546; AID2551
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.0891	0.8913	12.0676	28.1838	AID1487
Interferon beta	Homo sapiens (human)	Potency	0.0829	0.0033	9.1582	39.8107	AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Prostaglandin G/H synthase 2	Homo sapiens (human)	IC50 (µMol)	0.0400	0.0001	0.9950	10.0000	AID403340
Proteinase-activated receptor 2	Homo sapiens (human)	IC50 (µMol)	0.0185	0.0025	1.3479	6.6000	AID772482; AID772483
dCTP pyrophosphatase 1	Homo sapiens (human)	IC50 (µMol)	30.9000	0.0790	0.0790	0.0790	AID1281051; AID1440808; AID1448206; AID1487635
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
prostaglandin biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
angiogenesis	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to oxidative stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
embryo implantation	Prostaglandin G/H synthase 2	Homo sapiens (human)
learning	Prostaglandin G/H synthase 2	Homo sapiens (human)
memory	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of blood pressure	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of cell population proliferation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to xenobiotic stimulus	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to nematode	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to fructose	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to manganese ion	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of vascular endothelial growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
cyclooxygenase pathway	Prostaglandin G/H synthase 2	Homo sapiens (human)
bone mineralization	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of prostaglandin biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of fever generation	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of synaptic plasticity	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Prostaglandin G/H synthase 2	Homo sapiens (human)
prostaglandin secretion	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to estradiol	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to lipopolysaccharide	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to vitamin D	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to heat	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to tumor necrosis factor	Prostaglandin G/H synthase 2	Homo sapiens (human)
maintenance of blood-brain barrier	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of protein import into nucleus	Prostaglandin G/H synthase 2	Homo sapiens (human)
hair cycle	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of apoptotic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of cell cycle	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of vasoconstriction	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of smooth muscle contraction	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of smooth muscle contraction	Prostaglandin G/H synthase 2	Homo sapiens (human)
decidualization	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of inflammatory response	Prostaglandin G/H synthase 2	Homo sapiens (human)
brown fat cell differentiation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to glucocorticoid	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of calcium ion transport	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to fatty acid	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to mechanical stimulus	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to lead ion	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to ATP	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to hypoxia	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to non-ionic osmotic stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to fluid shear stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of transforming growth factor beta production	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of fibroblast growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of brown fat cell differentiation	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of platelet-derived growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular oxidant detoxification	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of neuroinflammatory response	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to homocysteine	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to angiotensin	Prostaglandin G/H synthase 2	Homo sapiens (human)
vasodilation	Proteinase-activated receptor 2	Homo sapiens (human)
T cell activation involved in immune response	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of leukocyte chemotaxis	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of cytokine production involved in immune response	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of glomerular filtration	Proteinase-activated receptor 2	Homo sapiens (human)
inflammatory response	Proteinase-activated receptor 2	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Proteinase-activated receptor 2	Homo sapiens (human)
blood coagulation	Proteinase-activated receptor 2	Homo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathway	Proteinase-activated receptor 2	Homo sapiens (human)
regulation of blood coagulation	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of cell migration	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of actin filament depolymerization	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of pseudopodium assembly	Proteinase-activated receptor 2	Homo sapiens (human)
negative regulation of chemokine production	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of chemokine production	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of type II interferon production	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of interleukin-10 production	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of interleukin-6 production	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of interleukin-8 production	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of superoxide anion generation	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of toll-like receptor 2 signaling pathway	Proteinase-activated receptor 2	Homo sapiens (human)
negative regulation of toll-like receptor 3 signaling pathway	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of toll-like receptor 3 signaling pathway	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of toll-like receptor 4 signaling pathway	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of Rho protein signal transduction	Proteinase-activated receptor 2	Homo sapiens (human)
neutrophil activation	Proteinase-activated receptor 2	Homo sapiens (human)
regulation of canonical NF-kappaB signal transduction	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of eosinophil degranulation	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of GTPase activity	Proteinase-activated receptor 2	Homo sapiens (human)
innate immune response	Proteinase-activated receptor 2	Homo sapiens (human)
cell-cell junction maintenance	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Proteinase-activated receptor 2	Homo sapiens (human)
regulation of JNK cascade	Proteinase-activated receptor 2	Homo sapiens (human)
negative regulation of JNK cascade	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of JNK cascade	Proteinase-activated receptor 2	Homo sapiens (human)
negative regulation of insulin secretion	Proteinase-activated receptor 2	Homo sapiens (human)
leukocyte migration	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of chemotaxis	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of positive chemotaxis	Proteinase-activated receptor 2	Homo sapiens (human)
defense response to virus	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of phagocytosis, engulfment	Proteinase-activated receptor 2	Homo sapiens (human)
establishment of endothelial barrier	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Proteinase-activated receptor 2	Homo sapiens (human)
thrombin-activated receptor signaling pathway	Proteinase-activated receptor 2	Homo sapiens (human)
leukocyte proliferation	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of neutrophil mediated killing of gram-negative bacterium	Proteinase-activated receptor 2	Homo sapiens (human)
mature conventional dendritic cell differentiation	Proteinase-activated receptor 2	Homo sapiens (human)
potassium channel activating, G protein-coupled receptor signaling pathway	Proteinase-activated receptor 2	Homo sapiens (human)
positive regulation of renin secretion into blood stream	Proteinase-activated receptor 2	Homo sapiens (human)
regulation of chemokine (C-X-C motif) ligand 2 production	Proteinase-activated receptor 2	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Proteinase-activated receptor 2	Homo sapiens (human)
dTTP catabolic process	dCTP pyrophosphatase 1	Homo sapiens (human)
dCTP catabolic process	dCTP pyrophosphatase 1	Homo sapiens (human)
nucleoside triphosphate catabolic process	dCTP pyrophosphatase 1	Homo sapiens (human)
DNA protection	dCTP pyrophosphatase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
peroxidase activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
prostaglandin-endoperoxide synthase activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
enzyme binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
heme binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein homodimerization activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
metal ion binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen	Prostaglandin G/H synthase 2	Homo sapiens (human)
G-protein alpha-subunit binding	Proteinase-activated receptor 2	Homo sapiens (human)
protease binding	Proteinase-activated receptor 2	Homo sapiens (human)
G protein-coupled receptor activity	Proteinase-activated receptor 2	Homo sapiens (human)
signaling receptor binding	Proteinase-activated receptor 2	Homo sapiens (human)
protein binding	Proteinase-activated receptor 2	Homo sapiens (human)
thrombin-activated receptor activity	Proteinase-activated receptor 2	Homo sapiens (human)
G-protein beta-subunit binding	Proteinase-activated receptor 2	Homo sapiens (human)
signaling receptor activity	Proteinase-activated receptor 2	Homo sapiens (human)
magnesium ion binding	dCTP pyrophosphatase 1	Homo sapiens (human)
protein binding	dCTP pyrophosphatase 1	Homo sapiens (human)
pyrimidine deoxyribonucleotide binding	dCTP pyrophosphatase 1	Homo sapiens (human)
identical protein binding	dCTP pyrophosphatase 1	Homo sapiens (human)
nucleoside triphosphate diphosphatase activity	dCTP pyrophosphatase 1	Homo sapiens (human)
dCTP diphosphatase activity	dCTP pyrophosphatase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
nuclear inner membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
nuclear outer membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum lumen	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
caveola	Prostaglandin G/H synthase 2	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein-containing complex	Prostaglandin G/H synthase 2	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 2	Homo sapiens (human)
early endosome	Proteinase-activated receptor 2	Homo sapiens (human)
Golgi apparatus	Proteinase-activated receptor 2	Homo sapiens (human)
plasma membrane	Proteinase-activated receptor 2	Homo sapiens (human)
pseudopodium	Proteinase-activated receptor 2	Homo sapiens (human)
plasma membrane	Proteinase-activated receptor 2	Homo sapiens (human)
nucleus	dCTP pyrophosphatase 1	Homo sapiens (human)
nucleoplasm	dCTP pyrophosphatase 1	Homo sapiens (human)
mitochondrion	dCTP pyrophosphatase 1	Homo sapiens (human)
cytosol	dCTP pyrophosphatase 1	Homo sapiens (human)
cytosol	dCTP pyrophosphatase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (211)

Assay ID	Title	Year	Journal	Article
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID330294	Effect on Pkd1+/- and Pkd1+/- inter crossed mouse assessed as Pdk1-/- genotype distribution in embryo at 0.07 mg/kg, ip from E10.5 stage to untill birth relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID422036	Cytotoxicity against human PC3 cells by SRB assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1424467	Increase in lifespan of Caenorhabditis elegans	2017	European journal of medicinal chemistry, Dec-15, Volume: 142	From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
AID1373533	Antiinflammatory activity in African green monkey CV1 cells assessed as inhibition of LPS-induced TNF-alpha production pre-incubated for 1 hr before LPS stimulation for 23 hrs by ELISA method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Triptolide derivatives as potential multifunctional anti-Alzheimer agents: Synthesis and structure-activity relationship studies.
AID1690070	Antiproliferative activity against human BGC-823 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies.
AID422044	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID330287	Increase in PC2 dependent calcium release in mouse Pkd1+/- cells at 100 nM	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1324618	Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced receptor transcriptional activity at 500 nM after 24 hrs by dual luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID772483	Antagonist activity at human PAR2 expressed in human A549 cells assessed as inhibition of 2f-LIGRLO-NH2-induced NFkappaB activation by luciferase reporter gene assay	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Toward drugs for protease-activated receptor 2 (PAR2).
AID772482	Antagonist activity at human PAR2 expressed in human A549 cells coexpressing TACR1 assessed as inhibition of substance P-induced IL-8 production by ELISA	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Toward drugs for protease-activated receptor 2 (PAR2).
AID1448206	Inhibition of human full length N-terminal His-tagged dCTPase expressed in Escherichia coli BL21(DE3) using dCTP as substrate by HTS-based malachite green assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors.
AID1586799	Antitumor activity against human HepG2 cells xenografted in Balb/c nude mouse assessed as reduction in tumor growth at 0.2 mg/kg, ip administered once daily for 15 days	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation.
AID1782196	Hepatotoxicity in transgenic zebrafish Tg(1-fabp:EGFP) assessed as liver damage by measuring decrease in fluorescence intensity and area at 0.5 uM measured after 96 hrs	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID1859336	Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases.
AID333842	Cytotoxicity against human KB cells
AID1782187	Toxicity in zebrafish AB assessed as mortality at 0.05 to 2 uM measured at 72 hrs postfertilization	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID1850627	Induction of apoptosis in human NCI-H460 cells assessed as late apoptotic cells at 0.01 uM measured after 48 hrs by Annexin V-FITC/PI staining method (Rvb = 8.57%)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1850651	Toxicity in BALB/c nude mouse xenografted with human NCI-H460 cells assessed as morphological change in heart at 0.2 mg/kg administered ip, qd for 2 weeks	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1068364	Cytotoxicity against human SKOV3 cells after 72 hrs by sulforhodamine B assay	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Design, synthesis and anticancer activity evaluation of novel C14 heterocycle substituted epi-triptolide.
AID1546493	Antitumour activity against human CFPAC-1 cells xenografted in ip dosed nude BALB/c mouse assessed as tumor weight for 18 days	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Artemisia: a promising plant for the treatment of cancer.
AID1782190	Toxicity in zebrafish AB assessed as decrease in hatching rate at 0.25 to 2 uM measured at 72 hrs postfertilization	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID1690071	Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies.
AID1850598	Cytotoxicity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1373546	Stability in neurobasal cell culture medium supplemented with B-27 and N2 assessed as compound hydrolysis by LC-HR MS method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Triptolide derivatives as potential multifunctional anti-Alzheimer agents: Synthesis and structure-activity relationship studies.
AID1850638	Induction of ROS accumulation in human NCI-H460 cells measured upto 100 nM after 42 to 48 hrs by DCFH-DA staining based flow cytometric analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1782149	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID461852	Aqueous solubility in water	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
AID1586810	Renal toxicity in Balb/c nude mouse xenografted with human HepG2 cells assessed as glomerular capillary loop lesions at 0.2 mg/kg, ip administered once daily for 15 days by hematoxylin and eosin staining based microscopic analysis	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation.
AID1850653	Toxicity in BALB/c nude mouse xenografted with human NCI-H460 cells assessed as morphological change in lung at 0.2 mg/kg administered ip, qd for 2 weeks	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1175361	Cytotoxicity against human U251 cells assessed as inhibition of cell proliferation by sulforhodamine B assay	2014	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24	Semisynthesis of triptolide analogues: effect of B-ring substituents on cytotoxic activities.
AID1850595	Cytotoxicity against human HCT-116 cells incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID422038	Cytotoxicity against human SKOV3 cells by SRB assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1850639	Induction of mitochondrial membrane potential loss in human NCI-H460 cells by flow cytometric analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1850635	Induction of apoptosis in human NCI-H460 cells assessed as late apoptotic cells at 1 uM measured after 48 hrs by Annexin V-FITC/PI staining method (Rvb = 8.57%)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID330288	Increase in PC2 dependent calcium release in mouse Pkd1-/- cells at 100 nM	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID330289	Increase in calcium release in mouse Pkd2-/- cells at 100 nM	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1718928	Cytotoxicity against human HPDE cells assessed as reduction in cell viability by MTT assay	2021	Bioorganic & medicinal chemistry letters, 02-01, Volume: 33	ATB
AID1718927	Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by MTT assay	2021	Bioorganic & medicinal chemistry letters, 02-01, Volume: 33	ATB
AID1850600	Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1850593	Cytotoxicity against human SW-620 cells incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID461855	Cytotoxicity against MEF after 72 hrs by MTS assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
AID1324617	Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced receptor transcriptional activity at 5 uM after 24 hrs by dual luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1850592	Octanol-water partition coefficient, logD of the compound in PBS at pH 7.4 by liquid chromatography based mass spectrometric analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID461856	Cytotoxicity against NHFB after 72 hrs by MTS assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
AID422032	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID330297	Effect on Pkd1+/- and Pkd1+/- inter crossed mouse assessed as decrease in kidney cyst burden in Pdk1-/- genotypic embryos at 0.07 mg/kg, ip from E10.5 stage to untill birth relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1373541	Toxicity in African green monkey CV1 cells assessed as effect on cell viability incubated for 24 hrs by CCK8 assay	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Triptolide derivatives as potential multifunctional anti-Alzheimer agents: Synthesis and structure-activity relationship studies.
AID330290	Increase in calcium response in mouse Pkd cells at 25 mM	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1850596	Cytotoxicity against human HT-29 cells incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID422051	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1586809	Renal toxicity in Balb/c nude mouse xenografted with human HepG2 cells assessed as increase in serum BUN levels at 0.2 mg/kg, ip administered once daily for 15 days	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation.
AID1782188	Toxicity in zebrafish AB assessed as decrease in body length at 0.25 to 2 uM measured at 72 hrs postfertilization	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID1373534	Neuroprotective activity against amyloid beta (1 to 42) peptide-induced cytotoxicty in CD1 mouse primary cortical neurons assessed as increase in cell viability at 0.01 to 1 nM pre-incubated for 1 hr before amyloid beta (1 to 42) addition and measured aft	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Triptolide derivatives as potential multifunctional anti-Alzheimer agents: Synthesis and structure-activity relationship studies.
AID1265936	Drug level in glycine buffer treated with Sodium (((5bS,6aS,7aR,8R,8aS,9aS,9bS,10aS,10bS)-8a-Isopropyl-10b-methyl-3-oxo-1,2,3,5,5b,6,6a,8,8a,9a,9b,10b-dodecahydrotris-(oxireno)[2',3':4b,5;'',3'':6,7;2''',3''':8a,9]phenanthro[1,2-c]furan-8-yl)oxy)methyl Ph	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1850641	Antitumor activity against human NCI-H460 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 0.2 mg/kg, ip, qd for 2 weeks relative to control	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID422035	Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID326745	Cytotoxicity against human A549 cells	2008	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7	Fluorination of triptolide and its analogues and their cytotoxicity.
AID1850603	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability in presence of Phloretin incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID422043	Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID330296	Effect on Pkd1+/- and Pkd1+/- inter crossed mouse assessed as embryonic developmental time at 0.07 mg/kg, ip from E10.5 stage to untill birth relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1690095	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies.
AID422033	Cytotoxicity against human A549 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1555829	Cytotoxicity against human Jurkat cells assessed as decrease in cell viability	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Triptolide: Medicinal chemistry, chemical biology and clinical progress.
AID1850601	Cytotoxicity against human HaCaT cells incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID461862	Cytotoxicity against imatinib-resistant human KBM5 cells harboring Bcr-Abl T315I mutant at 0.001 to 17 uM after 72 hrs by MTS assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
AID461854	Cytotoxicity against imatinib-resistant human KBM5 cells harboring Bcr-Abl T315I mutant after 72 hrs by MTS assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
AID1265866	Aqueous solubility of the compound in Tris buffer at pH 7.4 at room temperature by HPLC analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1782189	Toxicity in zebrafish AB assessed as increase in embryo malformation rate at 0.5 to 2 uM measured at 72 hrs postfertilization	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID1586767	Inhibition of XBP ATPase activity in human HeLa cell nuclear extracts	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation.
AID330282	Growth inhibition of mouse Pkd2-/- PC2-null cells assessed as cell death at 100 nM after 48 hrs	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID422034	Cytotoxicity against human K562 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID461861	Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl at 0.001 to 17 uM after 72 hrs by MTS assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
AID330283	Growth inhibition of PC2 reconstituted mouse Pkd2-/- cells assessed as cell death at 100 nM after 24 hrs	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1586803	Hepatotoxicity in Balb/c nude mouse xenografted with human HepG2 cells assessed as effect on serum AST levels at 0.2 mg/kg, ip administered once daily for 15 days	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation.
AID1555827	Cytotoxicity against human HeLa cells assessed as decrease in cell viability	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Triptolide: Medicinal chemistry, chemical biology and clinical progress.
AID422039	Cytotoxicity against human MKN28 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1424478	Solubility of the compound	2017	European journal of medicinal chemistry, Dec-15, Volume: 142	From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
AID422042	Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID525907	Antiproliferative activity against human SKOV3 cells after 72 hrs by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and biological evaluation of novel triptolide analogues for anticancer activity.
AID330291	Increase in calcium release in mouse Pkd1-/- cells at 50 uM in presence of RyR antagonist dantrolene	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1690096	Antiinflammatory activity against ICR mouse assessed as inhibition of croton oil-induced edema formation at 0.3 mg/kg, po measured after 4 hrs relative to control	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies.
AID1586769	Cytotoxicity against primary hepatocytes (unknown origin) after 48 hrs by XTT assay	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation.
AID1555840	Cytotoxicity against human Re-01 cells assessed as decrease in cell viability	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Triptolide: Medicinal chemistry, chemical biology and clinical progress.
AID1690072	Antiproliferative activity against human B16-F10 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies.
AID1850656	Toxicity in BALB/c nude mouse xenografted with human NCI-H460 cells assessed as reduction of cytoplasmic vacuoles at 0.2 mg/kg administered ip, qd for 2 weeks	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1242181	Inhibition of HSF1 in human HeLa cells assessed as potentiation of radicicol and heat-induced increase in cell death at 60 nM relative to radicicol and heat alone	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Regulating the master regulator: Controlling heat shock factor 1 as a chemotherapy approach.
AID403340	Inhibition of COX2	2005	Journal of natural products, Jul, Volume: 68, Issue:7	Expanding the ChemGPS chemical space with natural products.
AID1850597	Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1859335	Antiproliferative activity against androgen-sensitive human LNCaP cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases.
AID1850626	Induction of apoptosis in human NCI-H460 cells assessed as early apoptotic cells at 0.01 uM measured after 48 hrs by Annexin V-FITC/PI staining method (Rvb = 3.46%)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID461853	Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl after 72 hrs by MTS assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
AID422050	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1546492	Antitumour activity against human PANC1 cells xenografted in ip dosed nude BALB/c mouse assessed as tumor weight for 18 days	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Artemisia: a promising plant for the treatment of cancer.
AID1555839	Cytotoxicity against human OVCAR1 cells assessed as decrease in cell viability	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Triptolide: Medicinal chemistry, chemical biology and clinical progress.
AID1850633	Induction of apoptosis in human NCI-H460 cells assessed as viable cells at 1 uM measured after 48 hrs by Annexin V-FITC/PI staining method (Rvb = 86.4%)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1782146	Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID422037	Cytotoxicity against human MDA-MB-468 cells by SRB assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1850599	Cytotoxicity against HUVEC incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID422045	Cytotoxicity against human 786-O cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1782150	Cytotoxicity against human HBE cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID1424460	Growth inhibition of human A549 cells	2017	European journal of medicinal chemistry, Dec-15, Volume: 142	From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
AID1891783	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by CCK-8 assay	2022	Bioorganic & medicinal chemistry letters, 07-01, Volume: 67	Design and synthesis of cinnamic acid triptolide ester derivatives as potent antitumor agents and their biological evaluation.
AID1434295	Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Identification of a diverse synthetic abietane diterpenoid library for anticancer activity.
AID1850631	Induction of apoptosis in human NCI-H460 cells assessed as late apoptotic cells at 0.1 uM measured after 48 hrs by Annexin V-FITC/PI staining method (Rvb = 8.57%)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1690068	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies.
AID1586806	Hepatotoxicity in Balb/c nude mouse xenografted with human HepG2 cells assessed as pathological abnormalities at 0.2 mg/kg, ip administered once daily for 15 days by hematoxylin and eosin staining based microscopic analysis	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation.
AID1690069	Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies.
AID1586768	Cytotoxicity against human HepG2 cells after 48 hrs by XTT assay	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation.
AID330285	Increase in p21CIP/WAF expression in mouse Pkd1-/- cells at 100 nM after 96 hrs by Western blot analysis	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1850612	Down regulation of RNA polymerase II in human NCI-H460 cells measured after 48 hrs by Western blotting analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID263410	Cytotoxicity against human A549 lung tumor cells	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Semisynthesis of C-ring modified triptolide analogues and their cytotoxic activities.
AID1373542	Neuroprotective activity against amyloid beta (1 to 42) peptide-induced cytotoxicty in CD1 mouse primary cortical neurons assessed as increase in cell viability at 0.01 nM pre-incubated for 1 hr before amyloid beta (1 to 42) addition and measured after 24	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Triptolide derivatives as potential multifunctional anti-Alzheimer agents: Synthesis and structure-activity relationship studies.
AID1707230	Cytotoxicity against human Panc-1 cells incubated for 48 hrs by CCK8 assay	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID1586808	Renal toxicity in Balb/c nude mouse xenografted with human HepG2 cells assessed as increase in serum creatinine levels at 0.2 mg/kg, ip administered once daily for 15 days	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation.
AID422053	Cytotoxicity against human Rh30 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1782144	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID1782152	Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID422040	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1850629	Induction of apoptosis in human NCI-H460 cells assessed as viable cells at 0.1 uM measured after 48 hrs by Annexin V-FITC/PI staining method (Rvb = 86.4%)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1850657	Toxicity in BALB/c nude mouse xenografted with human NCI-H460 cells assessed as reduction of cytoplasmic nuclei at 0.2 mg/kg administered ip, qd for 2 weeks	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID263411	Cytotoxicity against human HT29 colon tumor cells	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Semisynthesis of C-ring modified triptolide analogues and their cytotoxic activities.
AID525908	Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and biological evaluation of novel triptolide analogues for anticancer activity.
AID422041	Cytotoxicity against human SW1116 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1434299	Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Identification of a diverse synthetic abietane diterpenoid library for anticancer activity.
AID330295	Effect on Pkd1+/- and Pkd1+/- inter crossed mouse assessed as wet kidney weight in Pdk1-/- genotypic embryo at 0.07 mg/kg, ip from E10.5 stage to untill birth relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1850634	Induction of apoptosis in human NCI-H460 cells assessed as early apoptotic cells at 1 uM measured after 48 hrs by Annexin V-FITC/PI staining method (Rvb = 3.46%)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1782185	Antitumor activity against human HepG2 cells xenografted in zebra fish AB assessed as tumor growth inhibition at 0.5 to 1 uM measured after 48 hrs by fluorescence microscopic analysis	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID1546491	Cytotoxicity against human CFPAC-1 cells assessed as cell viability after 24 hrs by MTT assay relative to control	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Artemisia: a promising plant for the treatment of cancer.
AID1850628	Induction of apoptosis in human NCI-H460 cells assessed as necrotic cells at 0.01 uM measured after 48 hrs by Annexin V-FITC/PI staining method (Rvb = 1.59%)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID422055	Cytotoxicity against human U251 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID594370	Cytotoxicity against human A549 cells	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Semisynthesis of triptolide analogues: effect of γ-lactone and C-14 substituents on cytotoxic activities.
AID1850658	Toxicity in BALB/c nude mouse xenografted with human NCI-H460 cells assessed as decreased spermatogenic cells at 0.2 mg/kg administered ip, qd for 2 weeks	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1242178	Inhibition of HSF1 in human INA63 cells assessed as potentiation of NVP-AUY-922-induced reduction in cell proliferation at 5 nM relative to NVP-AUY-922 alone	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Regulating the master regulator: Controlling heat shock factor 1 as a chemotherapy approach.
AID330281	Growth inhibition of mouse Pkd2-/- PC2-null cells assessed as cell viability at 100 nM after 24 hrs	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1690078	Toxicity in po dosed ICR mouse assessed as survival rate observed for 14 days	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies.
AID1782147	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID1586800	Toxicity in Balb/c nude mouse xenografted with human HepG2 cells assessed as change in body weight at 0.2 mg/kg, ip administered once daily for 15 days measured during compound dosing	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation.
AID422049	Cytotoxicity against human HO8910 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1782148	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID330280	Growth inhibition of PC2 expressing mouse Pkd2+/- cells as cell death at 100 nM after 24 hrs	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1850659	Toxicity in BALB/c nude mouse xenografted with human NCI-H460 cells assessed as degeneration of inter tube connective tissue at 0.2 mg/kg administered ip, qd for 2 weeks	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1175362	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation by sulforhodamine B assay	2014	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24	Semisynthesis of triptolide analogues: effect of B-ring substituents on cytotoxic activities.
AID1850636	Induction of apoptosis in human NCI-H460 cells assessed as necrotic cells at 1 uM measured after 48 hrs by Annexin V-FITC/PI staining method (Rvb = 1.59%)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1782145	Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID422048	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1242180	Inhibition of HSF1 in human H929 cells assessed as potentiation of 17-AAG-induced icrease in cell death at 100 nM relative to 17-AAG alone	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Regulating the master regulator: Controlling heat shock factor 1 as a chemotherapy approach.
AID1555828	Cytotoxicity against MDCK cells assessed as decrease in cell viability	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Triptolide: Medicinal chemistry, chemical biology and clinical progress.
AID1850655	Toxicity in BALB/c nude mouse xenografted with human NCI-H460 cells assessed as irregular spermatogenic tubules at 0.2 mg/kg administered ip, qd for 2 weeks	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1555820	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Triptolide: Medicinal chemistry, chemical biology and clinical progress.
AID1555830	Cytotoxicity against mouse NIH/3T3 cells assessed as decrease in cell viability	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Triptolide: Medicinal chemistry, chemical biology and clinical progress.
AID1434297	Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Identification of a diverse synthetic abietane diterpenoid library for anticancer activity.
AID1718926	Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability by MTT assay	2021	Bioorganic & medicinal chemistry letters, 02-01, Volume: 33	ATB
AID330286	Increase in p53 expression in mouse Pkd1-/- cells at 100 nM after 96 hrs by Western blot analysis	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1850602	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability in presence of WZB117 incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1586797	Toxicity in Balb/c nude mouse at 0.2 mg/kg, ip	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation.
AID594371	Cytotoxicity against human HT-29 cells	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Semisynthesis of triptolide analogues: effect of γ-lactone and C-14 substituents on cytotoxic activities.
AID1782198	Antitumor activity against human HepG2 cells xenografted in zebra fish AB assessed as tumor growth inhibition at 1 uM measured after 48 hrs by fluorescence microscopic analysis	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID1555836	Cytotoxicity against human Bre01 cells assessed as decrease in cell viability	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Triptolide: Medicinal chemistry, chemical biology and clinical progress.
AID422054	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1850654	Toxicity in BALB/c nude mouse xenografted with human NCI-H460 cells assessed as morphological change in kidney at 0.2 mg/kg administered ip, qd for 2 weeks	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID461858	Cytotoxicity against imatinib-resistant mouse 32D cells harboring Bcr-Abl T315I mutant after 72 hrs by MTS assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
AID1782186	Toxicity in zebrafish AB assessed as pericardial edema at 1 uM	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID330293	Toxicity in C57BL/6 mouse embryos at 0.7 mg/kg/day, ip	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1850652	Toxicity in BALB/c nude mouse xenografted with human NCI-H460 cells assessed as morphological change in liver at 0.2 mg/kg administered ip, qd for 2 weeks	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1782153	Cytotoxicity against human A549/DDP cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID1373539	Toxicity in CD1 mouse primary cortical neurons assessed as effect on cell viability at 50 nM incubated for 24 hrs by CCK8 assay	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Triptolide derivatives as potential multifunctional anti-Alzheimer agents: Synthesis and structure-activity relationship studies.
AID1850632	Induction of apoptosis in human NCI-H460 cells assessed as necrotic cells at 0.1 uM measured after 48 hrs by Annexin V-FITC/PI staining method (Rvb = 1.59%)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID422047	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID422046	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1782209	Toxicity in 12-month old zebrafish assessed as mortality at 1.6 uM	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID1546490	Cytotoxicity against human PANC1 cells assessed as cell viability after 24 hrs by MTT assay relative to control	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Artemisia: a promising plant for the treatment of cancer.
AID1690094	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies.
AID1373538	Toxicity in CD1 mouse primary cortical neurons assessed as effect on cell viability at 25 nM incubated for 24 hrs by CCK8 assay	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Triptolide derivatives as potential multifunctional anti-Alzheimer agents: Synthesis and structure-activity relationship studies.
AID1242179	Inhibition of HSF1 in human MM.1S cells assessed as potentiation of NVP-AUY-922-induced reduction in cell proliferation at 6 nM relative to NVP-AUY-922 alone	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Regulating the master regulator: Controlling heat shock factor 1 as a chemotherapy approach.
AID1487635	Inhibition of human dCTPase 1	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 1: Triazoles, triazolopyrimidines, triazinoindoles, quinoline hydrazones and arylpiperazines.
AID330292	Toxicity in C57BL/6 mouse embryos at >=0.1 mg/kg/day, ip	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1850604	Cytotoxicity against Glut-1 silenced human NCI-H460 cells assessed as decrease in cell viability incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1068363	Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Design, synthesis and anticancer activity evaluation of novel C14 heterocycle substituted epi-triptolide.
AID1850594	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1440808	Inhibition of dCTPase 1 (unknown origin) expressed in Escherichia coli BL21 Star (DE3) using dCTP as substrate by luminescence assay	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1850625	Induction of apoptosis in human NCI-H460 cells assessed as viable cells at 0.01 uM measured after 48 hrs by Annexin V-FITC/PI staining method (Rvb = 86.4%)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID326746	Cytotoxicity against human HT29 cells	2008	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7	Fluorination of triptolide and its analogues and their cytotoxicity.
AID461857	Cytotoxicity against mouse 32D cells harboring wild type Bcr-Abl after 72 hrs by MTS assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
AID422052	Cytotoxicity against human KB cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID1850666	Stability in mouse serum measured after 8 hrs by HPLC analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1424477	Increase in lifespan of Caenorhabditis elegans N2 CGCb under 2 mM H2O2-induced oxidative stress conditions at 1 to 50 mg/L	2017	European journal of medicinal chemistry, Dec-15, Volume: 142	From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
AID1281051	Inhibition of human recombinant DCTPP1 expressed in Escherichia coli BL21 Star (DE3) using dCTP as substrate by PPiLight assay	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1.
AID1586802	Hepatotoxicity in Balb/c nude mouse xenografted with human HepG2 cells assessed as effect on serum ALT levels at 0.2 mg/kg, ip administered once daily for 15 days	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation.
AID330284	Induction of cell growth arrest in mouse Pkd1-/- cells in presence of calcium	2007	Proceedings of the National Academy of Sciences of the United States of America, Mar-13, Volume: 104, Issue:11	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.
AID1555837	Cytotoxicity against human Col-06 cells assessed as decrease in cell viability	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Triptolide: Medicinal chemistry, chemical biology and clinical progress.
AID1850630	Induction of apoptosis in human NCI-H460 cells assessed as early apoptotic cells at 0.1 uM measured after 48 hrs by Annexin V-FITC/PI staining method (Rvb = 3.46%)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.
AID1373540	Toxicity in CD1 mouse primary cortical neurons assessed as effect on cell viability at 100 nM incubated for 24 hrs by CCK8 assay	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Triptolide derivatives as potential multifunctional anti-Alzheimer agents: Synthesis and structure-activity relationship studies.
AID1555838	Cytotoxicity against human SK-MEL-8 cells assessed as decrease in cell viability	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Triptolide: Medicinal chemistry, chemical biology and clinical progress.
AID1782151	Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1799646	Enzyme Assay from Article 10.1002/cbic.201100007: \\Triptolide directly inhibits dCTP pyrophosphatase.\\	2011	Chembiochem : a European journal of chemical biology, Jul-25, Volume: 12, Issue:11	Triptolide directly inhibits dCTP pyrophosphatase.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	7 (0.62)	18.7374
1990's	24 (2.11)	18.2507
2000's	236 (20.77)	29.6817
2010's	631 (55.55)	24.3611
2020's	238 (20.95)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	6 (0.52%)	5.53%
Reviews	73 (6.30%)	6.00%
Case Studies	1 (0.09%)	4.05%
Observational	0 (0.00%)	0.25%
Other	1,078 (93.09%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 1b Open-Label, Dose-Escalation, Safety, and Pharmacodynamic Study of Minnelide™ Capsules Given in Combination With Osimertinib in Patients With EGFR Mutated NSCLC [NCT05166616]	Phase 1	30 participants (Anticipated)	Interventional	2022-03-07	Recruiting
Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir of Chinese HIV/AIDS Patients In Acute HIV-1 Infection [NCT02219672]	Phase 3	18 participants (Anticipated)	Interventional	2014-07-31	Recruiting
Randomized Controlled Trial of Triptolide-Containing Formulation for Autosomal Dominant Polycystic Kidney Disease (ADPKD) [NCT02115659]	Phase 3	100 participants (Anticipated)	Interventional	2014-04-30	Recruiting
Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission [NCT02044952]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional	2014-01-31	Recruiting
Study of Triptolide Woldifiion T Cell Immune Activation and Inflammation Biomarkers in HIV-infected Immunological Non-responders [NCT01817283]	Phase 1/Phase 2	150 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Pilot Study: Safety and Efficacy Study of Tripterygium Wilfordii Hook F Extract in cART-Treated HIV Patients With Poor Immune Responses [NCT02002286]		23 participants (Actual)	Interventional	2011-08-31	Completed
Impact of Triptolide Wilfordii on Viral Suppression, Immune Recovery and Immune Activation Biomarkers in Treatment-naive HIV-1 Infection: a Randomized, Double-blinded, Placebo-controlled Study [NCT03403569]	Phase 3	353 participants (Actual)	Interventional	2018-09-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
acetylcarnitine Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.	2.11	1	0	O-acylcarnitine	human metabolite
adenine [no description available]	3.03	4	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
benzene [no description available]	2.6	1	0	aromatic annulene; benzenes; volatile organic compound	carcinogenic agent; environmental contaminant; non-polar solvent
carnitine [no description available]	2.49	2	0	amino-acid betaine	human metabolite; mouse metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	3.31	6	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
dimethylglycine dimethylglycine: metabolic product of calcium pangamate; mutagen when mixed with nitrite; RN given refers to parent cpd. N,N-dimethylglycine : An N-methylglycine that is glycine carrying two N-methyl substituents.	2.04	1	0	amino acid zwitterion; N-methyl-amino acid; N-methylglycines	Daphnia magna metabolite; human metabolite; mouse metabolite
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	2.11	1	0	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glycine [no description available]	2.55	2	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	2.25	1	0	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	4.31	4	0	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
melatonin [no description available]	8.76	2	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.1	1	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	2.43	2	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	2.08	1	0	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
propylene glycol Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.. propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.	2.73	3	0	glycol; propane-1,2-diols	allergen; human xenobiotic metabolite; mouse metabolite; protic solvent
purine 1H-purine : The 1H-tautomer of purine.. 3H-purine : The 3H-tautomer of purine.. 9H-purine : The 9H-tautomer of purine.. 7H-purine : The 7H-tautomer of purine.	2.25	1	0	purine
pyrogallol benzenetriol : A triol in which three hydroxy groups are substituted onto a benzene ring.	2.02	1	0	benzenetriol; phenolic donor	plant metabolite
sarcosine cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis	2.04	1	0	N-alkylglycine zwitterion; N-alkylglycine; N-methyl-amino acid; N-methylglycines	Escherichia coli metabolite; glycine receptor agonist; glycine transporter 1 inhibitor; human metabolite; mouse metabolite
succinic acid Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851). succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.	2.07	1	0	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent
trimethyloxamine trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure. trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.	2.04	1	0	tertiary amine oxide	Escherichia coli metabolite; metabolite; osmolyte
isopentenyl pyrophosphate isopentenyl pyrophosphate: substrate for isopentenyl pyrophosphate isomerase; RN given refers to unlabeled cpd; a nonpeptide mycobacterial antigen that stimulates gamma delta T cells. isopentenyl diphosphate : A prenol phosphate comprising 3-methylbut-3-en-1-ol having an O-diphosphate substituent.	7.31	1	0	prenol phosphate	antigen; antioxidant; epitope; Escherichia coli metabolite; mouse metabolite; phosphoantigen
huperzine a huperzine A: RN given refers to 5R-(5alpha,9beta,11E)-isomer; structure given in first source. huperzine A : A sesquiterpene alkaloid isolated from a club moss Huperzia serrata that has been shown to exhibit neuroprotective activity. It is also an effective inhibitor of acetylcholinesterase and has attracted interest as a therapeutic candidate for Alzheimer's disease.	3.12	1	0	quinolone
menthol Menthol: A monoterpene cyclohexanol produced from mint oils.	2.42	2	0	p-menthane monoterpenoid; secondary alcohol	volatile oil component
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	2.08	1	0	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
1-aminobenzotriazole [no description available]	2.1	1	0
pd 173074 [no description available]	2.08	1	0	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
3-nitropropionic acid 3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE. 3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.	2.1	1	0	C-nitro compound	antimycobacterial drug; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mycotoxin; neurotoxin
abt 702 [no description available]	2.08	1	0	bipyridines
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.11	1	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	2.41	1	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
anthralin Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.	7.02	1	0	anthracenes	antipsoriatic
aristolochic acid i aristolochic acid I: phospholipase A inhibitor. aristolochic acid A : An aristolochic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.	2.52	2	0	aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound	carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	7.76	3	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
berberine [no description available]	4.06	2	0	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	2.51	2	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
bisbenzimidazole Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.	2.45	2	0	bibenzimidazole; N-methylpiperazine	anthelminthic drug; fluorochrome
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	8.04	4	0	aromatic ether; nitrile; polyether; tertiary amino compound
celecoxib [no description available]	2.08	1	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
chelerythrine chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.	2.08	1	0	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
dapi DAPI: RN given refers to parent cpd.	2.42	2	0	indoles	fluorochrome
emodin Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.	8.94	3	0	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
etodolac Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).. etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.	3.15	1	0	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
fexofenadine fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.	7.31	1	0	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	3.33	6	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	2.15	1	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	2.08	1	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	4.37	3	0
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	2.08	1	0	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	2.02	1	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
indirubin-3'-monoxime indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.08	1	0
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.02	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	2.55	2	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	2.55	2	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	3.02	4	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	7.45	2	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
letrozole [no description available]	2.08	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lg 100268 LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source	2.08	1	0
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.76	3	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
memantine [no description available]	2.17	1	0	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	8.98	3	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	2.59	2	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	2.08	1	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
entinostat [no description available]	2.08	1	0	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	2.02	1	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source. NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.	2.02	1	0	aromatic ether; C-nitro compound; sulfonamide	antineoplastic agent; cyclooxygenase 2 inhibitor
olprinone olprinone: RN refers to HCl; structure given in first source	2.08	1	0	bipyridines
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	2.08	1	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	2.08	1	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.08	1	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
ag 1879 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor	3.25	1	0	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
probucol Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.	3.12	1	0	dithioketal; polyphenol	anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug
protopine [no description available]	2.21	1	0	dibenzazecine alkaloid	plant metabolite
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one [no description available]	2.08	1	0	indoles
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	2.08	1	0	benzothiazoles
rofecoxib [no description available]	2.02	1	0	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
rolipram [no description available]	2.13	1	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
sb 206553 SB 206553: a high-affinity 5-HT(2C/2B) antagonist; structure given in first source	2.08	1	0	pyrroloindole
sb 220025 SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source. SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.	2.08	1	0	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	2.08	1	0	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sk&f 86002 6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase	2.08	1	0	imidazoles
imatinib [no description available]	7.47	2	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
streptonigrin [no description available]	3.51	1	0	pyridines; quinolone	antimicrobial agent; antineoplastic agent
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.08	1	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.08	1	0
sulforaphane sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.	3.66	2	0	isothiocyanate; sulfoxide	antineoplastic agent; antioxidant; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite
2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine [no description available]	2.08	1	0	stilbenoid
temozolomide [no description available]	7.1	1	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.31	1	0	diarylmethane
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	2.06	1	0	phthalimides; piperidones
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.08	1	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
corticosterone [no description available]	2.05	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
hydroxyproline Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.	2.45	2	0	4-hydroxyproline; L-alpha-amino acid zwitterion	human metabolite; mouse metabolite; plant metabolite
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	2.46	2	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
dichlororibofuranosylbenzimidazole Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.	2.1	1	0
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.61	2	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
cantharidin Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.. cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.	7.13	1	0	cyclic dicarboxylic anhydride; monoterpenoid	EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; herbicide
desoxycorticosterone acetate Desoxycorticosterone Acetate: The 21-acetate derivative of desoxycorticosterone.	2.25	1	0	corticosteroid hormone
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.07	1	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
vincristine [no description available]	2.05	1	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
puromycin aminonucleoside 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine: structure in first source. 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine : Puromycin derivative that lacks the methoxyphenylalanyl group on the amine of the sugar ring.	7.81	3	0	3'-deoxyribonucleoside; adenosines
galactose galactopyranose : The pyranose form of galactose.	2.21	1	0	D-galactose; galactopyranose	Escherichia coli metabolite; mouse metabolite
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	3.16	1	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
dimethylnitrosamine Dimethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. It causes serious liver damage and is a hepatocarcinogen in rodents.	7.06	1	0	nitrosamine	geroprotector; mutagen
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	2.13	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.5	2	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
chloroform Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.	3.78	2	0	chloromethanes; one-carbon compound	carcinogenic agent; central nervous system drug; inhalation anaesthetic; non-polar solvent; refrigerant
norethindrone Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.	3.19	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	progestin; synthetic oral contraceptive
cytarabine [no description available]	2.48	2	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
dinitrofluorobenzene Dinitrofluorobenzene: Irritants and reagents for labeling terminal amino acid groups.. 1-fluoro-2,4-dinitrobenzene : The organofluorine compound that is benzene with a fluoro substituent at the 1-position and two nitro substituents in the 2- and 4-positions.	2.07	1	0	C-nitro compound; organofluorine compound	agrochemical; allergen; chromatographic reagent; EC 2.7.3.2 (creatine kinase) inhibitor; protein-sequencing agent; spectrophotometric reagent
n-pentanol n-pentanol: RN given refers to parent cpd. pentan-1-ol : A short-chain primary fatty alcohol that is pentane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It has been isolated from Melicope ptelefolia.	2.07	1	0	pentanol; short-chain primary fatty alcohol	human metabolite; plant metabolite
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	2.05	1	0	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
threonine Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.	2.21	1	0	amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.	7.41	1	0	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
acetonitrile acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.	2.07	1	0	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent
acetyleugenol acetyleugenol: from cloves; inhibits arachidonate-, adrenaline-, & collagen-induced platelet aggregation	2.02	1	0	benzoate ester; phenols
benzylamine aminotoluene : Any member of the class of toluenes carrying one or more amino groups.	7.06	1	0	aralkylamine; primary amine	allergen; EC 3.5.5.1 (nitrilase) inhibitor; plant metabolite
4-vinyl-1-cyclohexene dioxide 4-vinyl-1-cyclohexene dioxide: activates caspase cascades; structure. 4-vinylcyclohexene dioxide : The diepoxide of 4-vinylcyclohexene.	2.52	2	0	epoxide	carcinogenic agent
2-methylpentane Hexanes: Six-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives. Various polyneuropathies are caused by hexane poisoning.	2.05	1	0	alkane
maleic anhydride Maleic Anhydrides: Used in copolymerization reactions, in the Diels-Alder(diene)synthesis, in the preparation of resins, pharmaceuticals and agricultural chemicals. It is a powerful irritant and causes burns.. maleic anhydride : A cyclic dicarboxylic anhydride that is the cyclic anhydride of maleic acid.	2.17	1	0	cyclic dicarboxylic anhydride; furans	allergen
furan furan : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing four carbons and one oxygen, with formula C4H4O. It is a toxic, flammable, low-boiling (31degreeC) colourless liquid.	2.06	1	0	furans; mancude organic heteromonocyclic parent; monocyclic heteroarene	carcinogenic agent; hepatotoxic agent; Maillard reaction product
isopropyl myristate isopropyl myristate: used for microemulsions; structure	2.43	2	0	fatty acid ester
n-hexane hexane : An unbranched alkane containing six carbon atoms.	2.05	1	0	alkane; volatile organic compound	neurotoxin; non-polar solvent
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	2.15	1	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
scoparone scoparone: structure. scoparone : A member of the class of coumarins that is esculetin in which the two hydroxy groups at positions 6 and 7 are replaced by methoxy groups. It is a major constituent of the Chinese herbal medicine Yin Chen Hao, and exhibits a variety of pharmacological activities such as anti-inflammatory, anti-allergic, and anti-tumor activities.	3.35	1	0	aromatic ether; coumarins	anti-allergic agent; anti-inflammatory agent; antihypertensive agent; antilipemic drug; immunosuppressive agent; plant metabolite
ethyl acetate ethyl acetate : The acetate ester formed between acetic acid and ethanol.	9.29	4	0	acetate ester; ethyl ester; volatile organic compound	EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor; metabolite; polar aprotic solvent; Saccharomyces cerevisiae metabolite
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	3.54	2	0	catechin	antioxidant; plant metabolite
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.11	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	3.19	1	0	indazole
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	3.05	4	0	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	4.06	4	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.1	1	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2.75	3	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrimidine pyrimidine : The parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions.	2.25	1	0	diazine; pyrimidines	Daphnia magna metabolite
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	2.76	3	0	diazine; pyrazines	Daphnia magna metabolite
monocrotaline Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.	7.71	3	0	pyrrolizidine alkaloid
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.08	1	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
kainic acid Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.	7.17	1	0	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist
capillin capillin: insecticidal principle of Artemisia nilagirica Clarke	3.35	1	0	aromatic ketone; ynone
sodium carbonate sodium carbonate: used topically for dermatitides, mouthwash, vaginal douche; veterinary use as emergency emetic; RN given refers to carbonic acid, di-Na salt; structure	2.07	1	0	carbonate salt; organic sodium salt
carvacrol carvacrol : A phenol that is a natural monoterpene derivative of cymene. An inhibitor of bacterial growth, it is used as a food additive. Potent activator of the human ion channels transient receptor potential V3 (TRPV3) and A1 (TRPA1).	2.02	1	0	botanical anti-fungal agent; p-menthane monoterpenoid; phenols	agrochemical; antimicrobial agent; flavouring agent; TRPA1 channel agonist; volatile oil component
oleanolic acid [no description available]	2.46	2	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
abietic acid abietic acid : An abietane diterpenoid that is abieta-7,13-diene substituted by a carboxy group at position 18.	2.15	1	0	abietane diterpenoid; monocarboxylic acid	plant metabolite
hematoxylin Hematoxylin: A dye obtained from the heartwood of logwood (Haematoxylon campechianum Linn., Leguminosae) used as a stain in microscopy and in the manufacture of ink.	2.41	1	0	organic heterotetracyclic compound; oxacycle; polyphenol; tertiary alcohol	histological dye; plant metabolite
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	3.87	3	0	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
tricaprylin tricaprylin: 13C-labeled trioctanoin used in breath tests to detect fat malabsorption. trioctanoin : A triglyceride obtained by acylation of the three hydroxy groups of glycerol by octanoic acid. Used as an alternative energy source to glucose for patients with mild to moderate Alzheimer's disease.	2.03	1	0	octanoate ester; triglyceride	anticonvulsant; plant metabolite
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	3.04	4	0	dialdehyde	biomarker
trinitrobenzenesulfonic acid Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.	2.11	1	0	arenesulfonic acid; C-nitro compound	epitope; explosive; reagent
eosine yellowish-(ys) Eosine Yellowish-(YS): A versatile red dye used in cosmetics, pharmaceuticals, textiles, etc., and as tissue stain, vital stain, and counterstain with HEMATOXYLIN. It is also used in special culture media.. eosin YS dye : An organic sodium salt that is 2',4',5',7'-tetrabromofluorescein in which the carboxy group and the phenolic hydroxy group have been deprotonated and the resulting charge is neutralised by two sodium ions.	2.41	1	0	organic sodium salt; organobromine compound	fluorochrome; histological dye
formestane [no description available]	2.08	1	0	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
3-hydroxyflavone 3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.	2.25	1	0	flavonols; monohydroxyflavone
triphenylphosphine triphenylphosphine: RN given refers to parent cpd. triphenylphosphine : A member of the class of tertiary phosphines that is phosphane in which the three hydrogens are replaced by phenyl groups.	7.31	1	0	benzenes; tertiary phosphine	NMR chemical shift reference compound; reducing agent
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.06	1	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.06	1	0	cyclic ketone; erythromycin
hydroxychloroquine sulfate [no description available]	2.08	1	0
2,3-dimethylmaleic anhydride [no description available]	2.17	1	0	butenolide
deoxycytidine [no description available]	2.81	3	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
arsenic trioxide Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.	8.59	2	0
glycyrrhizic acid glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.	8.2	5	0	enone; glucosiduronic acid; pentacyclic triterpenoid; tricarboxylic acid; triterpenoid saponin	EC 3.4.21.5 (thrombin) inhibitor; plant metabolite
2,2'-biphenol biphenyl-2,2'-diol : A member of the class of hydroxybiphenyls carrying hydroxy groups at positions 2 and 2'.	3.51	1	0	hydroxybiphenyls
paraquat Paraquat: A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.. paraquat : An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.	7.17	1	0	organic cation	geroprotector; herbicide
amiloride hydrochloride, anhydrous amiloride hydrochloride : A hydrochloride obtained by combining amiloride with one molar equivalent of hydrochloric acid.	2.08	1	0	hydrochloride	diuretic; sodium channel blocker
menthol (+-)-menthol : A racemate comprising equimolar amounts of (+)- and (-)-menthol. Both (+-)- and (-)-menthol are used to relieve symptoms of conditions such as bronchitis and sinusitis. When applied to the skin, menthol dilates the blood vessels, giving a sensation of coldness followed by an analgesic effect that relieves itching. It is therefore used in creams and ointments for the relief of pruritis and urticaria.. (-)-menthol : A p-menthan-3-ol which has (1R,2S,5R)-stereochemistry. It is the most common naturally occurring enantiomer.	2.02	1	0	p-menthan-3-ol	antipruritic drug; antispasmodic drug; antitussive
fluorescein Fluorescein: A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium such as the aqueous humor.. fluorescein (lactone form) : A xanthene dye that is highly fluorescent, detectable even when present in minute quantities. Used forensically to detect traces of blood, in analytical chemistry as an indicator in silver nitrate titrations and in microscopy.	2.02	1	0	2-benzofurans; gamma-lactone; organic heteropentacyclic compound; oxaspiro compound; polyphenol; xanthene dye	fluorescent dye; radioopaque medium
acadesine [no description available]	2.08	1	0	1-ribosylimidazolecarboxamide; aminoimidazole; nucleoside analogue	antineoplastic agent; platelet aggregation inhibitor
fluorescein-5-isothiocyanate Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.	2.45	2	0	fluorescein isothiocyanate
dithiothreitol 1,4-dimercaptobutane-2,3-diol : A glycol that is butane-2,3-diol in which a hydrogen from each of the methyl groups is replaced by a thiol group.. 1,4-dithiothreitol : The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.	2.31	1	0	1,4-dimercaptobutane-2,3-diol; butanediols; dithiol; glycol; thiol	chelator; human metabolite; reducing agent
carbonates Carbonates: Salts or ions of the theoretical carbonic acid, containing the radical CO2(3-). Carbonates are readily decomposed by acids. The carbonates of the alkali metals are water-soluble; all others are insoluble. (From Grant & Hackh's Chemical Dictionary, 5th ed). carbonates : Organooxygen compounds that are salts or esters of carbonic acid, H2CO3.	2.07	1	0	carbon oxoanion
cladribine [no description available]	3.58	2	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
1,3-dithiolane [no description available]	7.05	1	0	dithiolane
buthionine sulfoximine Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.	2.1	1	0	diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
palladium Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.	2.1	1	0	metal allergen; nickel group element atom; platinum group metal atom
titanium Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.	2.52	2	0	titanium group element atom
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	2.15	1	0	f-block element atom; lanthanoid atom
gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.	2.25	1	0	copper group element atom; elemental gold
acetylglucosamine Acetylglucosamine: The N-acetyl derivative of glucosamine.. N-acetyl-beta-D-glucosamine : An N-acetyl-D-glucosamine having beta-configuration at the anomeric centre.	2.08	1	0	N-acetyl-D-glucosamine	epitope
galactosamine 2-amino-2-deoxy-D-galactopyranose : The pyranose form of D-galactosamine.. D-galactosamine : The D-stereoisomer of galactosamine.	2.07	1	0	D-galactosamine; primary amino compound	toxin
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	4.6	7	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
tricalcium phosphate tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues.	2.17	1	0	calcium phosphate
fluorine Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.	2.04	1	0	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
chlorine Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.	2.49	2	0	diatomic chlorine; gas molecular entity	bleaching agent
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	4.17	6	0	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
fluorides [no description available]	2.04	1	0	halide anion; monoatomic fluorine
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	2.31	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	5.04	9	0	benzenes; phenyl acetates
8-bromo cyclic adenosine monophosphate 8-Bromo Cyclic Adenosine Monophosphate: A long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.. 8-Br-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP bearing an additional bromo substituent at position 8 on the adenine ring. An activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.	2.07	1	0	3',5'-cyclic purine nucleotide; adenyl ribonucleotide; organobromine compound	antidepressant; protein kinase agonist
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.44	2	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
azoxymethane Azoxymethane: A potent carcinogen and neurotoxic compound. It is particularly effective in inducing colon carcinomas.	2.25	1	0
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.08	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	10.37	9	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
substance p [no description available]	2.48	2	0	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
1-methyl-4-phenylpyridinium 1-Methyl-4-phenylpyridinium: An active neurotoxic metabolite of 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE. The compound reduces dopamine levels, inhibits the biosynthesis of catecholamines, depletes cardiac norepinephrine and inactivates tyrosine hydroxylase. These and other toxic effects lead to cessation of oxidative phosphorylation, ATP depletion, and cell death. The compound, which is related to PARAQUAT, has also been used as an herbicide.. N-methyl-4-phenylpyridinium : A pyridinium ion that is N-methylpyridinium having a phenyl substituent at the 4-position.	2.04	1	0	pyridinium ion	apoptosis inducer; herbicide; human xenobiotic metabolite; neurotoxin
lonidamine lonidamine: structure. lonidamine : A member of the class of indazoles that is 1H-indazole that is substituted at positions 1 and 3 by 2,4-dichlorobenzyl and carboxy groups, respectively.	3.59	2	0	dichlorobenzene; indazoles; monocarboxylic acid	antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	2.79	3	0	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	2.08	1	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	7.31	1	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
itraconazole Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.	2.08	1	0	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
pravadoline [no description available]	2.08	1	0
zileuton [no description available]	2.08	1	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
niguldipine [no description available]	2.08	1	0	diarylmethane
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	2.08	1	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
eliprodil 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol : A member of the class of piperidines that is piperidine substituted by a 2-(4-chlorophenyl)-2-hydroxyethyl group at position 1 and by a 4-fluorobenzyl group at position 4.	2.08	1	0	monochlorobenzenes; monofluorobenzenes; piperidines; secondary alcohol; tertiary amino compound
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	3.02	4	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
atorvastatin [no description available]	7.31	1	0	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
irinotecan [no description available]	2.76	3	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	2.05	1	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
3-n-butylphthalide 3-n-butylphthalide: isolated from phenolic part of Ligusticum wallichii Franch; structure given in first source	3.12	1	0	benzofurans
dimethylhydrazines Dimethylhydrazines: Hydrazines substituted with two methyl groups in any position.	2.05	1	0
verapamil hydrochloride verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride.	2.08	1	0
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	2.08	1	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	4.36	4	1	D-glucopyranose	epitope; mouse metabolite
ursolic acid [no description available]	3.51	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	geroprotector; plant metabolite
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.43	2	0	organic bromide salt	colorimetric reagent; dye
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	2.58	2	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	2.41	1	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.54	2	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
gallocatechol gallocatechol: structure give in first source; RN given for (trans-(+-))-omer; inhibits DNA-dependent DNA & RNA polymerases. (+)-gallocatechin : A gallocatechin that has (2R,3S)-configuration. It is found in green tea and bananas.. gallocatechin : A catechin that is a flavan substituted by hydroxy groups at positions 3, 3', 4', 5, 5' and 7 (the trans isomer). It is isolated from Acacia mearnsii.	2.02	1	0	gallocatechin	antioxidant; metabolite; radical scavenger
25-hydroxycholesterol [no description available]	2.07	1	0	25-hydroxy steroid; oxysterol	human metabolite
pyrrolidine dithiocarbamate pyrrolidine dithiocarbamic acid: spelled pyrolidine in J Nutr 1979 reference; RN given refers to parent cpd. pyrrolidine dithiocarbamate : A member of the class of dithiocarbamic acids that is the N-dithiocarboxy derivative of pyrrolidine.	2.25	1	0	dithiocarbamic acids; pyrrolidines	anticonvulsant; antineoplastic agent; geroprotector; neuroprotective agent; NF-kappaB inhibitor; radical scavenger
triptonide triptonide: extracted from Tripterygium wilfordii; structure given in first source. triptonide : A diterpene triepoxide that is triptobenzene K in which the acylhydroquinone moiety has undergone oxidation to the corresponding triepoxyketone derivative. It has been isolated from the roots of Tripterygium wilfordii.	5.48	19	0	butenolide; cyclic ketone; diterpene triepoxide; organic heteroheptacyclic compound	anti-inflammatory agent; antineoplastic agent; immunosuppressive agent
bendamustine [no description available]	2.08	1	0	benzimidazoles
caroverine caroverine: structure	2.08	1	0	quinoxaline derivative
rutecarpine rutacarpine: from Evodia rutaecarpa; an ingredient in zhuyu hewei zhitong capsules	2.02	1	0	beta-carbolines
cgs 9343b [no description available]	2.08	1	0	benzimidazoles
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	2.08	1	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
2-methoxyestradiol 2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2.	2.08	1	0	17beta-hydroxy steroid; 3-hydroxy steroid	angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite
naphthalimides Naphthalimides: Compounds with three fused rings that appear like a naphthalene fused to piperidone or like a benz(de)isoquinoline-1,3-dione (not to be confused with BENZYLISOQUINOLINES which have a methyl separating the naphthyl from the benzyl rings). Members are CYTOTOXINS.	2.25	1	0
1,7-phenanthroline [no description available]	2.05	1	0	phenanthroline
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.55	2	0	1,2,3-triazole
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	4.93	4	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
artemether Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	3.35	1	0	artemisinin derivative; cyclic acetal; organic peroxide; semisynthetic derivative; sesquiterpenoid	antimalarial
alacepril [no description available]	2.08	1	0	dipeptide; thioacetate ester	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
ubenimex ubenimex: growth inhibitor	2.08	1	0
avarol avarol: RN given refers to parent cpd; extract from Dysidea avara(sea sponge)	2.02	1	0
epicatechin (-)-epicatechin : A catechin with (2R,3R)-configuration.	2.02	1	0	catechin; polyphenol	antioxidant
sesamin (+)-sesamin : A lignan that consists of tetrahydro-1H,3H-furo[3,4-c]furan substituted by 1,3-benzodioxole groups at positions 1 and 4 (the 1S,3aR,4S,6aR stereoisomer). Isolated from Cinnamomum camphora, it exhibits cytotoxic activity.	3.35	1	0	benzodioxoles; furofuran; lignan	antineoplastic agent; neuroprotective agent; plant metabolite
nagilactone c nagilactone C: norditerpene lactone isolated from leaves of Podocarpus; structure	2.25	1	0
tetrandrine tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity	7.04	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
isoalantolactone isoalantolactone: RN given refers to (3aR-(3aalpha,4aalpha,8abeta,9aalpha))-isomer; structure. isoalantolactone : A sesquiterpene lactone of the eudesmanolide group. It has been isolated from Inula helenium.	3.35	1	0	eudesmane sesquiterpenoid; sesquiterpene lactone	antifungal agent; apoptosis inducer; plant metabolite
brusatol brusatol: quassinoid from B. javanica; structure	2.25	1	0	triterpenoid
fangchinoline [no description available]	2.02	1	0	aromatic ether; bisbenzylisoquinoline alkaloid; macrocycle	anti-HIV-1 agent; anti-inflammatory agent; antineoplastic agent; antioxidant; neuroprotective agent; plant metabolite
tryptanthrine tryptanthrine: minor constituent of traditional Chinese medicine qing dai	2.02	1	0	alkaloid antibiotic; organic heterotetracyclic compound; organonitrogen heterocyclic compound
c.i. direct red 80 Solophenyl red 3BL: structure in first source. Sirius red F3B : An organic sodium salt resulting from the formal condensation of Sirius red F3B (acid form) with six equivalents of sodium hydroxide. A polyazo dye used principally in staining methods for collagen and amyloid.	2.08	1	0	organic sodium salt	fluorochrome; histological dye
aucubin [no description available]	2.21	1	0	organic molecular entity	metabolite
hydroxyflutamide [no description available]	2.13	1	0
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	2.02	1	0
dehydroabietic acid dehydroabietic acid: major aquatic toxicant in effluent of pulp and paper mills. dehydroabietic acid : An abietane diterpenoid that is abieta-8,11,13-triene substituted at position 18 by a carboxy group.. dehydroabietate : A monocarboxylic acid anion that is the conjugate base of dehydroabietic acid, obtained by deprotonation of the carboxy group.	3.13	4	0	abietane diterpenoid; carbotricyclic compound; monocarboxylic acid	allergen; metabolite
eupatorin eupatorin: a flavonoid from the East Asian medicinal plant Orthosiphon spicatus; prevents oxidative inactivation of 15-lipoxygenase; structure given in first source. eupatorin : A trimethoxyflavone that is 6-hydroxyluteolin in which the phenolic hydogens at positions 4', 6 and 7 have been replaced by methyl groups.	3.35	1	0	dihydroxyflavone; polyphenol; trimethoxyflavone	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; Brassica napus metabolite; calcium channel blocker; P450 inhibitor; vasodilator agent
10-hydroxycamptothecin [no description available]	7.21	1	0	pyranoindolizinoquinoline
diosgenin [no description available]	2.13	1	0	3beta-sterol; hexacyclic triterpenoid; sapogenin; spiroketal	antineoplastic agent; antiviral agent; apoptosis inducer; metabolite
arctiin arctiin: from fruits of Arctium lappa L; RN given refers to (3R-trans)-isomer; RN for cpd without isomeric designation not avail 12/92	2.66	2	0	glycoside; lignan
l-phenylalanine ethylester L-phenylalanine ethylester: structure in first source	2.13	1	0
cobalt Cobalt: A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.. cobalt(1+) : A monovalent inorganic cation obtained from cobalt.. cobalt atom : A cobalt group element atom that has atomic number 27.	2.1	1	0	cobalt group element atom; metal allergen	micronutrient
sn 38 SN-38 : A member of the class of pyranoindolizinoquinolines that is (4S)-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione bearing two additional ethyl substituents at positions 4 and 11 as well as two additional hydroxy substituents at positions 4 and 9. It is the active metabolite of irinotecan and is ~1000 times more active than irinotecan itself.	2.06	1	0	delta-lactone; phenols; pyranoindolizinoquinoline; tertiary alcohol	antineoplastic agent; apoptosis inducer; drug metabolite; EC 5.99.1.2 (DNA topoisomerase) inhibitor
artesunic acid [no description available]	2.08	1	0
vinpocetine [no description available]	2.08	1	0
deguelin deguelin: a natural product from Mundulea sericea; RN refers to (7aS-cis)-isomer; structure given in first source. deguelin : A rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers.	2.08	1	0	aromatic ether; diether; organic heteropentacyclic compound; rotenones	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor; plant metabolite
fingolimod hydrochloride Fingolimod Hydrochloride: A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.. fingolimod hydrochloride : The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).	3.16	1	0	hydrochloride	immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist
parthenolide [no description available]	2.82	3	0	germacranolide
tesmilifene [no description available]	2.17	1	0	diarylmethane
tanshinone tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent	8.61	2	0	abietane diterpenoid	anticoronaviral agent
obacunone obacunone: from bark of Chinese plant Phellodendron amurense; shortens sleeping time induced in mice by alpha-chloralose-urethane	2.25	1	0	limonoid
sr 48692 SR 48692: structure in first source; a neurotensin receptor-1 antagonist	2.08	1	0	N-acyl-amino acid
dioscin [no description available]	2.13	1	0	hexacyclic triterpenoid; spiroketal; spirostanyl glycoside; trisaccharide derivative	anti-inflammatory agent; antifungal agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 1.14.18.1 (tyrosinase) inhibitor; hepatoprotective agent; metabolite
elacridar Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source	2.08	1	0
caprylates Caprylates: Derivatives of caprylic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a carboxy terminated eight carbon aliphatic structure.. octanoate : A straight-chain saturated fatty acid anion that is the conjugate base of octanoic acid (caprylic acid); believed to block adipogenesis.	2.03	1	0	fatty acid anion 8:0; straight-chain saturated fatty acid anion	human metabolite; Saccharomyces cerevisiae metabolite
celastrol [no description available]	6.92	21	0	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite
diethylaminosulfur trifluoride diethylaminosulfur trifluoride: fluorinating agent for carbohydrates	2.04	1	0
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	3.16	5	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	2.82	3	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
bay x 1005 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid: inhibits synthesis of leukotriene B4 and 5-hydroxyeicosatetraenoic acid; inhibits five-lipoxygenase activating protein(FLAP)and leukotriene A4 hydrolase(LTA4H); structure given in first source;	2.08	1	0
gyki 53655 GYKI 53655: an AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate) receptor antagonist	2.08	1	0
methotrexate [no description available]	3.24	5	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
chlorolissoclimide chlorolissoclimide: structure given in first source; a labdane cytotoxin isolated from Lissoclinum voeltzkowi Michaelson	2.25	1	0
clausenamide clausenamide: Chinese drug isolated from leaves of Clausena lansium (Lour) Skeels; used in treatment of viral hepatitis; structure given in first source	3.12	1	0
cyanidin cyanidin: RN given refers to parent cpd; structure. cyanidin cation : An anthocyanidin cation that is flavylium substituted at positions 3, 3', 4', 5 and 7 by hydroxy groups.	2.02	1	0	5-hydroxyanthocyanidin	antioxidant; metabolite; neuroprotective agent
ml-3000 [no description available]	2.08	1	0
cd 437 CD 437: selective for retinoic acid receptors gamma. CD437 : A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells.	2.08	1	0	adamantanes; monocarboxylic acid; naphthoic acid; phenols	apoptosis inducer; retinoic acid receptor gamma agonist
proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.	2.08	1	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
docetaxel [no description available]	2.06	1	0	hydrate; secondary alpha-hydroxy ketone	antineoplastic agent
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.57	2	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
perifosine [no description available]	2.08	1	0	ammonium betaine; phospholipid	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
tariquidar [no description available]	2.5	2	0	benzamides
mk 767 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source	2.08	1	0
5-hydroxy-3',4',6,7-tetramethoxyflavone 5-hydroxy-3',4',6,7-tetramethoxyflavone: isolated from Artemisia argyi	3.35	1	0
bazedoxifene acetate [no description available]	2.08	1	0
canertinib [no description available]	2.08	1	0	monochlorobenzenes; morpholines; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
birb 796 [no description available]	2.08	1	0	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
wilforlide a wilforlide A: form Tripterygium regelii; Chinese medicinal plant extract	7.52	2	0
rhodioloside [no description available]	2.02	1	0	glycoside
tipifarnib [no description available]	2.08	1	0	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
tripchlorolide tripchlorolide: a chloro-tri-epoxide analog of triptolide; from woody part of the root of Tripterygium wilfordii Hook; structure given in first source	8.8	3	0
bruceine a bruceine A: quassinoid which inhibits protein synthesis & DNA synthesis in cells; RN given refers to (11 beta,12 alpha,15 beta)-isomer; structure given in first source	2.25	1	0	quassinoid
cirsiliol cirsiliol: potent inhibitor of arachidonate lipooxygenase. cirsiliol : A dimethoxyflavone that is flavone substituted by methoxy groups at positions 6 and 7 and hydroxy groups at positions 5, 3' and 4' respectively.	3.35	1	0	dimethoxyflavone; trihydroxyflavone	plant metabolite
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	2.08	1	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bruceine b bruceine B: quassinoid which inhibits protein synthesis & DNA synthesis in cells; structure in first source	2.25	1	0	triterpenoid
ampelopsin ampelopsin: hepatoprotective agent; isolated from Hovenia dulcis; RN given for (2R-trans)-isomer; structure in first source. (+)-dihydromyricetin : An optically active form of dihydromyricetin having (2R,3R)-configuration.	2.25	1	0	dihydromyricetin; secondary alpha-hydroxy ketone	antineoplastic agent; antioxidant; metabolite
jolkinolide a jolkinolide A: isolated from Euphorbia fischeriana	2.25	1	0	diterpene lactone	metabolite
jolkinolide b jolkinolide B: isolated from Euphorbia fischeriana	2.25	1	0	diterpene lactone	metabolite
cirsilineol cirsilineol: isolated from Thymus carnosus Boiss.. cirsilineol : A trimethoxyflavone that is flavone substituted by methoxy groups at positions 6, 7 and 3' and hydroxy groups at positions 5 and 4' respectively.	3.35	1	0	dihydroxyflavone; trimethoxyflavone	antineoplastic agent; plant metabolite
anacardic acid anacardic acid: isolated from Anacardium occidentale; monophenol monooxygenase inhibitor. anacardic acid : A hydroxybenzoic acid that is salicylic acid substituted by a pentadecyl group at position 6. It is a major component of cashew nut shell liquid and exhibits an extensive range of bioactivities.	3.51	1	0	hydroxy monocarboxylic acid; hydroxybenzoic acid	anti-inflammatory agent; antibacterial agent; anticoronaviral agent; apoptosis inducer; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; neuroprotective agent; plant metabolite
leucodin leucodin: structure in first source	3.35	1	0	sesquiterpene lactone
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	7.58	2	0	amino acid zwitterion; angiotensin II	human metabolite
methyl abietate methyl abietate: RN given refers to (1R-(1alpha,4abeta,4balpha,10aalpha))-isomer	2.15	1	0
triptophenolide triptophenolide: structure given in first source	9.43	6	0	oxo steroid
yomogin yomogin: eudesmane sesquiterpene from Artemisia princeps; inhibits inducible nitric oxide synthase production in macrophages; structure in first source	3.35	1	0
dendrophenol dendrophenol: isolated from Dendrobium loddigesii	3.15	1	0
sb 203580 [no description available]	2.48	2	0	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
sb 216763 [no description available]	2.25	1	0	indoles; maleimides
enzastaurin [no description available]	2.08	1	0	indoles; maleimides
scoparianoside b scoparianoside B: isolated from the fruit of Japanese Kochia scoparia; structure given in first source	3.51	1	0	triterpenoid saponin
erlotinib [no description available]	2.08	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
4'-o-methylepigallocatechin 4'-methylepigallocatechin: antispasmodic from Maytenus rigida Mart (Celestraceae); structure in first source	2.02	1	0	catechin	metabolite
piboserod Serotonin 5-HT4 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT4 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN RECEPTOR AGONISTS.	2.08	1	0
l 163191 [no description available]	2.08	1	0
limonin [no description available]	2.25	1	0	epoxide; furans; hexacyclic triterpenoid; lactone; limonoid; organic heterohexacyclic compound	inhibitor; metabolite; volatile oil component
ergolide ergolide: a potent cytotoxic sesquiterpene lactone from Inula sp.; structure given in first source. ergolide : A sesquiterpene lactone that is decahydroazuleno[6,5-b]furan-2,5-dione substituted by methyl groups at positions 4a and 8, a methylidene group at position 3 and an acetyloxy group at position 4. It has been isolated from the aerial parts of Inula hupehensis.	2.02	1	0	acetate ester; cyclic ketone; gamma-lactone; organic heterotricyclic compound; sesquiterpene lactone	anti-inflammatory agent; antineoplastic agent; metabolite; NF-kappaB inhibitor; plant metabolite
cirsimaritin cirsimaritin: has antagonist or partial agonist activity on benzodiazepine receptors. cirsimaritin : A dimethoxyflavone that is flavone substituted by methoxy groups at positions 6 and 7 and hydroxy groups at positions 5 and 4' respectively.	2.02	1	0	dihydroxyflavone; dimethoxyflavone
bd 1047 N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin: sigma receptor ligand; putative sigma receptor antagonist with antidystonic activity	2.08	1	0	primary amine
lapatinib [no description available]	2.08	1	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
sorafenib [no description available]	3.06	4	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
lenalidomide [no description available]	2.08	1	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide [no description available]	2.08	1	0	aminoquinoline
sr 142806 [no description available]	2.08	1	0
erythritol [no description available]	2.25	1	0	butane-1,2,3,4-tetrol	antioxidant; human metabolite; plant metabolite
tenulin tenulin: toxic constituent of Helenium amarum (bitter sneezeweed); structure	2.02	1	0	sesquiterpene lactone
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	3.54	2	0
lupeol [no description available]	3.35	1	0	pentacyclic triterpenoid; secondary alcohol	anti-inflammatory drug; plant metabolite
homoharringtonine Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.	7.17	1	0	alkaloid ester; enol ether; organic heteropentacyclic compound; tertiary alcohol	anticoronaviral agent; antineoplastic agent; apoptosis inducer; protein synthesis inhibitor
tripdiolide tripdiolide: structure	5.82	11	0	oxacycle
elesclomol [no description available]	2.08	1	0	carbohydrazide; thiocarbonyl compound	antineoplastic agent; apoptosis inducer
anthricin anthricin: antitumor constituent from Anthriscus sylvestris (L.) Hoffm; structure in first source. deoxypodophyllotoxin : A member of the class of furonaphthodioxoles that is (5R,5aR,8aR)-5,8,8a,9-tetrahydro-2H-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one substituted at position 5 by a 3,4,5-trimethoxyphenyl group.	3.19	1	0	furonaphthodioxole; gamma-lactone; lignan; methoxybenzenes	antineoplastic agent; apoptosis inducer; plant metabolite
nsc 663284 NSC 663284: structure in first source	2.08	1	0	quinolone
bortezomib [no description available]	7.98	4	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.52	2	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
bardoxolone methyl methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source	2.08	1	0	cyclohexenones
nsc 23766 [no description available]	2.08	1	0	aminopyrimidine; aminoquinoline; primary amino compound; secondary amino compound; tertiary amino compound	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist
carboplatin [no description available]	3.03	4	0
lithium chloride Lithium Chloride: A salt of lithium that has been used experimentally as an immunomodulator.. lithium chloride : A metal chloride salt with a Li(+) counterion.	2.17	1	0	inorganic chloride; lithium salt	antimanic drug; geroprotector
glycogen glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.	2.21	1	0
glucosamine D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.	2.11	1	0	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite
naringenin (S)-naringenin : The (S)-enantiomer of naringenin.	3.59	2	0	(2S)-flavan-4-one; naringenin	expectorant; plant metabolite
cysteinylglycine cysteinylglycine: RN given refers to (L)-isomer; RN for cpd without isomeric designation not in Chemlne 7/13/83. L-cysteinylglycine : A dipeptide consisting of glycine having an L-cysteinyl attached to its alpha-amino group. It is an intermediate metabolite in glutathione metabolism.	2.1	1	0	dipeptide zwitterion; dipeptide	Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite
strychnine Strychnine: An alkaloid found in the seeds of STRYCHNOS NUX-VOMICA. It is a competitive antagonist at glycine receptors and thus a convulsant. It has been used as an analeptic, in the treatment of nonketotic hyperglycinemia and sleep apnea, and as a rat poison.. strychnine : A monoterpenoid indole alkaloid that is strychnidine bearing a keto substituent at the 10-position.	2.15	1	0	monoterpenoid indole alkaloid; organic heteroheptacyclic compound	avicide; cholinergic antagonist; glycine receptor antagonist; neurotransmitter agent; rodenticide
pulegone pulegone: component of peppermint oil; RN given refers to cpd without isomeric designation; structure in Merck. (+)-pulegone : The (5R)-enantiomer of p-menth-4(8)-en-3-one.	2	1	0	p-menth-4(8)-en-3-one
lignans Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)	3.54	2	0
2-c-methylerythritol 4-phosphate 2-C-methylerythritol 4-phosphate: structure in first source	2.25	1	0	tetritol phosphate	Escherichia coli metabolite
epiafzelechin epiafzelechin: antioxidant; 3'-deoxy form of epicatechin; structure in first source. (-)-epiafzelechin : A catechin derivative having (2R,3R)-configuration.	2.02	1	0	catechin	plant metabolite
kerriamycin b kerriamycin B: from a streptomycete; structure given in first source	3.51	1	0	angucycline antibiotic	antineoplastic agent
acetyl coenzyme a Acetyl Coenzyme A: Acetyl CoA participates in the biosynthesis of fatty acids and sterols, in the oxidation of fatty acids and in the metabolism of many amino acids. It also acts as a biological acetylating agent.	2.21	1	0	acyl-CoA	acyl donor; coenzyme; effector; fundamental metabolite
e-z cinnamic acid cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia.. trans-cinnamic acid : The E (trans) isomer of cinnamic acid	2.41	1	0	cinnamic acid	plant metabolite
fumaric acid fumaric acid: see also record for ferrous fumarate; use FUMARATES for general fumaric acid esters. fumaric acid : A butenedioic acid in which the C=C double bond has E geometry. It is an intermediate metabolite in the citric acid cycle.	3.16	1	0	butenedioic acid	food acidity regulator; fundamental metabolite; geroprotector
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	4.82	5	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.	2.02	1	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	4.63	8	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
ferulic acid ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.	7.17	1	0	ferulic acids	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	2.55	2	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	2.04	1	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
geranylgeranyl pyrophosphate geranylgeranyl pyrophosphate: RN given refers to (E,E,E)-isomer. geranylgeranyl diphosphate : A polyprenol diphosphate having geranylgeranyl as the polyprenyl component.. 2-trans,6-trans,10-trans-geranylgeranyl diphosphate : The all-trans-isomer of geranylgeranyl diphosphate.	2.11	1	0	geranylgeranyl diphosphate	mouse metabolite
obeticholic acid obeticholic acid: A farnesoid X receptor agonist and anticholestatic agent that is used in the treatment of chronic liver diseases; structure in first source.. obeticholic acid : A dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatment of primary biliary cholangitis.	7.6	1	0	3alpha-hydroxy steroid; 7alpha-hydroxy steroid; dihydroxy-5beta-cholanic acid	farnesoid X receptor agonist; hepatoprotective agent
gw 3965 GW 3965: a liver X receptor ligand	2.08	1	0	diarylmethane
y 27632 Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.	2.51	2	0	aromatic amide
6-bromoindirubin-3'-oxime 6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.08	1	0
purvalanol b purvalanol B: protein kinase inhibitor; structure in first source	2.08	1	0	purvalanol	protein kinase inhibitor
y-700 [no description available]	2.08	1	0
repsox RepSox: inhibits TGF-beta signaling; structure in first source appears to be incorrect	2.08	1	0	pyrazolopyridine
steviol steviol: aglucon of stevioside; RN given refers to (4alpha)-isomer. steviol : An ent-kaurane diterpenoid that is 5beta,8alpha,9beta,10alpha-kaur-16-en-18-oic acid in which the hydrogen at position 13 has been replaced by a hydroxy group.	3.41	1	0	bridged compound; ent-kaurane diterpenoid; monocarboxylic acid; tertiary allylic alcohol; tetracyclic diterpenoid	antineoplastic agent
artenimol [no description available]	3.35	1	0
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.31	1	0	actinomycin	mutagen
shikonin shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities	3.15	1	0	hydroxy-1,4-naphthoquinone
kazinol b kazinol B: a natural isoprenylated flavan	2.02	1	0
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide [no description available]	2.08	1	0	tropane alkaloid
IPA-3 IPA-3 : An organic disulfide obtained by oxidative dimerisation of 1-sulfanylnaphthalen-2-ol.	3.25	1	0	naphthols; organic disulfide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cinnamaldehyde 3-phenylprop-2-enal : A member of the class of cinnamaldehydes that is prop-2-enal in which a hydrogen at position 3 has been replaced by a phenyl group. The configuration of the double bond is not specified; the name "cinnamaldehyde" is widely used to refer to the E (trans) isomer.. (E)-cinnamaldehyde : The E (trans) stereoisomer of cinnamaldehyde, the parent of the class of cinnamaldehydes.	2.02	1	0	3-phenylprop-2-enal; cinnamaldehydes	antifungal agent; EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor; flavouring agent; hypoglycemic agent; plant metabolite; sensitiser; vasodilator agent
glycosides [no description available]	3.11	4	0
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	2.13	1	0	stilbene
isoliquiritigenin [no description available]	7.13	1	0	chalcones	antineoplastic agent; biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; GABA modulator; geroprotector; metabolite; NMDA receptor antagonist
propolin c propolin C: a PAK1 inhibitor; from Taiwanese propolis; structure in first source. nymphaeol A : A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy group at positions 5, 7, 3' and 4' and a geranyl group at position 6. Isolated from Macaranga tanarius and propolis collected in Okinawa, it exhibits radical scavenging activity.	3.25	1	0	4'-hydroxyflavanones; tetrahydroxyflavanone	metabolite; radical scavenger
cardamonin cardamonin: found in Zingiberaceae; structure in first source	3.41	1	0	chalcones
s 1033 [no description available]	2.08	1	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
cardionogen-2 [no description available]	2.15	1	0
sesquiterpenes [no description available]	3.56	2	0
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.08	1	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
caffeic acid trans-caffeic acid : The trans-isomer of caffeic acid.	3.25	1	0	caffeic acid	geroprotector; mouse metabolite
rg108 RG108: DNA methyltransferase inhibitor; structure in first source	2.08	1	0	indolyl carboxylic acid
stf 083010 [no description available]	2.08	1	0
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide [no description available]	2.08	1	0	naphthalenecarboxamide
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	5.41	7	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
cct018159 CCT018159: structure in first source. CCT-018159 : A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively.	2.08	1	0	benzodioxine; pyrazoles; resorcinols	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
secinh3 SecinH3: a small molecule antagonist of cytohesins; structure in first source	2.08	1	0	triazoles
jk184 JK184: structure in first source	2.08	1	0
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	2.43	2	0	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
chlorogenic acid caffeoylquinic acid: Antiviral Agent; structure in first source. chlorogenate : A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.	4.06	3	0	cinnamate ester; tannin	food component; plant metabolite
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	2.1	1	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	2.11	1	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
tamoxifen citrate [no description available]	2.08	1	0	citrate salt	angiogenesis inhibitor; anticoronaviral agent
tamoxifen [no description available]	3.14	1	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
nadp [no description available]	2.1	1	0
hc-067047 HC-067047: a TRPA1 antagonist; structure in first source	2.08	1	0
bi-78d3 [no description available]	2.08	1	0	aryl sulfide
gsk 3787 [no description available]	2.08	1	0
methyl-thiohydantoin-tryptophan methyl-thiohydantoin-tryptophan: structure in first source	2.53	2	0	organonitrogen compound; organooxygen compound
2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenyl-4-pyrazolylidene)methyl]phenoxy]acetic acid methyl ester [no description available]	2.08	1	0	monocarboxylic acid
4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide [no description available]	2.08	1	0	sulfonamide
artemotil artemotil: structure given in first source; RN given refers to cpd without isomeric designation	3.35	1	0	artemisinin derivative
LSM-1318 [no description available]	2.08	1	0	oxa-steroid
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.75	3	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
rwj 67657 RWJ 67657: inhibits p38 mitogen-activated protein kinase; structure in first source	2.08	1	0
6-methyl-2-(phenylethynyl)pyridine 6-methyl-2-(phenylethynyl)pyridine: an mGlu5 antagonist. 2-methyl-6-(phenylethynyl)pyridine : A methylpyridine that coinsists of 2-methylp[yridine bearing an additional phenylethynyl group at position 6. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw.	2.08	1	0	acetylenic compound; methylpyridines	anxiolytic drug; metabotropic glutamate receptor antagonist
bms 387032 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.	2.08	1	0	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
cobaltous chloride cobaltous chloride: RN given refers to unlabeled cpd; RN in Chemline for cobalt trichloride: 10241-04-0; RN for 60-labeled cpd: 14543-09-0; RN for 57-labeled cpd: 164113-89-1; RN for 58-labeled cpd: 29377-09-1; structure. cobalt dichloride : A cobalt salt in which the cobalt metal is in the +2 oxidation state and the counter-anion is chloride. It is used as an indicator for water in desiccants.	2.1	1	0	cobalt salt; inorganic chloride	allergen; calcium channel blocker; sensitiser; two-colour indicator
tandutinib [no description available]	2.08	1	0	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
vx-745 [no description available]	2.08	1	0	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
corlanor ivabradine hydrochloride : A hydrochloride obtained by combining ivabradine with one molar equivalent of hydrochloric acid. Used to treat patients with angina who have intolerance to beta blockers and/or heart failure.	2.08	1	0	hydrochloride	cardiotonic drug
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.08	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
1-(3-chloro-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone 1-(3-chloro-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone: structure given in first source; endogenous differentiation-inducing factor; induces stalk-cell differentiation in the cellular slime mold Dictyostelium discoideum	3.25	1	0
zd 6474 CH 331: structure in first source	2.08	1	0	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
ginsenosides ginsenoside : Triterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.	2.21	1	0
compound 968 compound 968: a glutaminase inhibitor. 5-[3-bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one : A partially hydrogenated benzophenanthridine carrying an oxo group at C-4, geminal methyl groups at C-2 and a 3-bromo-4-(dimethylamino)phenyl group at C-5.	2.08	1	0	benzophenanthridine	EC 3.5.1.2 (glutaminase) inhibitor
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	7.42	2	0
sb-224289 SB 224289 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid with the secondary amino group of 1'-methyl-6,7-dihydro-5H-spiro[furo[2,3-f]indole-3,4'-piperidine]. Selective 5-HT1B receptor antagonist (pKi = 8.2). Displays >60-fold selectivity over 5-HT1D, 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A and 5-HT2C receptors in radioligand binding and functional assays. Centrally active following oral administration in vivo.	2.08	1	0	1,2,4-oxadiazole; azaspiro compound; benzamides; organic heterotetracyclic compound	serotonergic antagonist
gw 7647 GW 7647: a PPAR-alpha agonist; structure in first source. GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.	2.08	1	0	aryl sulfide; monocarboxylic acid; ureas	PPARalpha agonist
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	2.02	1	0	organic sodium salt	detergent; protein denaturant
sto 609 STO 609: structure in first source	2.25	1	0	naphthoic acid
l 663536 MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.	2.08	1	0	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
Artemin [no description available]	3.35	1	0	sesquiterpene lactone
1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine [no description available]	2.08	1	0	imidazoles
N4-ethyl-N6,1,2-trimethyl-N4-phenylpyrimidin-1-ium-4,6-diamine [no description available]	2.08	1	0	aromatic amine; tertiary amino compound
2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester [no description available]	2.08	1	0	isoquinolines
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	3.62	2	0
sch 79797 [no description available]	2.08	1	0	quinazolines
jhw 015 [no description available]	2.07	1	0	indolecarboxamide
am 630 iodopravadoline: an aminoalkylindole; a competitive cannabinoid receptor antagonist; structure given in first source	2.07	1	0	N-acylindole
osteoprotegerin Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.	2.03	1	0	long-chain fatty acid
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	2.08	1	0	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one [no description available]	2.08	1	0	monobactam
imd 0354 N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source	2.08	1	0	benzamides
ex 527 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine.	2.08	1	0	carbazoles; monocarboxylic acid amide; organochlorine compound
fraxetin fraxetin : A hydroxycoumarin that is 6-methoxycoumarin in which the hydrogens at positions 7 and 8 have been replaced by hydroxy groups.	2.02	1	0	aromatic ether; hydroxycoumarin	anti-inflammatory agent; antibacterial agent; antimicrobial agent; antioxidant; apoptosis inducer; apoptosis inhibitor; Arabidopsis thaliana metabolite; hepatoprotective agent; hypoglycemic agent
eupatilin eupatilin: isolated from Artemisia argyi. eupatilin : A trimethoxyflavone that is flavone substituted by hydroxy groups at C-5 and C-7 and methoxy groups at C-6, C-3' and C-4' respectively. Isolated from Citrus reticulata and Salvia tomentosa, it exhibits anti-inflammatory, anti-ulcer and antineoplastic activities.	3.35	1	0	dihydroxyflavone; trimethoxyflavone	anti-inflammatory agent; anti-ulcer drug; antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; metabolite
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	8.62	2	0	sphing-4-enine	human metabolite; mouse metabolite
quercetin [no description available]	6.25	13	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	5.84	11	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	2.01	1	0	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
coniferin coniferin : A monosaccharide derivative that is coniferol attached to a beta-D-glucopyranosyl residue at position 1 via a glycosidic linkage.	2.02	1	0	aromatic ether; cinnamyl alcohol beta-D-glucoside; monosaccharide derivative	plant metabolite
acacetin 5,7-dihydroxy-4'-methoxyflavone : A monomethoxyflavone that is the 4'-methyl ether derivative of apigenin.	3.35	1	0	dihydroxyflavone; monomethoxyflavone	anticonvulsant; plant metabolite
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	3.58	2	0	trihydroxyflavone	antineoplastic agent; metabolite
luteolin [no description available]	3.9	3	0	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
7,3'-dihydroxy-4'-methoxyisoflavone 7,3'-dihydroxy-4'-methoxyisoflavone: isolated from Astragali radix; structure in first source. calycosin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone which is substituted by an additional hydroxy group at the 3' position and a methoxy group at the 4' position.	2.6	1	0	4'-methoxyisoflavones; 7-hydroxyisoflavones	antioxidant; metabolite
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	2.02	1	0	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
scopoletin [no description available]	3.35	1	0	hydroxycoumarin	plant growth regulator; plant metabolite
leukotriene b4 Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.	2.03	1	0	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
daphnetin [no description available]	2.02	1	0	hydroxycoumarin
quercetin 3-o-glucopyranoside quercetin 3-O-glucopyranoside: structure in first source. quercetin 3-O-beta-D-glucopyranoside : A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 3. Isolated from Lepisorus contortus, it exhibits antineoplastic activityand has been found to decrease the rate of polymerization and sickling of red blood cells	2.02	1	0	beta-D-glucoside; monosaccharide derivative; quercetin O-glucoside; tetrahydroxyflavone	antineoplastic agent; antioxidant; antipruritic drug; bone density conservation agent; geroprotector; histamine antagonist; osteogenesis regulator; plant metabolite
rutin Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.	7.6	1	0	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite
kaempferol [no description available]	2.02	1	0	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
genistein [no description available]	2.45	2	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	2.13	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
mycophenolate mofetil mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.	3.25	1	0	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
bruceantin [no description available]	2.25	1	0	triterpenoid
cucurbitacin i cucurbitacin I: toxic constituent in edible gourd; see also records for cucurbitacins & specific cucurbitacins. cucurbitacin I : A cucurbitacin that is 9,10,14-trimethyl-4,9-cyclo-9,10-secocholesta-2,5,23-triene substituted by hydroxy groups at positions 2, 16, 20 and 25 and oxo groups at positions 1, 11 and 22.	3.25	1	0	cucurbitacin; tertiary alpha-hydroxy ketone	antineoplastic agent; plant metabolite
capillarisin capillarisin: from Artemisiae capillaris Herba.; structure	3.35	1	0	coumarins
esculetin esculetin: used in filters for absorption of ultraviolet light; structure. esculetin : A hydroxycoumarin that is umbelliferone in which the hydrogen at position 6 is substituted by a hydroxy group. It is used in filters for absorption of ultraviolet light.	2.02	1	0	hydroxycoumarin	antioxidant; plant metabolite; ultraviolet filter
costunolide [no description available]	2.02	1	0	germacranolide; heterobicyclic compound	anthelminthic drug; antiinfective agent; antineoplastic agent; antiparasitic agent; antiviral drug; metabolite
galangin 5,7-dihydroxyflavonol: antimicrobial from the twigs of Populus nigra x Populus deltoides; structure in first source. galangin : A 7-hydroxyflavonol with additional hydroxy groups at positions 3 and 5 respectively; a growth inhibitor of breast tumor cells.	2.02	1	0	7-hydroxyflavonol; trihydroxyflavone	antimicrobial agent; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; plant metabolite
genkwanin genkwanin: structure. genkwanin : A monomethoxyflavone that is apigenin in which the hydroxy group at position 7 is methylated.	3.35	1	0	dihydroxyflavone; monomethoxyflavone	metabolite
hyperoside quercetin 3-O-beta-D-galactopyranoside : A quercetin O-glycoside that is quercetin with a beta-D-galactosyl residue attached at position 3. Isolated from Artemisia capillaris, it exhibits hepatoprotective activity.	7.41	1	0	beta-D-galactoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	hepatoprotective agent; plant metabolite
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	7.25	1	0	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
3-methylquercetin isorhamnetin : A monomethoxyflavone that is quercetin in which the hydroxy group at position 3' is replaced by a methoxy group.	3.35	1	0	7-hydroxyflavonol; monomethoxyflavone; tetrahydroxyflavone	anticoagulant; EC 1.14.18.1 (tyrosinase) inhibitor; metabolite
morusin morusin: from Morus root bark; structure given in first source. morusin : An extended flavonoid that is flavone substituted by hydroxy groups at positions 5, 2' and 4', a prenyl group at position 3 and a 2,2-dimethyl pyran group across positions 7 and 8.	2.02	1	0	extended flavonoid; trihydroxyflavone	antineoplastic agent; plant metabolite
wogonin wogonin: structure in first source. wogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.	2.5	2	0	dihydroxyflavone; monomethoxyflavone	angiogenesis inhibitor; antineoplastic agent; cyclooxygenase 2 inhibitor; plant metabolite
caffeic acid phenethyl ester phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.	3.57	2	0	alkyl caffeate ester	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent
rosmarinic acid rosmarinic acid: RN given refers to parent cpd; promote OT project. (R)-rosmarinic acid : A stereoisomer of rosmarinic acid having (R)-configuration.. rosmarinic acid : The 1-carboxy-2-(2,4-dihydroxyphenyl)ethyl ester of trans-caffeic acid.	2.02	1	0	rosmarinic acid	geroprotector; plant metabolite
ginkgolic acid [no description available]	3.51	1	0	hydroxybenzoic acid
rhoifolin rhoifolin: from many plants. apigenin 7-O-neohesperidoside : An apigenin derivative having an alpha-(1->2)-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety attached to the 7-hydroxy group.	2.02	1	0	dihydroxyflavone; glycosyloxyflavone; neohesperidoside	metabolite
sphingosine 1-phosphate sphingosine 1-phosphate: RN given refers to (R-(R,S-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1	2.72	2	0	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.81	3	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	2.53	2	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
fenretinide Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.	2.08	1	0	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant
ter 199 [no description available]	2.08	1	0
arachidonylcyclopropylamide arachidonylcyclopropylamide: a potent and selective agonist of neuronal cannabinoid receptor; structure in first source	2.08	1	0
ly 320135 LY 320135: cannabinoid receptor antagonist; structure in first source	2.08	1	0	benzofurans
pd 166285 [no description available]	2.08	1	0
kn 62 KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II	2.08	1	0	piperazines
su 6656 SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.	2.08	1	0
syringin syringin: a phenylpropanoid glycoside; see also eleutherosides & lyoniside for eleutheroside A: 474-58-8. syringin : A monosaccharide derivative that is trans-sinapyl alcohol attached to a beta-D-glucopyranosyl residue at position 1 via a glycosidic linkage.	2.02	1	0	beta-D-glucoside; dimethoxybenzene; monosaccharide derivative; primary alcohol	hepatoprotective agent; plant metabolite
andrographolide [no description available]	2.25	1	0	carbobicyclic compound; gamma-lactone; labdane diterpenoid; primary alcohol; secondary alcohol	anti-HIV agent; anti-inflammatory drug; antineoplastic agent; metabolite
isofraxidin isofraxidin: also see fraxidin	3.35	1	0	hydroxycoumarin
Kumatakenin [no description available]	3.35	1	0	ether; flavonoids
osthenol osthenol: structure in first source. osthenol : A hydroxycoumarin that is umbelliferone in which the hydrogen at position 8 has been replaced by a prenyl group.	2.02	1	0	hydroxycoumarin	antifungal agent; plant metabolite
artemetin [no description available]	3.35	1	0	ether; flavonoids
angiotensin amide psilostachyin A: has antineoplastic, anti-inflammatory, leishmanicidal, and molluscicidal activities; isolated from Ambrosia psilostachya; structure in first source	2.02	1	0
shihulimonin a shihulimonin A: isolated from Evodia rutaecarpa; structure in first source	2.25	1	0	limonoid
semaxinib semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.	2.08	1	0	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
su 11248 [no description available]	2.08	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
palbociclib [no description available]	2.08	1	0	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621 [no description available]	2.08	1	0	sulfonamide
bay 11-7082 (E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.	2.08	1	0	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	8.59	2	0	metalloid atom; pnictogen	micronutrient
indium Indium: A metallic element, atomic number 49, atomic weight 114.818, symbol In. It is named from its blue line in the spectrum.. indium atom : A metallic element first identified and named from the brilliant indigo (Latin indicum) blue line in its flame spectrum.	2.1	1	0	boron group element atom
sulfur Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.	2.04	1	0	chalcogen; nonmetal atom	macronutrient
glyceryl behenate 1-behenoylglycerol : A fatty acid ester resulting from the formal condensation of the hydroxy group at position-1 of glycerol with the carboxy group of docosanoic acid.	2.03	1	0	1-monoglyceride; fatty acid ester	antineoplastic agent; plant metabolite
geldanamycin [no description available]	2.1	1	0
jaceosidin jaceosidin : A trihydroxyflavone that is flavone with hydroxy groups at positions 5, 7 and 4' and methoxy groups at positions 3' and 6. Isolated from Salvia tomentosa and Artemisia asiatica, it exhibits anti-allergic, anti-inflammatory and apoptosis inducing activties.	3.35	1	0	dimethoxyflavone; trihydroxyflavone	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; metabolite
ajoene ajoene: major antiplatelet compound in methanol extract of garlic; also inhibits trypanothione reductase.	2.02	1	0	sulfoxide
sinomenine sinomenine: isolated from root of Sinomenium acutum; antirheumatic, antineuralgic	3.15	1	0	morphinane alkaloid
cisplatin [no description available]	2.08	1	0	diamminedichloroplatinum	antineoplastic agent; apoptosis inducer; cross-linking reagent; ferroptosis inducer; genotoxin; mutagen; nephrotoxin; photosensitizing agent
fumarates Fumarates: Compounds based on fumaric acid.. fumarate(2-) : A C4-dicarboxylate that is the E-isomer of but-2-enedioate(2-)	3.16	1	0	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.1	1	0	cysteinium	fundamental metabolite
gamma-mangostin gamma-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3, 6 and 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antitumour activity.	2.02	1	0	phenols; xanthones	antineoplastic agent; plant metabolite; protein kinase inhibitor
bakuchiol bakuchiol: chief component of Psoralea corylifolia Linn; structure	3.15	1	0
dichapetalin a dichapetalin A: isolated from Dichapetalum; structure in first source	2.25	1	0
artepillin c artepillin C: RN refers to (E)-isomer	3.25	1	0
myricetin 3-o-glucuronide myricetin 3-O-glucuronide: from Epilobium angustifolium. myricetin 3-O-glucuronide : A myricetin O-glucuronide that is myricetin with a beta-D-glucosiduronic acid residue attached at the 3-position.	2.02	1	0	monosaccharide derivative; myricetin O-glucuronide; pentahydroxyflavone	metabolite
vx680 [no description available]	2.08	1	0	N-arylpiperazine
monorden monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II	2.02	1	0	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
ginkgolide b [no description available]	2.25	1	0
d 4476 [no description available]	2.08	1	0	imidazoles
cyc 116 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine: an aurora kinase inhibitor; structure in first source	2.08	1	0
bay 19-8004 BAY 19-8004: a PDE4 inhibitor; structure in first source	2.08	1	0
axitinib [no description available]	2.08	1	0	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
pai 039 tiplaxtinin: inhibitor of plasminogen activator inhibitor-1	2.08	1	0	indole-3-acetic acids
verlukast verlukast: LTD4 receptor antagonist	2.15	1	0
beta-escin [no description available]	4.43	5	0
gw2974 GW2974: quinazoline derivative, which is able to block the activation of both the EGFR and erbB2	2.08	1	0	pyridopyrimidine
17-hydroxyjolkinolide b 17-hydroxyjolkinolide B: isolated from Euphorbia fischeriana	2.25	1	0	diterpene lactone	metabolite
ispinesib [no description available]	2.08	1	0	benzamides
morphinans Morphinans: Compounds based on a partially saturated iminoethanophenanthrene, which can be described as ethylimino-bridged benzo-decahydronaphthalenes. They include some of the OPIOIDS found in PAPAVER that are used as ANALGESICS.	3.15	1	0	isoquinoline alkaloid fundamental parent; morphinane alkaloid
fk 866 N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source	2.31	1	0	benzamides; N-acylpiperidine
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	3.35	1	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
stepholidine stepholidine: protoberberine alkaloid isolated from opium; dual D1 receptor agonist and D2 receptor antagonist	3.12	1	0
temsirolimus [no description available]	2.08	1	0	macrolide lactam
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	2.08	1	0	aminobenzoic acid
bibx 1382bs BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001	2.08	1	0	substituted aniline
omtriptolide omtriptolide: a water-soluble, semisynthetic derivative of PG490 (triptolide) purified from the Chinese herb Tripterygium Wilfordii; structure in first source	4.09	4	0
hdac-42 HDAC-42: structure in first source	2.08	1	0	amidobenzoic acid
[4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone [no description available]	2.08	1	0	benzamides; N-acylpiperidine
iniparib [no description available]	2.08	1	0	carbonyl compound; organohalogen compound
mk 0752 [no description available]	2.08	1	0
gw 501516 GW 501516: a selective PPARdelta agonist; structure in first source. GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.	2.08	1	0	1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound	carcinogenic agent; PPARbeta/delta agonist
av 412 [no description available]	2.08	1	0
ag-041r AG-041R: structure in first source	2.08	1	0
telatinib [no description available]	2.08	1	0
cp 547632 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: inhibits vascular endothelial growth factor receptor-2 tyrosine kinase; structure in first source	2.08	1	0
spc-839 SPC-839: an inhibitor of activator protein 1; structure in first source	2.08	1	0
lenvatinib lenvatinib : A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.	2.08	1	0	aromatic amide; aromatic ether; cyclopropanes; monocarboxylic acid amide; monochlorobenzenes; phenylureas; quinolines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist; orphan drug; vascular endothelial growth factor receptor antagonist
andarine [no description available]	2.08	1	0	acetamides; anilide
gw843682x [no description available]	2.08	1	0	(trifluoromethyl)benzenes
pd 0325901 mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).	2.08	1	0	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	2.08	1	0	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide: a proteinase-activated receptor-2-activating peptide; SL-NH2 is NOT Ser-Leu-NH2 here	2.08	1	0
sincalide Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.	2.1	1	0	oligopeptide
ag 14361 [no description available]	2.08	1	0	benzimidazoles
sb 265610 [no description available]	2.08	1	0
knk 437 KNK 437: inhibits thermotolerance acquisition and heat shock protein induction in colon carcinoma cells; structure in first source	3.21	1	0
fr 148083 5Z-7-oxozeaenol : A macrolide that is the 7-oxo derivative of zeaenol (the 5Z stereoisomer). Isolated from Fungi, it exhibits cytotoxic, antibacterial and inhibitory activity against NF-kappaB.	2.08	1	0	aromatic ether; macrolide; phenols; secondary alcohol; secondary alpha-hydroxy ketone	antibacterial agent; antineoplastic agent; metabolite; NF-kappaB inhibitor
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	3.19	5	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
osi 930 OSI 930: inhibits both receptor tyrosine kinase Kit and kinase insert domain receptor; structure in first source	2.08	1	0	aromatic amide
ki 20227 [no description available]	2.08	1	0
scio-469 SCIO-469: a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor for potential oral therapy for inflammatory disorders; in phase lib clinical trials for rheumatoid arthritis 4/2004. talmapimod : An indolecarboxamide obtained by formal condensation of the carboxy group of 6-chloro-3-[(dimethylamino)(oxo)acetyl]-1-methylindole-5-carboxylic acid with the secondary amino group of (2S,5R)-1-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine. It is a potent inhibitor of MAPK and exhibits anti-cancer properties.	2.08	1	0	aromatic amide; aromatic ketone; chloroindole; dicarboxylic acid diamide; indolecarboxamide; monofluorobenzenes; N-acylpiperazine; N-alkylpiperazine	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ssr 69071 SSR 69071: structure in first source	2.08	1	0	pyridopyrimidine
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	2.08	1	0	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
sb 210313 [no description available]	2.08	1	0
xestospongin a xestospongin A: blocks inositol 1,4,5-trisphosphate receptors; structure in first source; from Xestospongia sponge	2.1	1	0
gw 4064 [no description available]	2.5	2	0	stilbenoid
sa 4503 [no description available]	2.08	1	0
ic 87114 IC 87114: structure in first source	2.08	1	0	6-aminopurines; biaryl; quinazolines	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
bn 52020 [no description available]	2.25	1	0
zibotentan ZD4054: a potent endothelin receptor A antagonist that inhibits ovarian carcinoma cell proliferation	2.08	1	0	phenylpyridine
tivozanib N-(2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea: KNR-951 is the HCl, monohydrate salt; an antineoplastic agent; structure in first source	2.55	2	0	aromatic ether
hki 272 [no description available]	2.08	1	0	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor
ginsenoside rg3 ginsenoside Rg3: from Red ginseng; inhibits lung metastasis of tumor cells; structure given in first source. (20S)-ginsenoside Rg3 : A ginsenoside found in Panax ginseng and Panax japonicus var. major that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranosyl-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.	7.21	1	0	ginsenoside; glycoside; tetracyclic triterpenoid	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; plant metabolite
tofacitinib tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.	2.08	1	0	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bibr 1532 [no description available]	2.08	1	0
hirsutanonol hirsutanonol: a diarylheptanoid from the bark of Alnus hirsuta var. sibirica; inhibits cyclooxygenase-2 expression; structure in first source	2.02	1	0
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide [no description available]	2.08	1	0
rucaparib AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source	2.08	1	0	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cediranib [no description available]	2.08	1	0	aromatic ether
gw0742 GW 610742: structure in first source	2.08	1	0	monocarboxylic acid
phenylalanyl-glycyl-leucyl-methioninamide phenylalanyl-glycyl-leucyl-methioninamide: a substance P-derived peptide	3.14	1	0	tetrapeptide
ps1145 PS1145: IkappaB kinase inhibitor; structure in first source	2.08	1	0	beta-carbolines
bay 41-8543 BAY 41-8543: structure in first source	2.08	1	0	pyrazolopyridine
chir 99021 Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.	2.08	1	0	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
sb 525334 6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline: a TGF-betaR kinase inhibitor	2.08	1	0	quinoxaline derivative
way-362450 [no description available]	2.08	1	0	indoles
masitinib [no description available]	2.08	1	0	1,3-thiazoles; benzamides; N-alkylpiperazine; pyridines	antineoplastic agent; antirheumatic drug; tyrosine kinase inhibitor
bx795 BX795: structure in first source	2.08	1	0	ureas
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	2.08	1	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
sepantronium sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.	2.55	2	0	organic cation
azd 6244 AZD 6244: a MEK inhibitor	2.08	1	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea 1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea: structure in first source	2.08	1	0
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide : A member of the class of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)[1,1'-biphenyl]-4-carboxylic acid with the amino group of 3-cyanoaniline.	2.08	1	0	1,3,4-oxadiazoles; benzamides; biphenyls; nitrile	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ar c155858 AR C155858: an MCT1 inhibitor; structure in first source	2.08	1	0
aee 788 AEE 788: structure in first source	2.08	1	0	6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist; trypanocidal drug
saracatinib [no description available]	2.08	1	0	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent
alpha-synuclein alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.	2.15	1	0
sd-208 [no description available]	2.08	1	0
demethylzeylasteral demethylzeylasteral: a phenolic nortriterpene; isolated from the root cortex of Tripterygium Wilfordii Hook f.. demethylzeylasteral : A carbopolycyclic compound with formula C29H36O6, originally isolated from Tripterygium wilfordii.	2.88	3	0	arenecarbaldehyde; benzenediols; carbopolycyclic compound; cyclic ketone; enone; oxo monocarboxylic acid	anti-inflammatory agent; EC 2.4.1.17 (glucuronosyltransferase) inhibitor; immunosuppressive agent; nephroprotective agent; plant metabolite
nymphaeol c nymphaeol C: from the leaves of Macaranga tanarius; structure in first source. nymphaeol C : A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy group at positions 5, 7, 3' and 4', a geranyl group at position 2' and a prenyl group at position 6. Isolated from Macaranga tanarius and propolis collected in Okinawa, it exhibits radical scavenging activity.	3.25	1	0	4'-hydroxyflavanones; tetrahydroxyflavanone	metabolite; radical scavenger
vx 702 VX 702: a p38 MAP kinase inhibitor	2.08	1	0	phenylpyridine
ngr peptide [no description available]	2.25	1	0
2-furoyl-ligrlo-amide 2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist	2.08	1	0
volasertib BI 6727: a polo-like kinase inhibitor with broad antitumor activity; structure in first source	2.08	1	0
PB28 PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.	2.08	1	0	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist
dichlorolissoclimide dichlorolissoclimide: structure given in first source; a labdane cytotoxin isolated from Lissoclinum voeltzkowi Michaelson	2.25	1	0
azd 7762 [no description available]	2.08	1	0	aromatic amide; thiophenes
krp-203 [no description available]	2.08	1	0
mk 0354 [no description available]	2.08	1	0
regorafenib [no description available]	2.08	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
ym 155 sepantronium bromide : An organic bromide salt consisting of sepantronium cations and bromide anions. It has been found to selectively inhibit survivin (BIRC5) gene promoter activity and to down-regulate survivin in vitro, so leading to induction of apoptosis.	3.25	1	0	organic bromide salt	antineoplastic agent; apoptosis inducer; survivin suppressant
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester [no description available]	2.08	1	0	pyrroloquinoline
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one [no description available]	2.08	1	0	methoxybenzenes; substituted aniline
abt-737 [no description available]	2.07	1	0	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
brivanib [no description available]	2.08	1	0	aromatic ether; diether; fluoroindole; pyrrolotriazine; secondary alcohol	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; drug metabolite; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
icg 001 [no description available]	2.08	1	0	peptide
mp470 [no description available]	2.08	1	0	N-arylpiperazine
nu 7441 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source	2.08	1	0	dibenzothiophenes
at 7519 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide : A member of the class of pryrazoles that is 4-amino-1H-pyrazole-3-carboxylic acid in which the primary amino group has been acylated by a 2,6-dichlorobenzoyl group and in which the carboxylic acid has been converted into a carboxamide by formal condensation with the primary amino group of 4-aminopiperidine.	2.08	1	0	dichlorobenzene; piperidines; pyrazoles; secondary carboxamide	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bi 2536 [no description available]	2.08	1	0
mitoquinone mitoquinone: has antineoplastic activity	2.6	1	0
nutlin-3a nutlin 3: an MDM2 antagonist; structure in first source	2.04	1	0	stilbenoid
clematichinenoside ar clematichinenoside AR: Immunosuppressive Agent from Clematidis Radix et Rhizoma	7.41	1	0
danusertib [no description available]	2.08	1	0	piperazines
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide [no description available]	2.08	1	0	benzamides
N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide [no description available]	2.08	1	0	benzamides
abt 869 [no description available]	2.08	1	0	aromatic amine; indazoles; phenylureas	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
dorsomorphin dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.	2.54	2	0	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
ac 261066 [no description available]	2.08	1	0
quisinostat [no description available]	2.31	1	0	indoles
carfilzomib [no description available]	2.08	1	0	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor
gw9508 GW9508: structure in first source	2.08	1	0	aromatic amine
jnj 26854165 [no description available]	2.08	1	0
pf 573228 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one: structure in first source	2.08	1	0	quinolines
gw 2580 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine: a cFMS kinase inhibitor; structure in first source	2.08	1	0
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	2.08	1	0	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
crizotinib Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)	2.08	1	0	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile [no description available]	2.08	1	0	benzimidazoles
4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide Vx-11e: ERK1-2 inhibitor	2.08	1	0	aromatic amide; heteroarene
osi 906 [no description available]	2.08	1	0	cyclobutanes; quinolines
ly2109761 [no description available]	2.08	1	0
chir-265 [no description available]	2.08	1	0	aromatic ether
motesanib [no description available]	2.08	1	0	pyridinecarboxamide
az-628 AZ-628: a multikinase inhibitor; structure in first source	2.08	1	0	benzamides
trametinib [no description available]	2.08	1	0	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pf-562,271 [no description available]	2.08	1	0	indoles
veliparib [no description available]	2.08	1	0	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
ku-0060648 [no description available]	2.08	1	0	dibenzothiophenes
cinobufagin cinobufagin: isolated from Chinese medicinal preparation ch'an su; derived from toad venom	2.6	1	0	steroid lactone
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.08	1	0	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
palomid 529 [no description available]	2.08	1	0
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	2.51	2	0
ludartin ludartin: a TRPA1 channel activator; structure in first source	3.35	1	0
oregonin oregonin: a diarylheptanoid from the bark of Alnus hirsuta var. sibirica; inhibits cyclooxygenase-2 expression; structure in first source	2.02	1	0	diarylheptanoid
tosedostat [no description available]	2.08	1	0	carboxylic ester; hydroxamic acid; secondary carboxamide
mdv 3100 [no description available]	2.51	2	0	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent
ku 60019 [no description available]	2.08	1	0
gsk 461364 GSK 461364: an antineoplastic agent that inhibits polo-like kinase 1	2.08	1	0	(trifluoromethyl)benzenes
n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide: a MEK inhibitor; structure in first source	2.08	1	0
nvp-tae684 [no description available]	2.08	1	0	piperidines
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	4.69	10	0
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide 4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-N-(3-(trifluoromethyl)phenyl)benzamide: structure in first source	2.08	1	0
gsk 269962a [no description available]	2.08	1	0
ceruletide Ceruletide: A specific decapeptide obtained from the skin of Hila caerulea, an Australian amphibian. Caerulein is similar in action and composition to CHOLECYSTOKININ. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction.. ceruletide : A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction.	2.72	2	0	oligopeptide	diagnostic agent; gastrointestinal drug
a-83-01 A-83-01: an ALK-5 inhibitor; structure in first source	2.08	1	0
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one [no description available]	2.08	1	0	indoles
vx-770 ivacaftor: a CFTR potentiator; structure in first source. ivacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis.	2.08	1	0	aromatic amide; monocarboxylic acid amide; phenols; quinolone	CFTR potentiator; orphan drug
buparlisib NVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first source	2.08	1	0	aminopyridine; aminopyrimidine; morpholines; organofluorine compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
azd 1480 [no description available]	2.08	1	0
fedratinib fedratinib: a selective small-molecule inhibitor of JAK2	2.08	1	0	sulfonamide
gsk690693 [no description available]	2.08	1	0	1,2,5-oxadiazole; acetylenic compound; aromatic amine; aromatic ether; imidazopyridine; piperidines; primary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cay10566 CAY10566: an SCD1 inhibitor; structure in first source	2.15	1	0
cnf 2024 [no description available]	2.08	1	0	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor
ku 0063794 Ku 0063794: an mTOR inhibitor; structure in first source	2.08	1	0	benzyl alcohols; monomethoxybenzene; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; mTOR inhibitor
azd 7545 AZD 7545: an anilide tertiary carbinol; a pyruvate dehydrogenase kinase 2 inhibitor. AZD7545 : A sulfone that is benzene substituted by [4-(dimethylcarbamoyl)phenyl]sulfonyl, chloro and [(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino groups at positions 1, 3 and 4, respectively. It is a potent and non-ATP-competitive inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2) with IC50 of 6.4 nM and exhibits glucose-lowering activity. Also inhibits PDHK1 at higher levels (IC50 = 36.8 nM).	2.08	1	0	benzamides; monochlorobenzenes; organofluorine compound; secondary carboxamide; sulfone; tertiary alcohol; tertiary carboxamide	EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor; hypoglycemic agent
nutlin-3b [no description available]	2.08	1	0	Nutlin; piperazinone	anticoronaviral agent
sphingosine kinase [no description available]	7.25	1	0
ubiquinone Ubiquinone: A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals.	2.6	1	0
pf 04217903 [no description available]	2.08	1	0	quinolines
gdc 0941 pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.	2.08	1	0	indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
sm 164 SM 164: a bivalent Smac mimetic with antineoplastic activity; structure in first source	2.08	1	0	benzenes; organic heterobicyclic compound; secondary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; radiosensitizing agent
calpain Calpain: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.	2.17	1	0
miltiradiene miltiradiene: from Saccharomyces cerevisiae; structure in first source. miltiradiene : An abietadiene in which the two doule bonds are located at positions 8 and 12. It is a key intermediate in the biosynthesis of many important natural diterpene compounds such as triptolide, tanshinones, carnosic acid and carnosol.	2.11	1	0	abietadiene; carbotricyclic compound	plant metabolite
triptotriterpenic acid a triptotriterpenic acid A: from Tripterygium wilfordii; RN given refers to (3beta,22alpha)-isomer; structure given in first source. triptotriterpenic acid A : A pentacyclic triterpenoid with formula C30H48O4, originally isolated from Tripterygium hypoglaucum.	2.6	1	0	diol; hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
chitosan [no description available]	7.21	1	0
ph 797804 PH 797804: an NSAID; structure in first source. PH 797804 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1-yl}-4-methylbenzoic acid with the amino group of methylamine.	2.08	1	0	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pha 408 PHA 408: an IKK-2 antagonist; structure in first source	2.08	1	0
2',3',4'-trihydroxyflavone 2',3',4'-trihydroxyflavone: inhibitor of protein sumoylation; structure in first source	3.51	1	0
gsk 1016790a GSK1016790A : A tertiary carboxamide that is piperazine in which one of the amino groups has undergone condensation with the carboxy group of N-[(2,4-dichlorophenyl)sulfonyl]-L-serine, while the other has undergone condensation with the carboxy group of N-(1-benzothiophen-2-ylcarbonyl)-L-leucine. It is a cell-permeable, potent and selective agonist of the TRPV4 (transient receptor potential vanilloid 4) channel.	2.08	1	0	1-benzothiophenes; aromatic primary alcohol; dichlorobenzene; N-acylpiperazine; sulfonamide; tertiary carboxamide	TRPV4 agonist
sodium glutamate Sodium Glutamate: One of the FLAVORING AGENTS used to impart a meat-like flavor.. monosodium glutamate : An organic sodium salt that is the monosodium salt of glutamic acid.	7.06	1	0	monosodium glutamate	flavouring agent
olaparib [no description available]	2.08	1	0	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
srt1720 [no description available]	2.08	1	0
plx 4720 PLX 4720: a B-Raf(V600E) kinase inhibitor; structure in first source	2.08	1	0	aromatic ketone; difluorobenzene; organochlorine compound; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
methyl jasmonate [no description available]	3.05	4	0
cx 4945 [no description available]	2.08	1	0
cudc 101 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide: a histone deacetylase inhibitor; structure in first source	2.08	1	0
mln 8237 MLN 8237: an aurora kinase A inhibitor	2.08	1	0	benzazepine
lde225 sonidegib: specific Smoothened/Smo antagonist. sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma.	2.08	1	0	aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist
gdc 0449 HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity	2.08	1	0	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent
sgx 523 [no description available]	2.08	1	0	aryl sulfide; biaryl; pyrazoles; quinolines; triazolopyridazine	c-Met tyrosine kinase inhibitor; nephrotoxic agent
bms 777607 N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide: a Met kinase inhibitor; structure in first source	2.08	1	0	aromatic amide
sgi 1776 SGI 1776: a Pim kinase inhibitor; structure in first source	2.08	1	0	imidazoles
pci 32765 ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.	2.08	1	0	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
ponatinib [no description available]	2.08	1	0	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor
amg 900 N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine: a pan-aurora kinase inhibitor; structure in first source	2.08	1	0
mk-1775 adavosertib: a Wee1 kinase inhibitor; structure in first source	2.08	1	0	piperazines
oxymatrine oxymatrine: structure in first source; has anti-apoptosis effects	3.19	1	0
bag956 BAG956: an imidazo[4,5-c]quinoline; dual PI3K/PDK-1 inhibitor, used in antileukemic therapies	2.08	1	0
quizartinib [no description available]	2.08	1	0	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester CAY10603: a HDAC6 inhibitor	2.08	1	0	carbamate ester
tak 733 [no description available]	2.08	1	0
mk 2206 MK 2206: a protein kinase inhibitor and antineoplastic agent	2.08	1	0	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
navitoclax [no description available]	2.49	2	0	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
sns 314 SNS 314: an aurora kinase inhibitor; structure in first source	2.08	1	0	ureas
jzl 184 JZL 184: inhibits monoacylglycerol lipase; structure in first source	2.08	1	0	benzodioxoles
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide: a Janus kinase 1 and Janus kinase 2 inhibitor; structure in first source. momelotinib : A benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis.	2.08	1	0	aminopyrimidine; benzamides; morpholines; nitrile; secondary amino compound; tertiary amino compound	anti-anaemic agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	2.31	1	0
dcc-2036 rebastinib: an inhibitor of Tie2 tyrosine kinase receptor and antineoplastic agent	2.08	1	0	organofluorine compound; phenylureas; pyrazoles; pyridinecarboxamide; quinolines	tyrosine kinase inhibitor
neurotensin neurotensin, Tyr(11)-: RN given refers to parent cpd & (D)-isomer; RN for cpd without isomeric designation not avail 5/91	2.06	1	0	peptide hormone	human metabolite; mitogen; neurotransmitter; vulnerary
cabozantinib cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.	2.08	1	0	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor
N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide [no description available]	2.08	1	0	benzamides
incb-018424 [no description available]	2.08	1	0	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bix 01294 [no description available]	2.08	1	0	piperidines
pf 3845 PF 3845: inhibits fatty acid amide hydrolase	2.08	1	0	piperidines
gsk 2126458 omipalisib: inhibitor of mTOR protein. omipalisib : A member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors.	2.55	2	0	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent
ixazomib ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.	2.55	2	0	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor
ldn 193189 LDN 193189: inhibits bone morphogenetic protein signaling	2.08	1	0	pyrimidines
kurarinone kurarinone: cytotoxic lavandulyl flavanone from Sophora flavescens; structure in first source	3.19	1	0
plx4032 [no description available]	2.08	1	0	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
(2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol [no description available]	2.08	1	0	biphenyls
gsk 1363089 GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source	2.08	1	0	aromatic ether
kin-193 [no description available]	2.08	1	0	pyridopyrimidine
bay 869766 [no description available]	2.08	1	0
4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester WYE-354: an mTOR inhibitor; structure in first source	2.08	1	0	carbamate ester
piperidines Piperidines: A family of hexahydropyridines.	2.86	3	0
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone ML-265: a small molecule activator of PKM2	2.08	1	0	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
manassantin a manassantin A: a dineolignan from Saururus cernuus; structure in first source. manassantin A : A lignan isolated from Saururus cernuus and Saururus chinensis and has been shown to exhibit antineoplastic activity.	2.07	1	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	9.66	10	0
kuraridin kuraridin: isolated from Sophora flavescens; structure in first source	2.02	1	0
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline [no description available]	2.08	1	0	benzenes; sulfonamide
cp 466722 [no description available]	2.08	1	0	quinazolines
gnaphalin gnaphalin: a lipophilic flavonol from Helichrysum sp.; structure in first source	2.02	1	0
phillyrin [no description available]	2.02	1	0
CAY10626 [no description available]	2.08	1	0	ureas
thiopental sodium [no description available]	2.08	1	0	organochlorine compound; piperazines; pyrimidines	antineoplastic agent; tyrosine kinase inhibitor
bufadienolide bufadienolide: isolated from liushen pills; RN given for (14beta)-isomer. bufadienolide : The simplest member of the class of bufadienolides that is bufanolide with unsaturation at positions 20 and 22.	8.12	1	0	bufadienolides
pha 793887 [no description available]	2.08	1	0	piperidinecarboxamide
14-o-phosphonooxymethyltriptolide 14-O-phosphonooxymethyltriptolide disodium salt: pro-drug of triptolide; has antineoplastic activity	6.86	24	0
nvp-bsk805 [no description available]	2.08	1	0
xmd 8-92 XMD8-92 : A dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one carrying at C-2 on the pyrimidine ring a [2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino substituent. It is an inhibitor of the BMK1 kinase pathway.	2.08	1	0	pyrimidobenzodiazepine	protein kinase inhibitor
jq1 compound [no description available]	2.08	1	0	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer
jnj38877605 [no description available]	2.08	1	0	quinolines
N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide [no description available]	2.08	1	0	benzothiazoles
dinaciclib [no description available]	2.1	1	0	pyrazolopyrimidine
torin 1 torin 1 : A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	2.08	1	0	N-acylpiperazine; N-arylpiperazine; organofluorine compound; pyridoquinoline; quinolines	antineoplastic agent; mTOR inhibitor
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	7.25	1	0	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
ly2940680 [no description available]	2.08	1	0
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea [no description available]	2.08	1	0	ureas
ro 4929097 [no description available]	2.08	1	0	dibenzoazepine; dicarboxylic acid diamide; lactam; organofluorine compound	EC 3.4.23.46 (memapsin 2) inhibitor
gsk4112 GSK4112: a Rev-erbalpha agonist; structure in first source	2.08	1	0
torin 2 torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	2.08	1	0	aminopyridine; organofluorine compound; primary amino compound; pyridoquinoline	antineoplastic agent; mTOR inhibitor
pf-4708671 [no description available]	2.08	1	0
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide [no description available]	2.08	1	0	benzamides; N-acylpiperidine
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide 2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide : A member of the class of quinazolines that is quinazoline substituted by {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino and 3-(2-methoxyacetamido)prop-1-en-1-yl groups at positions 4 and 6, respectively.	2.08	1	0	aromatic ether; methylpyridines; olefinic compound; quinazolines; secondary amino compound; secondary carboxamide; toluenes
belinostat [no description available]	2.08	1	0	olefinic compound
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.98	4	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	3.15	1	0
dicumarol Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.	2.17	1	0	hydroxycoumarin	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; Hsp90 inhibitor; vitamin K antagonist
laquinimod [no description available]	3.16	1	0	aromatic amide
ethyl 1-benzyl-3-hydroxy-2(5h)-oxopyrrole-4-carboxylate ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate: RN & structure given in first source	2.08	1	0	carboxylic acid; pyrroline
teriflunomide [no description available]	3.16	1	0	(trifluoromethyl)benzenes; aromatic amide; enamide; enol; nitrile; secondary carboxamide	drug metabolite; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; hepatotoxic agent; non-steroidal anti-inflammatory drug; tyrosine kinase inhibitor
mna 715 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide: structure in first source; a derivative of A77 1726, the active metabolite of the antirheumatic drug leflunomide, where the isoxazole ring has opened to become a nitrile and an alkyne	3.12	1	0
a 769662 [no description available]	2.08	1	0	biphenyls
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	2.06	1	0
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	3.45	7	0
LimKi 3 LIMKi3: LIMK inhibitor. LimKi 3 : A member of the class of pyrazoles that is 1-(2,6-dichlorophenyl)-1H-pyrazole which is substituted by a difluoromethyl group at position 3 and by a 2-(isobutyrylamino)-1,3-thiazol-5-yl group at position 5. It is a a potent cell-permeable inhibitor of LIM kinase 1 and 2.	2.08	1	0	1,3-thiazoles; dichlorobenzene; organofluorine compound; pyrazoles; secondary carboxamide	LIM kinase inhibitor
1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanone [no description available]	2.08	1	0	pyrroles
2-[5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxy-2-pyrrolylidene]indole [no description available]	2.08	1	0	dipyrrins
N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide [no description available]	2.08	1	0	tryptamines
3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione [no description available]	2.08	1	0	pyrazines
gsk837149a GSK837149A: structure in first source	2.08	1	0
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide [no description available]	2.08	1	0	quinazolines
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide [no description available]	2.08	1	0	quinazolines
wnt-c59 2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl)acetamide: a PORCN acyltransferase inhibitor; structure in first source	2.08	1	0
5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime [no description available]	2.08	1	0	indanes
frax486 [no description available]	3.25	1	0
n2-(1h-indazole-5-yl)-n6-methyl-3-nitropyridine-2,6-diamine N2-(1H-indazole-5-yl)-N6-methyl-3-nitropyridine-2,6-diamine: a heat shock factor 1 antagonist; structure in first source. KRIBB11 : A member of the class of indazoles that is 1H-indazole substituted by a [6-(methylamino)-3-nitropyridin-2-yl]amino group at position 5. It is an inhibitor of heat shock factor 1 (IC50 = 1.2muM) and suppresses tumour growth in mouse xenograft models.	3.21	1	0
frax597 FRAX597: structure in first source	3.25	1	0
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.25	1	0
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor	2.54	2	0
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2.07	1	0
nephrin nephrin: gene nephrin is mutated in congenital nephrotic syndrome; amino acid sequence in first source; GenBank F19541; RefSeq NM_019459 (mouse), NM_004646 (human), NM_022628 (rat)	2.5	2	0
oridonin [no description available]	3.25	1	0
morroniside morroniside: from Cornus officinalis; protects cultured human umbilical vein endothelial cells from damage by high ambient glucose; a component of cornel iridoid glycoside; structure in first source	2.17	1	0
gibberellins [no description available]	2.21	1	0
aconitine Aconitine: A C19 norditerpenoid alkaloid (DITERPENES) from the root of ACONITUM; DELPHINIUM and larkspurs. It activates VOLTAGE-GATED SODIUM CHANNELS. It has been used to induce ARRHYTHMIAS in experimental animals and it has anti-inflammatory and anti-neuralgic properties.. aconitine : A diterpenoid that is 20-ethyl-3alpha,13,15alpha-trihydroxy-1alpha,6alpha,16beta-trimethoxy-4-(methoxymethyl)aconitane-8,14alpha-diol having acetate and benzoate groups at the 8- and 14-positions respectively.	2.21	1	0
as 1411 AGRO 100: an antineoplastic agent that inhibits nuclear factor-kappaB activation; base sequence in first source	2.13	1	0
wilforgine wilforgine: isolated from Tripterygium wilfordii; structure in first source. wilforgine : A dihydroagarofuran sesquiterpenoid and pyridine alkaloid with formula C41H47NO19 originally isolated from the roots of Tripterygium wilfordii.	2.78	3	0	acetate ester; dihydroagarofuran sesquiterpenoid; furans; macrocyclic lactone; organic heteropentacyclic compound; pyridine alkaloid	plant metabolite
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	4.54	9	0
catalpol catalpol: component of dihuang; RN given refers to (1aS-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-isomer; RN for cpd without isomeric designation not avail 12/92	2.96	3	0
thromboplastin Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.	2.31	1	0
muramidase Muramidase: A basic enzyme that is present in saliva, tears, egg white, and many animal fluids. It functions as an antibacterial agent. The enzyme catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin. EC 3.2.1.17.	2.73	3	0
amyloid beta-peptides amyloid beta-protein (1-40): although acutely neurotoxic in both rat & monkey cerebral cortex, neuronal degeneration in primates resembles more closely to that found in Alzheimer's disease; amino acid sequence has been determined	2.49	2	0
chir 258 [no description available]	2.08	1	0
osi 027 OSI 027: inhibits both mTORC1 and mTORC2; structure in first source	2.08	1	0
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	3.16	4	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
3-methyladenine N3-methyladenine: structure in first source	2.52	2	0
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	2.1	1	0	dacarbazine
hli 373 [no description available]	2.08	1	0
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	2.08	1	0	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
sildenafil citrate Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.	2.08	1	0	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	2.08	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
xav939 XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source. XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.	2.54	2	0	(trifluoromethyl)benzenes; thiopyranopyrimidine	tankyrase inhibitor
ag-879 AG-879: structure given in first source	3.25	1	0
2-carboxyarabinitol 1-phosphate [no description available]	2.08	1	0
nintedanib nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.	2.08	1	0
ver 52296 luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.	2.08	1	0	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor
sb-590885 N-{5-[2-{4-[2-(dimethylamino)ethoxy]phenyl}-4-(pyridin-4-yl)-1H-imidazol-5-yl]-2,3-dihydro-1H-inden-1-ylidene}hydroxylamine : A ketoxime that is the oxime of indan-1-one in which the hydrogen at position 5 has been replaced by an imidazol-5-yl group which has itself been substituted at positions 2 and 4 by p-[2-(dimethylamino)ethoxy]phenyl and pyridin-4-yl groups, respectively.	2.08	1	0	aromatic ether; imidazoles; ketoxime; pyridines; tertiary amino compound
pf-477736 PF 00477736: a Chk1 inhibitor; structure in first source. PF-00477736 : A diazepinoindole that is 8-amino-4,5-dihydro-6H-[1,2]diazepino[4,5,6-cd]indol-6-one which is substituted at position 2 by a 1-methylpyrazol-4-yl group and in which the amino group at position 8 has undergone condensation with the carboxy group of (2R)-2-cyclohexylglycine to give the corresponding carboxamide. It is an inhibitor of checkpoint kinase 1 (Chk 1).	2.08	1	0
fenobam fenobam: in USAN fenobam refers to monohydrate	2.08	1	0	ureas
wilforine wilforine: isolated from Tripterygium wilfordii; structure in first source. wilforine : An organic heteropentacyclic compound and pyridine alkaloid with formula C43H49NO18 originally isolated from the roots of Tripterygium wilfordii.	8	4	0
pseudolaric acid b [no description available]	2.03	1	0
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	1.98	1	0
chlorotoxin [no description available]	2.1	1	0
phenanthrenes Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.	19.37	1,053	6

Condition	Indicated	Relationship Strength	Studies	Trials
Kidney, Polycystic [description not available]	0	2.48	2	0
Polycystic Kidney Diseases Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.	0	2.48	2	0
Granulocytic Leukemia, Chronic [description not available]	0	3.14	5	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	0	3.14	5	0
Encephalitis, Polio [description not available]	0	2.06	1	0
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	0	2.06	1	0
Glial Cell Tumors [description not available]	0	3.48	7	0
Cancer of Prostate [description not available]	0	4.1	14	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	0	3.48	7	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	4.1	14	0
Benign Neoplasms [description not available]	0	8.24	36	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	8.24	36	0
Adenocarcinoma, Basal Cell [description not available]	0	3.82	10	0
Cancer of Colon [description not available]	0	4.17	15	0
Cancer of Ovary [description not available]	0	4.55	21	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	3.82	10	0
Colonic Neoplasms Tumors or cancer of the COLON.	0	4.17	15	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	4.55	21	0
Anemia, Fanconi [description not available]	0	2.13	1	0
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	0	2.13	1	0
Leucocythaemia [description not available]	0	4.84	11	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	0	4.84	11	0
Experimental Neoplasms [description not available]	0	4.37	7	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	6.74	81	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Cancer of Pancreas [description not available]	0	8.35	62	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	0	8.35	62	0
Experimental Hepatoma [description not available]	0	2.57	2	0
Malignant Melanoma [description not available]	0	4.74	10	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	4.74	10	0
Alloxan Diabetes [description not available]	0	3.73	9	0
Diabetic Glomerulosclerosis [description not available]	0	7.81	19	1
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	0	7.81	19	1
Hepatocellular Carcinoma [description not available]	0	4.15	13	0
Cancer of Liver [description not available]	0	5.23	16	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	4.15	13	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	5.23	16	0
Fatty Liver, Nonalcoholic [description not available]	0	2.31	1	0
Innate Inflammatory Response [description not available]	0	6.44	37	0
Cirrhosis, Liver [description not available]	0	2.82	2	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	6.44	37	0
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	0	2.82	2	0
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	0	7.31	1	0
Cirrhosis [description not available]	0	3.85	10	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	0	3.85	10	0
Arthritis, Degenerative [description not available]	0	2.66	2	0
Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.	0	2.66	2	0
Cancer of the Thyroid [description not available]	0	3.01	4	0
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	0	3.01	4	0
Adjuvant Arthritis [description not available]	0	4.65	25	0
Rheumatoid Arthritis [description not available]	0	8.65	48	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	0	8.65	48	1
Acute Liver Injury, Drug-Induced [description not available]	0	6.41	53	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	6.41	53	0
Experimental Mammary Neoplasms [description not available]	0	3.91	4	0
Cancer of Stomach [description not available]	0	4.47	8	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	0	4.47	8	0
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	0	3.25	5	0
Cancer of Nasopharynx [description not available]	0	3.41	6	0
Emesis [description not available]	0	2.31	1	0
Local Neoplasm Recurrence [description not available]	0	2.61	2	0
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	0	3.41	6	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	0	2.31	1	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	0	2.31	1	0
Mucositis An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).	0	2.31	1	0
Diabetic Cardiomyopathies Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.	0	3.05	4	0
Cancer of Head [description not available]	0	4.02	4	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	0	4.02	4	0
Diffuse Parenchymal Lung Disease [description not available]	0	2.41	1	0
Connective Tissue Diseases A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.	0	2.41	1	0
Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.	0	2.41	1	0
Acute Edematous Pancreatitis [description not available]	0	2.49	2	0
Acute Disease Disease having a short and relatively severe course.	0	3.02	4	0
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	0	2.49	2	0
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	0	5.29	11	0
Colorectal Cancer [description not available]	0	3.64	8	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	0	3.64	8	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	0	5.74	8	0
Adverse Drug Event [description not available]	0	4.56	6	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	4.56	6	0
Leukemia, Lymphoblastic, Acute, T Cell [description not available]	0	2.84	3	0
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.	0	2.84	3	0
Berger Disease [description not available]	0	3.1	4	0
Glomerulonephritis, IGA A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.	0	3.1	4	0
Cardiac Toxicity [description not available]	0	4.42	14	0
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	0	4.42	14	0
Herpes Simplex Virus Infection [description not available]	0	2.41	1	0
Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)	0	7.41	1	0
Acute Confusional Senile Dementia [description not available]	0	4.74	10	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	0	4.74	10	0
Bone Cancer [description not available]	0	3.43	6	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	0	3.43	6	0
Dysplastic Nevus Syndrome, Hereditary [description not available]	0	2.41	1	0
Cancer of Skin [description not available]	0	3.37	6	0
Skin Neoplasms Tumors or cancer of the SKIN.	0	3.37	6	0
Grippe [description not available]	0	2.41	1	0
Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.	0	2.41	1	0
Acute Myelogenous Leukemia [description not available]	0	3.92	11	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	0	3.92	11	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	3.7	9	0
Glomerulonephritis, Lupus [description not available]	0	2.52	2	0
Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).	0	7.52	2	0
Peripheral Nerve Injury [description not available]	0	4.04	10	0
Nerve Pain [description not available]	0	4.15	12	0
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	0	4.15	12	0
Peripheral Nerve Injuries Injuries to the PERIPHERAL NERVES.	0	4.04	10	0
Extramembranous Glomerulopathy [description not available]	0	3.71	8	0
Glomerulonephritis, Membranous A type of glomerulonephritis that is characterized by the accumulation of immune deposits (COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane.	0	3.71	8	0
Muscle Pain [description not available]	0	2.41	1	0
Idiopathic Inflammatory Myopathies [description not available]	0	2.41	1	0
Myositis Inflammation of a muscle or muscle tissue.	0	2.41	1	0
Myalgia Painful sensation in the muscles.	0	2.41	1	0
Osteogenic Sarcoma [description not available]	0	3.51	7	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	0	3.51	7	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	0	3.65	8	0
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	0	5.28	11	1
Cholangiocellular Carcinoma [description not available]	0	5.13	6	0
Bile Duct Cancer [description not available]	0	4.96	5	0
Bile Duct Neoplasms Tumors or cancer of the BILE DUCTS.	0	4.96	5	0
Cholangiocarcinoma A malignant tumor arising from the epithelium of the BILE DUCTS.	0	5.13	6	0
Carcinoma, Non-Small Cell Lung [description not available]	0	5.65	15	0
Cancer of Lung [description not available]	0	6.39	34	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	1	7.65	15	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	6.39	34	0
Carcinoma, Epidermoid [description not available]	0	3.5	7	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	0	3.5	7	0
Chemical and Drug Induced Liver Injury, Chronic Liver disease lasting six months or more, caused by an adverse effect of a drug or chemical. The adverse effect may be caused by drugs, drug metabolites, chemicals from the environment, or an idiosyncratic response.	0	2.6	1	0
Palmoplantaris Pustulosis [description not available]	0	5.3	4	1
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	0	5.3	4	1
HIV Coinfection [description not available]	0	2.6	1	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	1	4.6	1	0
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	0	3.37	5	0
Metastase [description not available]	0	4.63	9	0
Invasiveness, Neoplasm [description not available]	0	4.13	14	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	4.63	9	0
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	0	3.37	5	0
Colitis, Mucous [description not available]	0	2.6	1	0
Irritable Bowel Syndrome A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.	0	7.6	1	0
Breast Cancer [description not available]	0	6.46	24	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	6.46	24	0
Hematologic Malignancies [description not available]	0	4.95	4	0
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	0	4.95	4	0
Cardiovascular Stroke [description not available]	0	2.63	2	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	0	7.63	2	0
Hepatitis INFLAMMATION of the LIVER.	0	3.52	1	0
Allodynia [description not available]	0	3.04	4	0
Asthma, Bronchial [description not available]	0	5.44	14	1
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	0	5.44	14	1
Alveolitis, Fibrosing [description not available]	0	3.21	5	0
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	0	3.21	5	0
Hematochezia The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.	0	2.6	1	0
Gastrointestinal Hemorrhage Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.	0	2.6	1	0
Polyploid [description not available]	0	7.21	1	0
Sterility, Male [description not available]	0	2.98	4	0
Infertility, Male The inability of the male to effect FERTILIZATION of an OVUM after a specified period of unprotected intercourse. Male sterility is permanent infertility.	0	2.98	4	0
Cognitive Decline [description not available]	0	2.69	2	0
Acute Onset Vascular Dementia [description not available]	0	2.61	2	0
Dementia, Vascular An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)	0	2.61	2	0
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	0	7.69	2	0
Acquired Immune Deficiency Syndrome [description not available]	0	2.21	1	0
Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.	0	2.21	1	0
Ankylosing Spondylarthritis [description not available]	0	2.59	2	0
Spondylitis, Ankylosing A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.	0	2.59	2	0
Cardiac Diseases [description not available]	0	3.07	4	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	0	3.07	4	0
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	0	2.21	1	0
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	0	2.21	1	0
Angiogenesis, Pathologic [description not available]	0	5.01	14	0
Airway Remodeling The structural changes in the number, mass, size and/or composition of the airway tissues.	0	8.34	6	0
Injuries, Spinal Cord [description not available]	0	3.21	5	0
Spinal Cord Injuries Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).	0	3.21	5	0
Chronic Pancreatitis [description not available]	0	2.25	1	0
Pancreatitis, Chronic INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.	0	2.25	1	0
Root Resorption Resorption in which cementum or dentin is lost from the root of a tooth owing to cementoclastic or osteoclastic activity in conditions such as trauma of occlusion or neoplasms. (Dorland, 27th ed)	0	7.21	1	0
Endotoxemia A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.	0	7.21	1	0
Atrophy, Muscle [description not available]	0	2.25	1	0
Muscular Atrophy Derangement in size and number of muscle fibers occurring with aging, reduction in blood supply, or following immobilization, prolonged weightlessness, malnutrition, and particularly in denervation.	0	2.25	1	0
Carcinoma, Ductal, Pancreatic [description not available]	0	3.49	7	0
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	0	3.49	7	0
Blood Poisoning [description not available]	0	2.25	1	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	0	2.25	1	0
Lung Adenocarcinoma [description not available]	0	3.05	4	0
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	0	3.05	4	0
Bone Loss, Osteoclastic [description not available]	0	3.25	5	0
Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.	0	2.25	1	0
Injuries, Radiation [description not available]	0	2.25	1	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	0	3.92	4	0
Genome Instability [description not available]	0	2.25	1	0
Epithelial Ovarian Cancer [description not available]	0	8.28	5	0
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	0	3.28	5	0
Blast Phase [description not available]	0	2.78	3	0
Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.	0	7.78	3	0
Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.	0	2.6	1	0
Colitis-Associated Cancer [description not available]	0	2.25	1	0
Hypospermatogenesis [description not available]	0	2.31	1	0
Choroid Neovascularization [description not available]	0	2.25	1	0
Blood Pressure, High [description not available]	0	2.25	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	0	7.25	1	0
Autoimmune Disease [description not available]	0	4.57	5	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	0	4.57	5	0
Cerebral Ischemia [description not available]	0	3.21	5	0
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	0	3.21	5	0
Bowel Diseases, Inflammatory [description not available]	0	2.25	1	0
Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.	0	2.25	1	0
Astrocytoma, Grade IV [description not available]	0	2.31	1	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	0	7.31	1	0
Carcinoma, Squamous Cell of Head and Neck [description not available]	0	2.66	2	0
Cancer of Mouth [description not available]	0	3.25	5	0
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	0	2.66	2	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	0	3.25	5	0
Injury, Ischemia-Reperfusion [description not available]	0	3.57	8	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	0	3.57	8	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	3.57	8	0
Atypical Lipomatous Tumor [description not available]	0	2.31	1	0
Liposarcoma A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)	0	2.31	1	0
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	0	4.17	5	0
Bile Duct Obstruction [description not available]	0	2.31	1	0
Cholestasis Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).	0	7.31	1	0
Polyarthritis [description not available]	0	2.99	4	0
Arthritis Acute or chronic inflammation of JOINTS.	0	2.99	4	0
2019 Novel Coronavirus Disease [description not available]	0	2.31	1	0
Hypercoagulability [description not available]	0	2.31	1	0
Chronic Lung Injury [description not available]	0	2.31	1	0
Acute Respiratory Distress Syndrome [description not available]	0	2.31	1	0
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	0	2.31	1	0
Thrombophilia A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.	0	2.31	1	0
ADPKD [description not available]	0	3.92	4	0
Polycystic Kidney, Autosomal Dominant Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.	1	5.92	4	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	0	2.78	3	0
Pneumonia Infection of the lung often accompanied by inflammation.	0	7.78	3	0
Adenoma, Prostatic [description not available]	0	2.15	1	0
Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.	0	7.15	1	0
Complication, Postoperative [description not available]	0	2.74	3	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	0	2.74	3	0
Albuminuria The presence of albumin in the urine, an indicator of KIDNEY DISEASES.	0	2.17	1	0
Cranial Nerve II Injuries [description not available]	0	2.15	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	0	2.58	2	0
Kahler Disease [description not available]	0	4.15	15	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	0	4.15	15	0
Cancer of Pituitary [description not available]	0	2.57	2	0
Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.	0	2.57	2	0
Cancer-Associated Pain [description not available]	0	2.15	1	0
Cancer Pain Pain that may be caused by or related to cellular, tissue, and systemic changes that occur during NEOPLASM growth, tissue invasion, and METASTASIS.	0	7.15	1	0
Cryptogenic Fibrosing Alveolitis [description not available]	0	2.17	1	0
Idiopathic Pulmonary Fibrosis A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.	0	7.17	1	0
Dermatitis Any inflammation of the skin.	0	2.15	1	0
Age-Related Osteoporosis [description not available]	0	3.77	3	0
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	0	3.77	3	0
Epithelial Neoplasms [description not available]	0	2.78	3	0
Adenoma, Basal Cell [description not available]	0	2.17	1	0
Adenoma A benign epithelial tumor with a glandular organization.	0	7.17	1	0
Anasarca [description not available]	0	3.44	7	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	0	3.44	7	0
African Lymphoma [description not available]	0	2.17	1	0
Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.	0	2.17	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	0	4.1	5	0
Disease Exacerbation [description not available]	0	3.47	7	0
Idiopathic Parkinson Disease [description not available]	0	4.71	4	0
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	0	4.71	4	0
Aura [description not available]	0	2.17	1	0
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	0	7.17	1	0
Chronic Illness [description not available]	0	4.55	5	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	4.55	5	0
Bladder Cancer [description not available]	0	3.92	4	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	0	3.92	4	0
Delayed Hypersensitivity [description not available]	0	2.74	3	0
Benign Cerebellar Neoplasms [description not available]	0	2.17	1	0
Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available]	0	2.17	1	0
Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)	0	7.17	1	0
Encephalopathy, Toxic [description not available]	0	2.21	1	0
Infections, Salmonella [description not available]	0	2.21	1	0
Cardiac Remodeling, Ventricular [description not available]	0	2.84	3	0
Carditis [description not available]	0	7.21	1	0
Myocarditis Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.	0	7.21	1	0
Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.	0	2.21	1	0
Cancer of Esophagus [description not available]	0	2.21	1	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	0	2.21	1	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	0	3.17	1	0
Libman-Sacks Disease [description not available]	0	2.21	1	0
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	0	2.21	1	0
Colitis, Granulomatous [description not available]	0	4.73	6	1
Crohn Disease A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.	0	4.73	6	1
Bilateral Wilms Tumor [description not available]	0	2.21	1	0
Wilms Tumor A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.	0	2.21	1	0
Degenerative Diseases, Central Nervous System [description not available]	0	4.18	3	0
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	0	4.18	3	0
Chromosomal Fragility [description not available]	0	2.08	1	0
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	0	2.1	1	0
Cancer of Cervix [description not available]	0	2.47	2	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	0	2.47	2	0
Glaucoma An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)	0	2.5	2	0
Intraocular Pressure The pressure of the fluids in the eye.	0	2.5	2	0
Granulocytic Leukemia [description not available]	0	2.45	2	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	0	2.45	2	0
Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)	0	2.1	1	0
Cancer of Endometrium [description not available]	0	2.78	3	0
Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.	0	2.78	3	0
Cancer of Larynx [description not available]	0	2.08	1	0
Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.	0	2.08	1	0
Lung Injury, Acute [description not available]	0	3.2	5	0
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	0	3.2	5	0
Acute Pain Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.	0	2.1	1	0
Nephritis Inflammation of any part of the KIDNEY.	0	8.86	2	1
IgA Vasculitis A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.	0	3.86	2	1
Cancer of the Tongue [description not available]	0	2.1	1	0
Tongue Neoplasms Tumors or cancer of the TONGUE.	0	2.1	1	0
Cancer of Gallbladder [description not available]	0	2.1	1	0
Gallbladder Neoplasms Tumors or cancer of the gallbladder.	0	2.1	1	0
Carcinoma, Ductal, Breast An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.	0	2.1	1	0
Acute Kidney Failure [description not available]	0	2.48	2	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	0	7.48	2	0
Carcinoma 256, Walker A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)	0	2.1	1	0
Ache [description not available]	0	2.5	2	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	0	7.5	2	0
Age-Related Memory Disorders [description not available]	0	2.52	2	0
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	0	2.1	1	0
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	0	2.52	2	0
HPV Infection [description not available]	0	2.1	1	0
Papillomavirus Infections Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.	0	2.1	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	2.74	3	0
Protein Folding Diseases [description not available]	0	2.1	1	0
Cystic Fibrosis of Pancreas [description not available]	0	2.1	1	0
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	0	2.1	1	0
Osteolysis Dissolution of bone that particularly involves the removal or loss of calcium.	0	2.52	2	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	0	7.11	1	0
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	0	2.11	1	0
B-Cell Lymphoma [description not available]	0	2.74	3	0
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	0	2.74	3	0
Apoplexy [description not available]	0	2.11	1	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	0	7.11	1	0
FMR1-Related Primary Ovarian Insufficiency [description not available]	0	2.11	1	0
Primary Ovarian Insufficiency Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections. The most commonly known genetic cause is the expansion of a CGG repeat to 55 to 199 copies in the 5' untranslated region in the X-linked FMR1 gene.	0	2.11	1	0
B16 Melanoma [description not available]	0	3.67	3	0
Injury, Myocardial Reperfusion [description not available]	0	2.13	1	0
B-Cell Chronic Lymphocytic Leukemia [description not available]	0	2.11	1	0
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	0	2.11	1	0
Adenocarcinoma Of Kidney [description not available]	0	2.49	2	0
Cancer of Kidney [description not available]	0	2.49	2	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	0	2.49	2	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	0	2.49	2	0
Fibrosis, Radiation [description not available]	0	2.11	1	0
Radiation Pneumonitis Inflammation of the lung due to harmful effects of ionizing or non-ionizing radiation.	0	2.11	1	0
Acute Hypercapnic Respiratory Failure [description not available]	0	2.11	1	0
Respiratory Insufficiency Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)	0	2.11	1	0
Cerebral Infarction, Middle Cerebral Artery [description not available]	0	2.46	2	0
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	0	2.46	2	0
Lymphoma, Primary Effusion A rare neoplasm of large B-cells usually presenting as serious effusions without detectable tumor masses. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. It is associated with HUMAN HERPESVIRUS 8, most often occurring in the setting of immunodeficiency.	0	2.53	2	0
Carcinoma, Anaplastic [description not available]	0	4.48	8	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	0	4.48	8	0
Kaposi Sarcoma [description not available]	0	7.5	2	0
Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.	0	2.5	2	0
Protein Aggregation, Pathological A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION; POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.	0	2.13	1	0
Cardiomyopathies, Primary [description not available]	0	2.13	1	0
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	0	2.13	1	0
Dysmyelopoietic Syndromes [description not available]	0	2.46	2	0
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	0	2.46	2	0
Cardiac Rupture, Traumatic [description not available]	0	2.13	1	0
Acute Lymphoid Leukemia [description not available]	0	2.51	2	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	0	2.51	2	0
Pouch Ileitis [description not available]	0	2.15	1	0
Pouchitis Acute INFLAMMATION in the INTESTINAL MUCOSA of the continent ileal reservoir (or pouch) in patients who have undergone ILEOSTOMY and restorative proctocolectomy (PROCTOCOLECTOMY, RESTORATIVE).	0	2.15	1	0
Left Ventricular Hypertrophy [description not available]	0	2.15	1	0
Hypertrophy, Left Ventricular Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.	0	2.15	1	0
Corneal Angiogenesis [description not available]	0	7.15	1	0
Eye Burns Injury to any part of the eye by extreme heat, chemical agents, or ultraviolet radiation.	0	2.15	1	0
Corneal Neovascularization New blood vessels originating from the corneal blood vessels and extending from the limbus into the adjacent CORNEAL STROMA. Neovascularization in the superficial and/or deep corneal stroma is a sequel to numerous inflammatory diseases of the ocular anterior segment, such as TRACHOMA, viral interstitial KERATITIS, microbial KERATOCONJUNCTIVITIS, and the immune response elicited by CORNEAL TRANSPLANTATION.	0	2.15	1	0
Pain, Chronic [description not available]	0	2.51	2	0
Brain Inflammation [description not available]	0	3.68	3	0
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	0	7.15	1	0
Encephalitis Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.	0	3.68	3	0
Chronic Pain Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.	0	7.51	2	0
Nephrosis Pathological processes of the KIDNEY without inflammatory or neoplastic components. Nephrosis may be a primary disorder or secondary complication of other diseases. It is characterized by the NEPHROTIC SYNDROME indicating the presence of PROTEINURIA and HYPOALBUMINEMIA with accompanying EDEMA.	0	2.04	1	0
Sarcoma 180 An experimental sarcoma of mice.	0	2.04	1	0
Allergy, Drug [description not available]	0	2.04	1	0
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	0	2.04	1	0
Allergic Encephalomyelitis [description not available]	0	3.14	5	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	0	2.46	2	0
Endocarditis, Loeffler [description not available]	0	2.05	1	0
Hypereosinophilic Syndrome A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.	0	7.05	1	0
Diffuse Large B-Cell Lymphoma [description not available]	0	3.34	2	0
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	0	3.34	2	0
Di Guglielmo Disease [description not available]	0	2.05	1	0
Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.	0	2.05	1	0
Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.	0	2.05	1	0
Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.	0	7.05	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	2.05	1	0
Astrocytosis [description not available]	0	2.45	2	0
Weight Gain Increase in BODY WEIGHT over existing weight.	0	2.41	2	0
Adrenal Cancer [description not available]	0	7.06	1	0
MS (Multiple Sclerosis) [description not available]	0	2.98	1	0
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	0	2.98	1	0
Cirrhoses, Experimental Liver [description not available]	0	2.06	1	0
Liver Dysfunction [description not available]	0	2.74	3	0
Liver Diseases Pathological processes of the LIVER.	0	2.74	3	0
Ureteral Obstruction Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.	0	7.06	1	0
Hematuria Presence of blood in the urine.	0	2.06	1	0
Nephrotic Syndrome A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.	0	2.06	1	0
Leishmaniasis, American [description not available]	0	2.06	1	0
Leishmaniasis, Cutaneous An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.	0	2.06	1	0
Liver Steatosis [description not available]	0	2.06	1	0
Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.	0	2.06	1	0
Adult Spinal Muscular Atrophy [description not available]	0	2.07	1	0
Muscular Atrophy, Spinal A group of disorders marked by progressive degeneration of motor neurons in the spinal cord resulting in weakness and muscular atrophy, usually without evidence of injury to the corticospinal tracts. Diseases in this category include Werdnig-Hoffmann disease and later onset SPINAL MUSCULAR ATROPHIES OF CHILDHOOD, most of which are hereditary. (Adams et al., Principles of Neurology, 6th ed, p1089)	0	2.07	1	0
Brain Swelling [description not available]	0	2.07	1	0
Acute Brain Injuries [description not available]	0	2.07	1	0
Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)	0	2.07	1	0
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	0	2.07	1	0
Paraganglioma, Gangliocytic [description not available]	0	2.07	1	0
Pheochromocytoma, Extra-Adrenal [description not available]	0	2.07	1	0
Paraganglioma A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion, such as the carotid body, or medulla of the adrenal gland (usually called a chromaffinoma or pheochromocytoma). It is more common in women than in men. (Stedman, 25th ed; from Segen, Dictionary of Modern Medicine, 1992)	0	2.07	1	0
Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)	0	2.07	1	0
Diabetes Mellitus, Adult-Onset [description not available]	0	2.07	1	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	0	2.07	1	0
Benign Neoplasms, Brain [description not available]	0	2.07	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	0	2.07	1	0
Cystadenocarcinoma, Serous A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)	0	2.07	1	0
Adhesions, Tissue [description not available]	0	2.07	1	0
Injuries, Tendon [description not available]	0	2.07	1	0
Autoimmune Diabetes [description not available]	0	7.08	1	0
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	0	2.08	1	0
Central Nervous System Disease [description not available]	0	3	1	0
Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.	0	3	1	0
Neurilemoma [description not available]	0	2.07	1	0
Neurilemmoma A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)	0	2.07	1	0
Thrombopenia [description not available]	0	2.07	1	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	0	7.07	1	0
Opisthorchis felineus Infection [description not available]	0	2.92	1	0
Liver Diseases, Parasitic Liver diseases caused by infections with PARASITES, such as tapeworms (CESTODA) and flukes (TREMATODA).	0	2.92	1	0
Opisthorchiasis Infection with flukes of the genus Opisthorchis.	0	2.92	1	0
Abnormalities, Autosome [description not available]	0	2.01	1	0
Chromosome-Defective Micronuclei [description not available]	0	2.01	1	0
Neuroretinitis [description not available]	0	2.01	1	0
Retinitis Inflammation of the RETINA. It is rarely limited to the retina, but is commonly associated with diseases of the choroid (CHORIORETINITIS) and of the OPTIC DISK (neuroretinitis).	0	7.01	1	0
Uveitis Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)	0	2.01	1	0
Arterial Obstructive Diseases [description not available]	0	2.02	1	0
Pulmonary Hypertension [description not available]	0	3.11	5	0
Arterial Occlusive Diseases Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.	0	2.02	1	0
Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.	0	3.11	5	0
Chromosomal Translocation [description not available]	0	2.02	1	0
Coronary Restenosis Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.	0	2.43	2	0
Congestive Ophthalmopathy [description not available]	0	2.03	1	0
Graves Ophthalmopathy An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.	0	7.03	1	0
Autosomal Dominant Juvenile Parkinson Disease [description not available]	0	2.44	2	0
Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.	0	2.44	2	0
Lymph Node Metastasis [description not available]	0	7.03	1	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	0	2.03	1	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	0	2.03	1	0
Dermatoses [description not available]	0	2.03	1	0
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	0	2.03	1	0
Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.	0	7.03	1	0
Hypertrophy, Right Ventricular Enlargement of the RIGHT VENTRICLE of the heart. This increase in ventricular mass is often attributed to PULMONARY HYPERTENSION and is a contributor to cardiovascular morbidity and mortality.	0	2.03	1	0
Corneal Diseases Diseases of the cornea.	0	2.96	1	0
Clinically Isolated CNS Demyelinating Syndrome [description not available]	0	2.04	1	0
Demyelinating Diseases Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.	0	2.04	1	0
Foreign-Body Granuloma [description not available]	0	1.98	1	0
Arteriosclerosis, Coronary [description not available]	0	2	1	0
Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	0	2	1	0
Acute Promyelocytic Leukemia [description not available]	0	1.97	1	0
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	0	1.97	1	0
Extravascular Hemolysis [description not available]	0	1.97	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	0	1.97	1	0

triptolide

Cross-References

Synonyms (84)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (4)

Protein Targets (11)

Potency Measurements

Inhibition Measurements

Biological Processes (144)

Molecular Functions (24)

Ceullar Components (19)

Bioassays (211)

Research

Studies (1,136)

Market Indicators

Research Demand Index: 44.51

Study Types

Clinical Trials (7)

Trial Overview

triptolide

Related Flora

Cross-References

Synonyms (84)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (4)

Protein Targets (11)

Potency Measurements

Inhibition Measurements

Biological Processes (144)

Molecular Functions (24)

Ceullar Components (19)

Bioassays (211)

Research

Studies (1,136)

Market Indicators

Research Demand Index: 44.51

Study Types

Clinical Trials (7)

Trial Overview

Related Drugs (823)

Related Conditions (462)